Patent Application
20140349969
The present invention relates to the field of method of treatment of pain and the provision of pharmaceutical compounds suitable for such treatments.
Acute and chronic pain affects millions of people after injury or surgery and those suffering from diseases like arthritis, cancer, and diabetes. Nociception (the detection of noxious or damaging stimuli) serves a crucial biological purpose: it alerts living organisms to environmental dangers, inducing the sensation of pain, reflex withdrawal and complex behavioural and emotional responses, which protect the organism from further damage. Noxious stimuli are detected by specialized high threshold primary sensory neurons (nociceptors), which transfer signals to the spinal cord and then transmit them to the brain for higher level processing that results in the conscious awareness of the sensation called pain. The functional importance of pain perception is exemplified by individuals with defects in nociception; patients with congenital insensitivity to pain do not survive past their twenties.
Two basic types of pain can be distinguished—acute and chronic. Acute or nociceptive pain is generally self-limiting and serves a protective biological function by warning of on-going tissue damage caused by noxious chemical, thermal and mechanical stimuli. Examples of nociceptive pain include: post-operative pain, pain associated with trauma, and the pain associated with arthritis. Chronic pain, on the other hand, serves no protective biological function, and reflects either poor resolution of the painful stimuli, or is itself a disease process. Chronic pain is unrelenting and not self-limiting and can persist for years and even decades after the initial injury. Chronic pain is predominantly neuropathic in nature and may involve damage either to the peripheral or central nervous systems.
It is a goal of the present invention to provide methods of treating, ameliorating or suppressing pain, in particular by the use of novel compounds for this purpose.
The present invention therefore provides the use of new classes of compounds for the treatment, prevention or reduction of pain. These compounds are given in the claims, and especially include Tenofovir (PMPA), dasatinib, AMG-706 (motesanib), BIRB 796 (Doramapimod), EKB-569 (Pelitinib), sorafenib, Vandetanib, CI-1033 (Canertinib), NSC161613, N6-Benzyladenosine-5′-phosphate, p-Aminobenzoly PAB-J acid, NSC47091, cilomilast, Nicotinamide (Nicotinamide), IBMX, Roflumilast, Filaminast, Piclamilast, V11294, CC-10004 (Apremilast), LAS31025 (Arofylline), CP80633 (Atizoram), Catramilast/Atopik (Catramilast), BRL-61063 (Cimpyfylline), Daxalipram/mesopram (Daxalipram), Doxofylline, Drotaverine, Efloxate, Etamiphylline, Etazolate, Etofylline, Glaucine Hydrobromide (Broncholytine), GRC3886 (oglemilast), oxtriphyllin (Choline theophyllinate), Pumafentrine, Revamilast, Tofimilast, Tolafentrine, Seoanin (Trapidil), GW 842470 (AWD 12-281), CDP-840, YM-976, CI-1018, D-4418, Lirimilast, SCH-351591, RPL-554, IPL-455903 (HT-0712), GSK256066, Zardaverine, Vardenafil, OPC-6535 (Tetomilast), IC485, L-826,141, ONO-6126, CI-1044, MK-0873, T-2585, R1533 (MEM-1414), Ronomilast (ELB-353), UK-500,001, AN2728, DE-103, Tofisopam, (R)-Tofisopam (Dextofisopam), (S)-Tofisopam (Levotofisopam (USAN)), EKB-568, SU-14813, LY-333531 (Ruboxistaurin), CGP-52421, SKI-606 (Bosutinib), Roscovitine, Tenofovir (PMPA), Methimazole, Adefovir dipivoxil (Bis-POM PMEA) (Adefovir), Acetazolamide, midostaurin (PKC-412), tozasertib (MK-0457, VX 680) or lestaurtinib (CEP-701). A further compound is imatinib (STI-571), which is preferably used in the treatment on non-inflammatory pain, especially in the treatment of neuropathic pain. Alternative names or identification of the compounds are given in brackets. Chemical structures of some of these compounds are given as follows:
SCH 351591
L-826,141 (Enantiomer 1)
indicates data missing or illegible when filed
In preferred embodiments the inventive compound is an inhibitor (i.e. an antagonist) or modulator of any one of FRK, PDE4D, LPAR3, CAMK1D, CSNK1G3 or FMO3. Inhibitors or ligands (i.e. binders) or modulators of FRK, PDE4D, LPAR3, CAMK1D, CSNK1G3 or FMO3 can be used in the treatment of pain in a subject. In preferred embodiments the FRK, PDE4D, LPAR3, CAMK1D, CSNK1G3 or FMO3 modulator is a selective FRK, PDE4D, LPAR3, CAMK1D, CSNK1G3 or FMO3 modulator. By “selective” it is meant that the affinity for one of FRK, PDE4D, LPAR3, CAMK1D or FMO3 is at least 10-fold, preferably 25-fold, more preferred 100-fold, still preferred 150-fold higher than the affinity of the other targets selected from FRK, PDE4D, LPAR3, CAMK1D or FMO3.
Surprisingly it has been shown that some of these targets, such as FRK, FMO3, LPAR3 can be both activated, e.g. by an agonist, or inhibited (e.g. by an inhibitor or antagonist) for an anti-pain effect in a patient. The group of agonists and antagonists is referred to herein as “modulators”. Although in most cases an inhibitor is preferred for greater effect, it seems that modulation of activity of these targets in any direction reduces the pain or sensation of pain. Preferably the modulator is a strong binder to these targets, especially with a Kd of 1000 nM or less or an IC50 of 1000 nM or less. Preferred lower values for Kd and IC50 are 800 nM or less, 600 nM or less, 500 nM or less, 400 nM or less, 300 nM or less, 200 nM or less, 100 nM or less, 50 nM or less or even 30 nM or less.
In particular preferred are FMO3 modulators or inhibitors for use in the treatment of pain. Such compounds are e.g. Tenofovir and Methimazole.
In particular preferred are FRK modulators or inhibitors for use in the treatment of pain. Such compounds are e.g. dasatinib, motesanib, Doramapimod, Pelitinib, sorafenib, Vandetanib and Canertinib.
Preferably the inhibitor is selected from compounds with a Kd of lower than 3000 nM, preferably lower than 2000 nM, especially preferred lower than 1000 nM. In particular, these compounds can be selected from dasatinib (Kd 0.31 nM), motesanib (Kd 99 nM), Doramapimod (Kd 360 nM), Pelitinib (Kd 190 nM), sorafenib (Kd 440 nM) and Vandetanib (Kd 480 nM). The Kd may also be up to 750 nM or up to 500 nM.
Kd, Ki or IC50 values of course relate to the binding or inhibiting capability of a given compound on a given target, such as one of FRK, PDE4D, LPAR3, CAMK1D, CSNK1G3 or FMO3, as associated herein.
In preferred embodiments the FRK modulator is selected from compounds comprising a substituted pyridine, quinoline, isoquinoline or pyridine group.
In especially preferred embodiments the FRK modulator is an FRK inhibitor. An inhibitor or antagonist is a compound that lowers or inhibits the activity of a given target here FRK. This can be achieved by binding to the target, e.g. but not necessarily to the catalytic center, and preventing the catalytic activity of the target.
Preferably an inhibitor or modulator, in particular of FRK, is selected from compounds comprising a substituted pyrimidine, quinoline, isoquinoline or pyridine group, such as from motesanib (AMG-706), Pelitinib (EKB-569), sorafenib (sorafenib), Vandetanib (Vandetanib), canertinib (CI-1033).
Preferably an inhibitor or modulator, in particular of FRK, is selected from compounds comprising a substituted aniline group with a Kd value less than 1000 nM, such as dasatinib (dasatinib), motesanib (AMG-706), Doramapimod (BIRB 796), Pelitinib (EKB-569), sorafenib (sorafenib), Vandetanib (Vandetanib).
Preferably an inhibitor or modulator, in particular of FRK, is selected from compounds comprising a chlorine, fluorine or chlorine and fluorine substituted aniline group. Such compounds are e.g. dasatinib, Pelitinib, sorafenib, Vandetanib and canertinib.
In preferred embodiments an FRK inhibitor selected from compounds comprising an aniline group, selected from dasatinib (dasatinib), motesanib (AMG-706), doramapimod (BIRB 796), pelitinib (EKB-569), sorafenib (sorafenib), vandetanib (vandetanib), canertinib (CI-1033) and imatinib (STI-571) is for use in the treatment of neuropathic pain, such as trigeminal neuralgia, such as post-herpetic neuralgia, such as painful diabetic neuropathy, such as painful diabetic peripheral neuropathy, such as diabetic polyneuropathy, such as sciatic pain, such as radiculopathy, such as radicular pain or such as non-inflammatory neuropathic pain. The aniline group is preferably a substituted aniline group and is e.g. selected from a chloride and/or fluoride substituted aniline group or a carbonyl substituted aniline. Preferably the aniline group is a carbonyl substitution, such as in dasatinib (dasatinib), motesanib (AMG-706), doramapimod (BIRB 796), pelitinib (EKB-569), sorafenib (sorafenib), canertinib (CI-1033) and imatinib (STI-571), and can be used in the treatment of neuropathic pain.
In preferred embodiments the FRK inhibitor is a selective FRK inhibitor. By “selective” it is meant that the affinity for FRK is at least 10-fold, preferably 25-fold, more preferred 100-fold, still preferred 150-fold higher than the affinity for other tyrosine kinase receptors, especially one or both of FLT3 or c-Kit.
In further embodiments there is provided an LPAR3 inhibitor or modulator for use in the treatment of pain. Such a compound is e.g. selected from NSC161613, NSC47091, N6-Benzyladenosine-5′-phosphate, p-Aminobenzoly PAB-J acid.
Surprisingly it could be shown that in case of LPAR3 both activators or agonists and inhibitors or antagonsits can be effective in the treatment of pain. Thus any artificial change in the expression or activity of LPAR3 can ameliorate pain. Preferably the LPAR3 modulator is selected from compounds comprising N6-Benzyladenosine-5′-phosphate, p-Aminobenzoly PAB-J acid, NSC161613 and NSC47091. In particular preferred cases the LPAR3 modulator is an LPAR3 inhibitor. Such an inhibitor is e.g. p-Aminobenzoly PAB-J acid, NSC161613 or NSC47091.
In further embodiments there is provided a PDE4D inhibitor or modulator for use in the treatment of pain. Such a compound may be selected from cilomilast, Roflumilast, Filaminast, Piclamilast, V11294, Luteolin, Apremilast, Arofylline, Atizoram, Catramilast, Cimpyfylline, Daxalipram, Doxofylline, drotaverin, Efloxate, Etamiphylline, Etazolate, Etofylline, Broncholytine, Irimilast, oglemilast, Choline theophyllinate, Pumafentrine, Revamilast, Ronomilast, Tofimilast, Tolafentrine, Trapidil, GW 842470 (AWD 12-281), CDP-840, YM-976, CI-1018, D-4418, Lirimilast, SCH-351591, RPL-554, IPL-455903 (HT-0712), GSK256066, Zardaverine, Vardenafil, Tetomilast, IC485, L-826,141, ONO-6126, CI-1044, MK-0873, T-2585, R1533 (MEM-1414), UK-500,001, AN2728, DE-103, Tofisopam, Dextofisopam, Levotofisopam (USAN).
Preferably the PDE4D inhibitor is selected from a compound comprising a 1,2-dioxy-aryl group with an IC50 value of 1100 nM or less, preferably 1050 nM or less, preferably 1000 nM or less, preferably 950 nM or less, preferably 950 nM or less, preferably 900 nM or less. Such a PDE4D inhibitor is preferably selected from cilomilast (cilomilast, IC50 of 11 nM), Roflumilast (Roflumilast, IC50 of 0.68 nM), Filaminast (Filaminast, IC50 of 1000 nM), Piclamilast (Piclamilast, IC50 of 0.02 nM), (V11294, IC50 of 200 nM), Apremilast (CC-10004), Atizoram (CP80633), Catramilast (Catramilast), Daxalipram (Daxalipram/mesopram, IC50 of 1100 nM), drotaverin (Drotaverine), (Glaucine Hydrobromide), oglemilast (GRC3886, IC50 of 166 nM), Pumafentrine (Pumafentrine), Revamilast (Revamilast, IC50 of 2.7 nM), Tolafentrine (Tolafentrine, IC50 of 30 nM), (CDP-840, IC50 of 2.1 nM), (RPL-554), (IPL-455903 (HT-0712)), Zardaverine (Zardaverine, IC50 of 390 nM), Tetomilast (OPC-6535, IC50 of 70 nM), (L-826,141, IC50 of 2.4 nM), Ronomilast (ELB353, IC50 of 3.5 nM), Tofisopam (Tofisopam, IC50 of 900 nM).
In a further preferred embodiment the PDE4D inhibitor or modulator comprises a 1,2-dioxy-aryl group substituted with an alkyl or flour-alkyl group, or 1,2-dioxy-aryl group condensed in a furan ring containing oxygen. Such a compound is e.g. selected from cilomilast (cilomilast), Roflumilast (Roflumilast), Filaminast (Filaminast), Piclamilast (Piclamilast), (V11294), Apremilast (CC-10004), Daxalipram (Daxalipram/mesopram), drotaverin (Drotaverine), broncholytine (Glaucine Hydrobromide), oglemilast (GRC3886), Pumafentrine (Pumafentrine), Revamilast (Revamilast), Tolafentrine (Tolafentrine), (RPL-554), Zardaverine (Zardaverine), Tetomilast (OPC-6535), (L-826,141), Ronomilast (ELB353), Tofisopam (Toflsopam).
In another aspect of PDE4D inhibitors or modulators there is provided a PDE4D inhibitor or modulator comprising a 3,5-dichlor-pyridine group or a pyridine group that is not condensed in a 2 ring structure. Such compounds may be selected from Roflumilast (Roflumilast), Piclamilast (Piclamilast), oglemilast (GRC3886), Revamilast (Revamilast), GW 842470 (AWD 12-281), D-4418, SCH-351591.
Also provided is a PDE4D inhibitor or modulator comprising a quinoline, isoquinoline or pyrimidine group. Such a compound can be selected from drotaverine (Drotaverine), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), Trapidil (Seoanin), D-4418, SCH-351591, RPL-554, SK256066, T-2585, Ronomilast (ELB353).
In a further embodiment the PDE4D inhibitor or modulator is selected from compounds comprising an aniline group, in particular preferred a carbonyl- or chlorine-substituted aniline. Such compounds are e.g. Apremilast (CC-10004), Arofylline (LAS31025), CI-1044, T-2585.
The PDE4D inhibitor or modulator for use according to the invention may comprise a purine ring. Such a compound can be selected from (IBMX), (V11294), Arofylline (LAS31025), Cimpyfylline (BRL-61063), Doxofylline (Doxofylline), Etamiphylline (Etamiphylline), Etofylline (Etofylline), Choline theophyllinate (oxtriphyllin), Theophylline (Theophylline). These compounds are preferably used for the treatment of neuropathic pain, especially non-inflammatory neuropathic pain.
In a further embodiment the PDE4D inhibitor or modulator for use according to the invention is essentially the only active pharmaceutical ingredient of the composition or medicament according to the invention, such as the only active pharmaceutical ingredient, in particular the only anti-pain compound, of the composition or medicament according to the invention. Preferably the PDE4D inhibitor or modulator for use according to the invention is not combined with or used in combination with a phospholipase inhibitor. Especially preferred, CI-1018 is not combined with or used in combination with a phospholipase inhibitor when used according to the invention.
In further embodiments there is provided a CAMK1D inhibitor or modulator for use in the treatment of pain. Such a compound may be selected from Bosutinib, Pelitinib, EKB-568, SU-14813, Ruboxistaurin, CGP-52421.
The CAMK1D inhibitor or modulator preferably comprises a chlorine-substituted aniline group. Such compounds can be selected from Bosutinib (SKI-606) and Pelitinib (EKB-569).
Preferably the CAMK1D inhibitor is selected from the group of bosutinib (SKI-606), pelitinib (EKB-569), EKB-568 and CGP-52421 for use in the treatment of pain.
In preferred embodiments the CAMK1D modulator is a selective CAMK1D modulator. By “selective” it is meant that the affinity for CAMK1D is at least 10-fold, preferably 25-fold, more preferred 100-fold, still preferred 150-fold higher than the affinity for other tyrosine kinase receptors, especially one or both of FLT3 or c-Kit.
In further embodiments there is provided a CSNK1G3 inhibitor or modulator for use in the treatment of pain. Such compound can be roscovitine.
The CSNK1G3 inhibitor or modulator preferably comprises a purine ring. Such compound can be roscovitine.
In preferred embodiments the CSNK1G3 inhibitor is a selective CSNK1G3 inhibitor. By “selective” it is meant that the affinity for CSNK1G3 is at least 10-fold, preferably 25-fold, more preferred 100-fold, still preferred 150-fold higher than the affinity for other tyrosine kinase receptors, especially one or both of FLT3 or c-Kit.
In preferred embodiments of the invention the compound for use in the treatment of pain comprises a quinoline or isoquinoline group. Such compounds are e.g. Bosutinib, Pelitinib (EKB-569), drotaverin (Drotaverine), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), D-4418, SCH-351591, RPL-554, (GSK256066), T-2585, Ronomilast (ELB353), preferably the compound being an inhibitor of FRK, PDE4D or CAMK1D. These compounds are preferably for use in the treatment of neuropathic pain, preferably non-inflammatory neuropathic pain.
In preferred embodiments of the invention the compound for use in the treatment of pain comprises a chlorine-substituted aniline group. Such compounds are e.g. selected from dasatinib (dasatinib), bosutinib (SKI-606), sorafenib (sorafenib), Canertinib (CI-1033), Arofylline (LAS31025), T-2585, Pelitinib (EKB-569), preferably the compound being an inhibitor of FRK, PDE4D or CAMK1D. These compounds are preferably for use in the treatment of neuropathic pain, preferably non-inflammatory neuropathic pain.
The inventive compound can be used in combination with other active analgesic/anti-pain compounds, preferably only with those described herein or above or in the claims, or used as single active analgesic/anti-pain compound.
In preferred embodiments the compound for use according to the invention comprises a 1,2-Dioxyaryl group. Especially preferred the compound comprises a 1,2-Dioxyaryl group substituted with a basic residue, such as Vandetanib (Vandetanib), SKI-606 (Bosutinib). The compound may comprise a 1,2-Dioxyaryl group substituted with a cycloaliphatic residue, such as cilomilast (cilomilast), Roflumilast (Roflumilast), Filaminast (Filaminast), Piclamilast (Piclamilast), V11294, CP80633 (Atizoram), Catramilast/Atopik (Catramilast), CDP-840, IPL-455903 (HT-0712). The compound may comprise a 1,2-dioxy-aryl substituted with an alkyl residue, such as CC-10004 (Apremilast), Daxalipram/mesopram (Daxalipram), Drotaverine (drotaverin), Glaucine Hydrobromide (Broncholytine), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), RPL-554, Zardaverine (Zardaverine), OPC-6535 (Tetomilast), Tofisopam (Tofisopam). The compound may comprise a 1,2-dioxy-aryl substituted with a fluor-alkyl group, such as GRC3886 (oglemilast), Revamilast (Revamilast), Zardaverine (Zardaverine), L-826,141, ELB353 (Ronomilast). The compound may comprise a 1,2-dioxy-aryl in a condensed furan ring with an oxygen, such as GRC3886 (oglemilast), Revamilast (Revamilast).
In preferred embodiments the compound for use according to the invention comprises an indole group, especially an indole group as part of a ringsystem, such as CGP-52421, midostaurin (PKC-412).
In preferred embodiments the compound for use according to the invention comprises a substituted indole, such as GW 842470 (AWD 12-281), AMG-706 (motesanib), SU-14813, LY-333531 (Ruboxistaurin), SKI-606 (Bosutinib).
In preferred embodiments the compound for use according to the invention comprises a purine ring, such as N6-Benzyladenosine-5′-phosphate, V11294, LAS31025 (Arofylline), BRL-61063 (Cimpyfylline), Doxofylline (Doxofylline), Etamiphylline (Etamiphylline), Etofylline (Etofylline), oxtriphyllin (Choline theophyllinate), Roscovitine (Roscovitine), Tenofovir (PMPA) (Tenofovir), Remofovir (Pradefovir), Adefovir dipivoxil (Bis-POM PMEA) (Adefovir).
In preferred embodiments the compound for use according to the invention comprises a sulfone or sulfonic acid or sulfonamide group, especially a methyl-suflone, such as Lirimilast (Lirimilast). The compound may comprise a siaryl-sulfone, such as GSK256066, Vardenafil (Vardenafil). The compound may comprise a sulfonic acid group, such as p-Aminobenzoly PAB-J acid. The compound may comprise a Sulfonamide group, such as Tolafentrine (Tolafentrine), Acetazolamide (Acetazolamide).
In preferred embodiments the compound for use according to the invention comprises a pyridine group. Preferably the compound comprises an unsubstituted pyridine radical, such as Nicotinamide (Nicotinamide), or CI-1044. The compound may comprise a 3,5-Dichlorpyridine group, such as Roflumilast (Roflumilast), Piclamilast (Piclamilast), GRC3886 (oglemilast), Revamilast (Revamilast), GW 842470 (AWD 12-281), D-4418, SCH-351591. The compound may comprise a substituted pyridine group, such as AMG-706 (motesanib), sorafenib (sorafenib), Etazolate (Etazolate), Tofimilast (Tofimilast), GSK256066, MK-0873.
In preferred embodiments the compound for use according to the invention comprises a quinolone or isoquinoline or condensed isoquinoline group. The compound may comprise a quinolone group such as EKB-569 (Pelitinib), D-4418, SCH-351591, GSK256066, MK-0873, SKI-606 (Bosutinib). The compound may comprise a isoquinoline or condensed isoquinoline group, such as Drotaverine (drotaverin), Pumafentrine (Pumafentrine), Tolafentrine (Tolafentrine), RPL-554, ELB353 (Ronomilast).
In preferred embodiments the compound for use according to the invention comprises a pyrimidine group, such as Vandetanib (Vandetanib), CI-1033 (Canertinib), Seoanin (Trapidil), tozasertib (MK-0457, VX 680).
In preferred embodiments the compound for use according to the invention is a compound with 3 nitrogens in a ring structures, such as YM-976.
In preferred embodiments the compound for use according to the invention comprises a carbonic or phosphoric acid group. The compound may comprise a carbonic acid group, such as OPC-6535 (Tetomilast). The compound may comprise a phosphoric acid group, such as N6-Benzyladenosine-5′-phosphate, Tenofovir (PMPA) (Tenofovir).
In preferred embodiments the compound for use according to the invention comprises an esther group, such as Remofovir (Pradefovir) (Pradefovir), Adefovir dipivoxil (Bis-POM PMEA) (Adefovir).
In preferred embodiments the compound for use according to the invention comprises a aniline group, especially preferred a chloride and/or fluoride substituted aniline group. The compound may comprise a Chlor-fluor-aniline, such as EKB-569 (Pelitinib), CI-1033 (Canertinib). The compound may comprise a Chlor-aniline or dichlor-aniline, such as dasatinib (dasatinib), sorafenib (sorafenib), LAS31025 (Arofylline), T-2585, SKI-606 (Bosutinib). The compound may comprise a Fluor-aniline, such as Vandetanib (Vandetanib), SU-14813.
In preferred embodiments the compound for use according to the invention comprises a carbonyl-substituted aniline, such as dasatinib (dasatinib), AMG-706 (motesanib), BIRB 796 (Doramapimod), EKB-569 (Pelitinib), sorafenib (sorafenib), CI-1033 (Canertinib), p-Aminobenzoly PAB-J acid, CC-10004 (Apremilast), CI-1044, NSC47091.
In preferred embodiments the compound for use according to the invention comprises a diaryl-thioether group, such as tozasertib (MK-0457, VX 680).
In preferred embodiments the compound for use according to the invention comprises a 1,3-Dioxyaryl group, such as Efloxate (Efloxate).
In preferred embodiments the compound for use according to the invention is selected from Methimazole, AN2728, NSC161613, especially a compound without one or more or all of the above mentioned groups.
The present invention also provides a method of treating pain in a subject comprising the administration of a therapeutic compound selected from the compounds of table 1. In a related aspect the present invention provides the use of a compound of table 1 for the manufacture of an analgesic or a medicament for the treatment of pain in a subject. The invention is further defined by the subject matter of the claims.
The inventive compounds have been identified by a thorough screening system based on genetic analysis, starting from drosophila hits. Drosophila (fruit flies) respond to noxious stimuli, and have become a powerful model organism for studying genetics, including the genetics of nociception. For instance, the TRP channel PAINLESS was previously identified as a heat-responsive channel mediating thermal-based nociception in fly larvae. Using genome-wide neuronal-specific RNAi knock-down, the present invention provides a global screen for an innate behavior and identify hundreds of novel genes implicated in nociception in the fly, including the α2δ-family calcium channel subunit straightjacket or the phospholipid kinase PI3Kgamma. The initial drosophila screen yielded targets having homologous targets in various organisms, including humans. For example, observation of the mammalian straightjacket ortholog, α2δ3, and PI3Kgamma in nociception was confirmed in knock-out mice that exhibit significantly impaired basal pain sensitivity and delayed thermal hyperalgesia after inflammation. In humans, single nucleotide polymorphisms (SNPs) in α2δ3 or PIK3CG were found that are associated with reduced acute pain sensitivity in healthy volunteers and chronic postsurgical back pain. Based on the validated genetic data various compounds have been identified that are capable of treating or suppressing pain in various organisms, in particular in humans. In a further screening, several compounds have been identified which modulate or antagonize or inhibit, that is lower the targets activity in vivo or as can be determined in an in vitro assay as described herein or known in the art (e.g. Enzyme activity assay to determine IC50 values), which are active in the treatment or reduction of pain in a subject. In particular the compounds to be used in any form of treatment according to the present invention are selected from any one of (1S,2S)-2-(2-(N-((3-benzimidazol-2-yl)propyl)-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride, (5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine, (6S)-5,6,7,8-tetrahydrofolic acid, (T,G)-A-L, 1 alpha-hydroxyergocalciferol, 1-(1-cyclohexylethylamino)-4-phenylphthalazine, 1-(2-methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline, 1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-((5-(4-fluorophenyl)-3-pyridinyl)methyl)piperazine, 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione, 1-adamantyl propargyl ether, 1-aminobenzotriazole, 1-aminooxy-3-aminopropane, 1-hydrazino-4-(3,5-dimethyl)-1-pyrazolyl-5H-pyridazino(4,5-b)indole, 1-hydroxymethylmidazolam, 1-hydroxypyrene, 1-Methyl-4-phenylpyridinium, 1-Nitropyren-8-ol, 1-phosphatidyl-1D-myo-inositol 3-phosphates, 1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1,1-bis(3′-indolyl)-1-(4-t-butylphenyl)methane, 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC, 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane, 1,2-bis(diphenylphosphino)ethane, 1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione, 1,2-diacyl-sn-glycero-3-phosphocholines, 1,2-ethanedithiol, 1,2-oleoylphosphatidylcholine, 1,2,4-triazines, 1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol, 1,25-dihydroxyergocalciferol, 1,25D3,1,3-Dcg, 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole, 1,3-dipropyl-8-(3-noradamantyl)xanthine, 1,3,5-trimethylbenzene, 1,7-dioxa-2,6-diaza-4,4-dioxide-4,7a-dithia-3H,5H-benzo(cd)pentalene, 10-deoxymethynolide, 10-propargyl-10-deazaaminopterin, 10-undecynoic acid, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone, 11-cis-retinal, 11-hydroxycannabinol, 12-Hht, 13-Lox, 13-oxo-9,11-octadecadienoic acid, 15 hete, 15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid, 17-(allylamino)-17-demethoxygeldanamycin, 17alpha-ethynylestradiol, 1843U89, 1D-myo-inositol 1,3,4,5-tetrakisphosphate, 1H-indole, 1H-pyrazole, 1H-pyrazolo(3,4-b)pyridine, 2 APB, 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-3(2H)-pyridazinone, 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone, 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole, 2-(4-morpholinoanilino)-6-cyclohexylaminopurine, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, 2-(4-toluidino)-6-naphthalenesulfonic acid, 2-(cyclohexylmethylidenehydrazino)adenosine, 2-AAF, 2-acetylthiomethyl-3-(4-methylbenzoyl)propionic acid, 2-AG, 2-amino-1-methyl-6-phenylimidazo(4,5-b)pyridine, 2-amino-3,4-dimethylimidazo(4,5-f)quinoline, 2-aminoethoxydiphenyl borate, 2-AP, 2-CADO, 2-chloro-5-nitrobenzanilide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide, 2-cyanomethylthiopyridine-4-carbonitrile, 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole, 2-DG, 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid, 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine, 2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline, 2-ME, 2-methoxyacetic acid [2-[2-[3-(1H-benzoimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl]ester, 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine, 2-N-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine, 2-Naftol, 2-oxothiazolidine-4-carboxylic acid, 2-phenyl-4-oxohydroquinoline, 2,2,2-trichloroethane-1,1-diol, 2,2′-(hydroxynitrosohydrazono)bis-ethanamine, 2,2′-azobis(2,4-dimethylvaleronitrile), 2,2′-bipyridine, 2,2′,4,4′-tetrachlorobiphenyl, 2,3-bis(3′-hydroxybenzyl)butane-1,4-diol, 2,3-dihydroxyterephthalamide, 2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate, 2,4-diaminoquinazoline, 2,4-thiazolidinedione, 21-hydroxy-9beta,10alpha-pregna-5,7-diene-3-ol-20-one, 25-desacetylrifabutin, 25-Hydroxycholesterol, 25(OH)D3, 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine, 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol, 3-(2h)-pyridazinone, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide, 3-aminopyrazole, 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one, 3-BHA, 3-hydroxybutanal, 3-hydroxyflunitrazepam, 3-Hydroxyquinine, 3-isobutyl-1-methyl-Xanthine, 3-keto-desogestrel, 3-methoxy-4-aminoazobenzene, 3-Methoxymorphinan, 3-Methoxyoestradiol, 3-methylcholanthrene, 3-MI, 3,3′,4,5′-tetrahydroxystilbene, 3,4-DCI, 3,4,5-trihydroxybenzamidoxime, 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol, 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol, 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole, 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide, 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, 4-AP, 4-azidosalicylic acid, 4-dimethylamino-3′,4′-dimethoxychalcone, 4-hydroxy-N-desmethyltamoxifen, 4-hydroxyacetophenone, 4-hydroxycoumarin, 4-hydroxyestradiol-17 beta, 4-hydroxynon-2-enal, 4-hydroxytriazolam, 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, 4-phenylbutyric acid, 4-S-cysteaminylphenol, 4-sulfophenylmethallyl ether, 4,4′-DDE, 4,4′-dipyridyl disulfide, 4,8-dimethoxy-7-hydroxyfuro(2,3-b)quinoline, 4′-epidoxorubicin, 4′-N-benzoylstaurosporine, 4(2′-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline, 4alpha-phorbol 12,13-didecanone, 4alphaPDD, 5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid, 5-(4′-(N-piperidinyl)phenylazo)indazole, 5-7-oxo-zeaenol, 5-AC, 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine, 5-azido-1H-indole-3-acetic acid, 5-HT, 5-methoxy-N,N-diisopropyltryptamine, 5-Mop, 5,10-methylenetetrahydrofolate, 5,6-dimethylxanthenoneacetic acid, 5′-O-(((2-decanoylamino-3-phenylpropyloxycarbonyl)amino)sulfonyl)uridine, 6 beta-hydroxycortisol, 6-Aminochrysene-1,2-dihydrodiol, 6-chloro-2-pyridylmethyl nitrate, 6-deoxy-6-bromoascorbic acid, 6-hydroxydexamethasone, 6-Mercaptopurine, 6,6′-oxybis(2,2-dimethylhexanoic acid), 64Gd, 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine, 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine, 7-benzyloxyquinoline, 7-CDL, 7-hydroxystaurosporine, 7-ketocholesterol, 7,8-BF, 7,8-dihydroneopterin, 7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol, 7C3MT, 7H-Pyrrolo(2,3-d)pyrimidine, 8-((4-bromo-2,3-dioxobutyl)thio)-adenosine 3′,5′-cyclic monophosphate, 8-(2,6-dichlorophenyl)-10-methyl-3-((4-morpholin-4-ylphenyl)amino)-2,4,10-triazabicyclo(4.4.0)deca-1,3,5,7-tetraen-9-one, 8-(3-chlorostyryl)caffeine, 8-anilinonaphthalene-1-sulfonic acid, 8-Hydroxy-2-(di-n-propylamino)tetralin, 8-Isoprostane, 8,10-bis((2,2-dimethyl-1-oxopropyl)oxy)-11-methyl-1234-tetrahydro-6H-benzo(beta)quinolizin-6-one, 9-(4′-aminophenyl)-9H-pyrido(3,4-b)indole, 9-anthroic acid, 9-CRA, 9-hydroxy-risperidone, 9,10-anthraquinone, 9H-xanthene, A 71915, A-300-I, a-ADP, A73025, Abbott, abciximab, Absele, ABT-737, acetamide 45, Aceton, acetonitrile, acetyl-11-ketoboswellic acid, acetylcholine, acetylvalerenolic acid, Aclarubicin, Acolen, ACON, ACT D, actinium, Actosin, adalimumab, Adalin, Adanon, Adfeed, adinazolam, Adofeed, Adrenor, Adrin, AEBSF, Aeromax, afloqualone, AGMATINE, AIDSVAX, ajoene, ajulemic acid, alachlor, Aladerm, alaninate, Alat, Alcolo, Alcuronium, Aldara, ALDO, Aldrich, alemtuzumab, Alfarol, Alfentanil, ALIMTA, aliskiren, Alli, ALLN, alloxazine, allyl isothiocyanate, almokalant, aloesin, Alprenolol, Alvesco, AM 1387, AM 251, Am 80, AMD 070, Amiloride, Aminacrine, Amine BB, amino-polyethyleneoxide-sulfonate, aminoflavone, Amiodarone, Amlodipine, Amphotericin B, amprenavir, Amrinone, amsonic acid, Amygdalin, AN 207, Anaboleen, anacardic acid, Anandamide, Anco, Andrographis, Androtine, Aneol, Ang II, Anisomycin, Anon, Anthocyanins, anthra(1,9-cd)pyrazol-6(2H)-one, anthracene, anthralin, Anthricin, anthrone, antibiotic G 418, antibiotic H107, Antimycin A, Anyvim, APAP, APDC, Aphidicolin, Aphloiol, apicidin, Apigenin, apocynin, Apotransferrin, aprepitant, APRL, AQ4N, arabinogalactan, Arac, Aralen, Arasine, Areca, Arecoline, Areether, argatroban, aripiprazole, Aron, Artein, Artra, arvanil, asiatic acid, asiaticoside, Asmax, Asmol, ASTA, astatine, Astemizole, Astragaloside A, atazanavir, ATL 146e, Atorel, atorvastatin, Atovaquone, ATRA, Atropine, Auranofin, AuTM, auxin, avasimibe, AVE 0118, avicularin, Avid, Axert, Axsain, Aza-dC, Aza-deoxycytidine, azacyclonol, Azadc, azamulin, azaspirane, azelaic acid, azelastine, azelnidipine, azido ruthenium, Azine, Azithromycin, Azobisisobutyramidinium dichloride, Azole, Azoles, Azolidine, Azophen, Azor, BA (VAN), Ba 0108E, bacitracin, Baclofen, bacterial lysate, bafilomycin A1, Bagren, baicalein, Barbiturate, Barnidipine, BAY 11-7085, BB-K8, BCNU, Beflavin, Belt, benazepril, bendamustine, Benidipine, benzamidine, benzimidazolide, Benzodiazepines, Benzodioxoles, Benzphetamine, benzydamine N-oxide, benzylamine, benzyloxycarbonylleucyl-leucyl-leucine aldehyde, benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone, beractant, berberine, bergamottin, bergaptol, beta-glycerophosphoric acid, beta-lapachone, beta-Naphthoflavone, beta-propiolactone, Bethanechol, betulinic acid, bexarotene, Bezafibrate, BG 9928, BGC945, biapigenin, BIBX 1382BS, biphenyl-4-ol, BIRB 796, bisindolylmaleimide I, bisindolylmaleimide III, Bisoprolol, bisperoxovanadium, Bisphenol A-Glycidyl Methacrylate, bizelesin, BL1521, Bla-S, Blow, BM 41.440, BML 241, BMS 310705, BMS204352, BMS453, Bo-Xan, Boltin, Bonopen, boron, Borrelia-burgdorferi, bortezomib, bosentan, bosutinib, botrocetin, BPDE, BR-II, Brake, bredinin, Brefeldin A, Bromazepam, bromo-cis-stilbene, brucine, bryostatin 1, Budesonide, bufalin, bufuralol, Bumetanide, BuOH, Bupivacaine, Buprenorphine, BUPROPION, Buspirone, Busulfan, Buthionine Sulfoximine, Butyrate, butyrolactone I, C 1027, C 76, CACP, Calcijex, Calcimycin, calphostin C, Calyculin, Camptothecin, Canef, cangrelor, Cannabinoids, Cannabis, Cantharidin, CAPE, Capsaicin, capsaicinoids, capsazepine, Carbachol, Carbamazepine, carbapenem, Carbapenems, carbobenzoxy-leucyl-leucyl-norvalinal, Carbolines, Carboxyethyl-phenethylamino-ethylcarboxamidoadenosine, Cardiolipins, carebastine, CARNOSOL, carrageenans, carvacrol, carvedilol, Casodex, caspofungin, casticin, catechins, CB 3717, Cbdca, CCPA, CD 437, CDP 840, Cefoxitin, celecoxib, cephalomannine, cephalosporins, cepharanthine, cerebrolysin, cerivastatin, Cetomacrogol, cetrorelix, cetuximab, CGP 12177, CGS 15943A, CGS 21680, CH-THF, CH2CHO, Chalcone, CHAPS, Chinine, Chitosan, Chloramphenicol, chlorophenyl-ethane, chlorophyllin, chlorophyllypt, chlorpromazine, Chlorpropham, Chlorzoxazone, Cholestanol, CHOLINE, Chonsurid, chromophore, Chrysin, chymostatin, CI1033, cicaprost, cifostodine, ciglitazone, Cilazapril, Cilomilast, cilostazol, Cimetidine, cinacalcet, cinitapride, cinnamic aldehyde, cionin, Cipol N, Ciprofloxacin, Ciprol, cis-9, trans-11-conjugated linoleic acid, Cisapride, Citalopram, Citox, CITRULLINE, clebopride, clevidipine, clobazam, Clodronic Acid, clofarabine, Clofibric Acid, Clomipramine, Clonazepam, Clonidine, clopidogrel, clotiazepam, Clozapine, clozapine N-oxide, CNI 1493, Co 2-1970, Coagulin, Colchicine, compactin, CONT, Cotinine, Cotrim, coumarin, CRA 024781, CRA 026440, Crestor, Crodacid, Crypt-2,2,2, cryptdin 3, cryptotanshinone, cryptoxanthin, CUBE, CVT 3146, cyanidin 3-rutinoside, cyanidin-3-glucoside, cyanoginosin-LA, Cyclandelate, cyclohexyl carbamic acid 3′-carbamoylbiphenyl-3-yl ester, cyclohexyl-methyl, cyclopamine, Cyclopentenone, cyclopiazonic acid, Cyproheptadine, Cyproterone Acetate, cystathionine, cysteamine, cysteinyl-leukotriene, Cytarabine, cytochalasin B, Cytochalasin D, cytochalasin E, D 22888, D 23129, DA 8159, Dacarbazine, DADSO, daidzein, danaproid, Dapsone, Daral, Darifenacin, darunavir, dasatinib, Daunorubicin, Dayfen, DBPC, DDB, DDE, Debrisoquin, decursin, Deethylamiodarone, deferiprone, Deferoxamine, deguelin, dehydroaripiprazole, Dehydroepiandrosterone Sulfate, dehydroxymethylepoxyquinomicin, Delavirdine, delta8-THC, Denagard, denbinobin, denileukin diftitox, denopamine, Depas, deramciclane, desethylchloroquine, desflurane, desisobutyrylciclesonide, desmethylazelastine, Desmethyldeprenyl, Devazepide, Dexfenfluramine, dexloxiglumide, Dextropropoxyphene, dFdC, DFMO, DHEA, DHLA, di-(1-isoquinolinyl)-di-(pyridyl-2)butane, Diaben, Diacomit, diadenosine tetraphosphate, Dial, Diamide, DIAN, diarsenic trioxide, Dibenzanthracene, Dicid, Diclofenac, Dicyclohexylcarbodiimide, diethyl maleate, Diethyl-benzoquinone-imine, Digicor, Digitin, Digoxin, Dihydroqinghaosu, Dihydroxycholecalciferols, diisopropyl fluorophosphate, dillapiol, Diltiazem, Dimethadione, dimethyl fumarate, Dimethyl Sulfoxide, dimethyl-hydrazide, dimethylamino-purine, dimuonium, dinitrophenol, Dinoprostone, dioxirane, Dipalmitoyl, diphenylalanine, Diphenylamine, diphenyleneiodonium, Dipyridamole, Dipyrone, discodermolide, Diterpenes, Dithionite, diuretic, Diuron, divinyl benzene, dl-Ipr, DMGG, DMPX, DMSO, Dobutamine, Doca, Doconexent, dodecyl-phosphocholine, dodecyloctaethyleneglycol monoether, Domperidone, DOTA, Doxazosin, Doxorubicin, Doxycycline, DPC 681, DPCPX, Droxia, DTMC, dulcin, Durapatite, DX 9065a, Dxms, Dynatra, E 10, E 3330, E-MIX 80, E.O., EACA, ebastine, ebrotidine, Echinomycin, Econ, econazole, ecteinascidin 743, Edetic Acid, Edex, efavirenz, EGCg, EGTA, eletriptan, Elicide, Empecid, Enalapril, Endocannabinoids, endomorphin 1, Enediynes, enflurane, enone, Enoximone, entacapone, Entex, enzastaurin, EOS, EPC-K(1), EPEG, EPIB, epibatidine, Epicar, Epoprostenol, epoxybergamottin, epsilon-viniferin, erastin, ergosterol-5,8-peroxide, Eril, erlotinib, erucin, Eryc, erythritol anhydride, esterbut-3, Estriol, ET18-Ome, Etfc cpd, Ethacrynic Acid, Ethan, Ethinyl-oestradiol, Ethylmorphine, Ethynodiol Diacetate, Eticol, Etidronic Acid, Etodolac, Etoposide, etoricoxib, etravirine, Eufor, Eugenol, eupatilin, everolimus, Evex, Evodin, exenatide, Exosurf, Expectorants, Extina, Ezerin, ezetimib, Facet, Facid, facile, Factor IIa, FAMP, Fanchinine, Farnesyl-PP, farnesylthiosalicylic acid, febuxostat, felbamate, Felodipine, Fenfluramine, fenitrothion, fenofibric acid, Fenretinide, Fentanyl, ferulic acid, Filipin, fingolimod, fipronil, fisetin, Flanin F, Flavon, flavonols, flavopiridol, Fla 1, FLCZ, Flecainide, Floxacillin, flufenamic acid, Flunitrazepam, fluorexon, Fluorouracil, fluvoxamine, FOLATE-ANALOG, fondaparinux, Fonofos, Format, Formyl-Tetrahydrofolate, Forskolin, fosamprenavir, Foscarnet, FR 120480, FR 235222, fraxin, FTY 720P, fucoidan, fulvestrant, fumagillin, Fura-2, furafylline, Furamon, Furylfuramide, Gabexate, gadolinium, Gadolinium DTPA, galactocerebroside, galactomannan, galangin, galaturonate, gallic acid, Gallogen, gambierol, Gambogic acid, gamma-butyric-acid, Ganciclovir, gastrin 17, gatifloxacin, gefitinib, Geldanamycin, Gemfibrozil, gemtuzumab, Gentamicins, gepirone, geraniol, geranylcoumarin, Gestodene, GF 120918, GGTI 298, GI 129471, gingerol, ginsenoside Rd, ginsenoside Rf, ginsenoside Rg1, ginsenoside Rh2, Ginsenosides, GLCa, Gliclazide, Glumin, Glyoxal, Gnidimacrin, GnRH, Go 6976, gossypol, GR 79236X, gramicidin S, Granisetron, Gravistat, Grofo, Guggulsterone, GW 4064, GW 501516, H 89, Halan, halofuginone, harmine, Harzol, hassium, HDMTX, Hecogenin, Hectorol, Heet, helenalin, Hemicholinium 3, herbimycin, hesperadin, HESPERETIN, Hexadimethrine, hexarelin, Hgln, himbacine, Hk, Hocus, HOE 33342, honokiol, Horner, HS 1200, HU 211, HyateC, Hydoxin, hydride, Hydromorphone, Hydroxychloroquine, hydroxycotinine, hydroxylamine, Hydroxytryptophol, Hyhorin, Hypaque, hyperforin, hypericin, Hypericum-perforatum, hypochlorous acid, iberin, IBMX, ibopamine, ibudilast, IC 831423, icariin, icaritin, icilin, ICRF 193, IDS 23, Ifosfamide, Ikarugamycin, ilimaquinone, Iloprost, Imadyl, imatinib, imidafenacin, imidazo-pyridine, imidazolidin-2-one, imidazolidin-one, imidazolidine, Imidazoline, imidazolyl-disulfide, Imipenem, Imizin, Immulina, Immunoferon, Impulsin, Imrecoxib, Imutex, Indinavir, indiplon, indirubin, indole-3-acetic acid, indole-3-methanol, indolin-2-one, indolin-one, infliximab, inhibin B, INOmax, inositol-1,3,4,5-tetrakisphosphate, inulin, Iodoacetamide, iodomethane, iodoresiniferatoxin, Ionomycin, ionophore, Iopanoic Acid, Iophendylate, IPADE, IPOMEANOL, Iressa, irinotecan, irisolidone, Isatin, isaxonine, isoamylol, isobutyl-methyl-Xanthine, Isodonol, isoflavone, isoflurane, Isol, Isoliquiritigenin, isometronidazole, isoprenoids, Isopropyl Thiogalactoside, Isoprostanes, Isorhamnetin, isosilybin A, Isosorbide Dinitrate, isothiocyanates, Isotretinoin, Isradipine, istradefylline, Itraconazole, ivabradine, Ivermectin, ixabepilone, jadomycin B, Jexin, JHW 015, JTE 013, K 252, K-PAM, K-SR, kaempferol, kaempferol-3-O-(2,3,4-tri-O-acetyl-alpha-1-rhamnopyranoside), KAFA, Kaken, Kamalin, Kaolin, Kathon 886, KB 141, Kemi, kenpaullone, Ketamine, Keto-desogestrel, Keto-pgfl alpha, ketoglutarate, Kipca, KMD 3213, KMTB, Kojic acid, KR-31543, KRM 1648, L 365260, L 740,093, L-454,560, L-696,474, L-T3, LAAM, lacidipine, lactacystin, lactisole, lamotrigine, Lanol, lansoprazole, lapatinib, laquinimod, latrunculin A, latrunculin B, lavendustin A, LBH589, leflunomide, lenalidomide, Lendorm, Lentinan, leptomycin B, Leucovorin, Leukotriene C4, Leukotriene D4, leukotrienes, Leupeptin, Levamisole, Levitra, levobupivacaine, Levonorgestrel, levugen, liarozole, Lidocaine, lilopristone, Lipoate, Lipofectamine, lipoteichoic acid, Lipoxins, lissamine rhodamine B, lithocholic acid, LMWH, LNAC, lonafarnib, Loperamide, lopinavir, Loratadine, Lorazepam, Lorex, lorglumide, Losartan, Lovan, loxiglumide, LUF 5831, lupeol, luteolin, LY 117018, LY 293111, LY231514, LYCOPENE, lysophosphatidic acid, Lysophosphatidylcholines, Lysophosphatidylglycerol, lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine, M&B22948, Malix, manidipine, manumycin, maraviroc, Matrine, MCYST-LR, Me-nle-asp-phe-NH2, mead ethanolamide, MeAsO(OH)2, Mebumal, Mechlorethamine, Medroxyprogesterone 17-Acetate, Mefenamic Acid, Megalomicin, Melarsoprol, Melatol, meletin, melitten, meloxicam, Melphalan, Memantine, menadiol, Menhaden oil, menthofuran, Meperidine, Mephenytoin, mesalamine, Mesaton, Meth, methanandamide, methanethiosulfonate ethylammonium, Methimazole, methionyl-leucyl-phenylalanine, Methorphan, Methoxsalen, Methoxy-psoralen, methoxyamine, methoxychlor, methoxymorphinan, methyl chloroformate, Methyl glycine, Methyl paraben, methyl salicylate, methyl tryptophan, methyl-dopa, methyl-phosphorothioate, methyl-Pyridinium, methylamine, Methylamylnitrosamine, Methylene-tetrahydrofolate, methylenetetrahydrofolates, methylglyoxal, methylnaltrexone, methyloxidanyl, methylparaben, methylphosphate, Methylprednisolone, methylxanthines, Metoclopramide, Metopiron, Metribolone, mevalonic acid, micafungin, miconazole, Mictonorm, Midazolam, Mifepristone, MIII, Milrinone, Mimosine, mirtazapine, Mit-C, mithramycin, MitoTracker-Red, Mitoxantrone, mizolastine, MLN8054, mofarotene, Monensin, mono-N-demethyladinazolam, mono(2-ethylhexyl) phthalate, monoethylglycinexylidide, monomethylarsonic acid, monoterpenes, monuron, MORIN, morpholine, morusin, motexafin gadolinium, Motuporin, moxifloxacin, MPEG, Muraglitazar, mutalipocin II, mycophenolic acid, Mycose, Myocol, myricetin, myxothiazol, N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide, N-(2-hydroxypropyl)methacrylamide, N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide, N-(3-methoxyphenyl)-4-chlorocinnamanilide, N-(3-oxododecanoyl)homoserine lactone, N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo(d)thiazol-2-yl)acetamide, N-(4-(6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy)benzothiazol-2-yl)acetamide, N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine, N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide, N-acetylcysteine lysinate, n-acetylmuramyl-1-alanyl-d-isoglutamine, N-acetylneuraminic acid, N-desmethylclobazam, N-ethylmaleimide, N-methyl-N-(trimethylsilyl)trifluoroacetamide, N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide, N-oleoyldopamine, N-phenyl-1-naphthylamine, N,N,N′,N′-tetramethylethylenediamine, N(6)-cyclohexyl-2-O-methyladenosine, N(6)-cyclopentyladenosine, N3-IQ, Nadroparin, naftifine, nal-NH2, NALS, nanchangmycin, Naproxen, naratriptan, narbonolide, NARIGENIN, Narkotil, Nasol, natalizumab, nateglinide, Naxy, nebivolol, Nefazodone, nefiracetam, Nelfinavir, Neomycin, Neopterin, Neostigmine, Neut, Nevirapine, NFBA, Nialk, Nicardipine, Niflumic Acid, nimesulide, niobium, nitecapone, nitroanilide, nitroaspirin, Nitrofurans, NITROPYRENE, nitrosamines, Nitrosoanabasine, Nitrosocysteine, nitrosulindac, Nizatidine, NK 104, NK314, NMDA, NN 703, Noan, Nobiletin, NOC 18, Nocodazole, nodularin, Nodularin v, nolatrexed, Nonoxynol, noralfentanil, norbuprenorphine, Norclozapine, Nordihydroguaiaretic Acid, Norethindrone, noreximide, norfluoxetine, Norgestrel, norharman, norketobemidone, norlaudanosoline, normeperidine, Nortilidine, norverapamil, novobiocin, NS-187, NSC 23766, NSC 366140, NSC 663284, NSC-134754, NU2058, number-one, nutlin 3, NVP-AEW541, Nylon, O-(chloroacetylcarbamoyl)fumagillol, O-desethylreboxetine, O-Due, o-quinone, obovatol, OCDD, octanediol, Octoxynol, Octreotide, Okadaic Acid, olanzapine, olefins, oleoylethanolamide, olmelin, olmesartan, olomoucine, olomoucine II, Oltipraz, omalizumab, omega-agatoxin, omega-Conotoxin GVIA, omega-N-Methylarginine, Omeprazole, omeprazole sulfone, onapristone, ONCB, Ondansetron, ON04819, Optef, OR 1246, oroxylin A, Orphenadrine, Osten, osteum, OSU 03012, Ouabain, OVEX, Ovex, oxaliplatin, Oxarol, oxaspirodion, oxatomide, Oxazepam, oxcarbazepine, Oxotremorine, oxotremorine M, Oxymorphone, Oxyntomodulin, Oxytrol, p-ABA, p-XSC, p-Xylol, Paclitaxel, paeonol, palladium, palmitoleate, PALMITOYL, Palmitoylcarnitine, pamidronate, panaxadiol, panepoxydone, pantoprazole, Papaverine, Papite, PAPP, parecoxib, Paroxetine, Parsal, Parthenolide, PC 314, PCA 4230, PCSO, PD 134308, PD 144795, PD 180988, PD 98059, pectin, Pemetrexed, Penicillins, Penite, Pentagastrin, Pentoxifylline, Peplomycin, peppermint oil, Pepstatin A, Perazine, Pergolide, Perillol, Perilymph, periodate, perospirone, perovskite, PFPA, Phebestin, phen, phenolate, Phenols, phenoxodiol, Phenprocoumon, Phentermine, phenyl-propionamide, phenyl-Pyridinium, Phenytoin, pheophorbide a, phloretin, PHOB, phorate, phorbol, phorbol 12-phenylacetate 13-acetate 20-homovanillate, phosphatidylethanolamines, Phosphatidylinositol 4,5-Diphosphate, phosphatidylinositol phosphate, PtdIns(4,5)P2, phytanic acid, Picibanil, picric acid, pifithrin, Pilot, pimecrolimus, pioglitazone, pipecoloxylidide, piperidine, piperine, Pira, pirinixic acid, Piroxicam, PKC412, plumbagin, Pluronic p 85, PMDT, PMPA, PMSF, PNPP, Podophyllotoxin, polidocanol, poly-gamma-glutamate, ponicidin, poractant alfa, posaconazole, potassium tellurate(IV), PQQ Cofactor, pranlukast, Pravastatin, Prazosin, PRDL, Precursor mrna, Prednisone, pregnane, Pregnanes, Pregnanolone, pregnenolone 16alpha-carbonitrile, Pregnyl, preussin, Primidone, Proadifen, Proanthocyanidins, Probenecid, Probucol, Procasil, Procetofen, procyanidin B2, Prodix, prolactin, polymeric, Propafenone, Propanesulfonate, Propofol, propyl pyrazole triol, propyne, prostratin, protopanaxadiol, protopanaxatriol, PS 15, Pseudohypericin, Pseudomonas-exotoxin, Psoralens, psychosine-3′-sulfate ester, PTBP, pteridine, Pterostilbene, PURAC, Puromycin, putrescine, Pyocyanine, Pyra, pyranones, pyrazole, Pyrethrins, pyridazine, Pyrimethamine, pyrimidin-2-one beta-ribofuranoside, Pyro, pyrogallol sulfonphthalein, pyrrole-2-carboxylic acid, pyrrolidine dithiocarbamic acid, pyrroloazepinone, Qingkailing, quercitrin, quetiapine, Quicifal, quinazoline, Quinolinium, Quinpirole, quinuclidin-3′-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate, quinupristin-dalfopristin, R-138727, R-99224, Raloxifene, raltitrexed, Ramipril, ramiprilat, RAMP, Ranitidine, RAPA, rasagiline, rebamipide, reboxetine, remifentanil, renzapride, repaglinide, Resiniferotoxin, resiquimod, Retardex, Riacon, Ribavirin, Riboflavin, Rifabutin, rifamycins, Rifocin, rimonabant, risedronic acid, risperidone, Ristocetin, Ritonavir, rituximab, Ro 13-8996, Ro 23-7553, Ro 23-7637, Ro 24-7429, Ro 31-6233, Ro 31-7549, Ro 31-8220, R04383596, Robitet, rofecoxib, roflumilast, rokitamycin, Rolipram, romidepsin, rooperol, ropivacaine, roscovitine, rosiglitazone, rosmarinic acid, rosuvastatin, Roxithromycin, Rozevin, RPR 121056, RU 58668, ruboxistaurin, rugosin E, rutecarpine, Rutin, S-(beta-p-methoxypropiophenone)thiamine, S-Nitroso-N-Acetylpenicillamine, S-Nitrosothiols, S-phenyl-N-acetylcysteine, sabarubicin, sabcomeline, Safingol, Safrole, SAGA, SAHA, saikosaponin, Salicin, salvin, samarium, SAMe, sanguinarine, sapogenins, Saquinavir, Sarasar, Sarna, sauchinone, saxatilin, SB 218078, SB 225002, SB 415286, SB-705498, scandium, SCH 66712, schizandrer A, scoparone, Scopoletin, Score, SDX 308, Selegiline, seocalcitol, Sep-Pak, Serad, sertindole, sevoflurane, SEW2871, shikonin, siderophore, Sildenafil, silvestrol, silybin, Sincalide, Sizofiran, SK-7041, SK&F 106528, SM 7368, Sodium pentosan poly sulfate, Sodium Salicylate, sorafenib, sorbinil, Sorbo, Sorbose, spiroglumide, Spironolactone, squamocin, SR 144528, SR 27897, SR 48692, SR 80327A, SR 90107A-ORG 31540, ST 638, stallimycin, Stanozolol, staurosporine, Stearin, Stereoisomerism, Steviol, Stevioside, STIL, stilbene-disulphonate, Stilbenes, Stim, Streptomycin, Styrene, styrene-methylmethacrylate copolymer, SU 5416, SU 6668, SU 9516, suberate, suberosin, succinic semialdehyde, Sufentanil, Suldox, sulfadoxine-pyrimethamine, Sulfamethazine, sulfamethoxazole hydroxylamine, Sulfaphenazole, Sulfasalazine, sulfate cellufine, sulfate-sulfate, sulfidonitrogen(.), Sulfinpyrazone, sulfo-N-succinimidyl oleate, sulfo-succinimidyl-oleate, sulfogalactosylglycerolipid, sulfones, sulfonic acid, sulfonyl-phenyl-ethyl, Sulforafan, Sulindac, sulindac sulfone, sultopride, sunitinib, Synthos, T 0070907, T 0901317, Tacrine, Tacrolimus, tadalafil, Tamogel, Tamoxifen, tandospirone, Tangeretin, tanshinone, taurocholic acid, Taurodeoxycholic Acid, tauroursodeoxycholic acid, tautomycetin, TAXOTERE, TBDZ, TBHQ, TCAT, technetium, Tegafur, Teleocidin, telithromycin, Temazepam, temozolomide, temsirolimus, terbinafine, terephthalic acid, Terfenadine, teriflunomide, terrein, territrem A, territrem B, territrem C, tertiapin, tetra-mu3-sulfido-tetrairon, tetrachloroethene, tetradecanoyl-phorbol-acetate, Tetrahydrocannabinol, tetramethylrhodamine, tetramethylsilane, tetraphene, Tetraprenol, tetrasulfanide, Thalidomide, Thapsigargin, thiamine disulfide, thiazole, Thiazolidinediones, thioacetamide, Thioacetazone, thiobenzamide, thiocoraline, Thiole, Thiopental, thioredoxin dithiol, thioridazine, Thiostrepton, thrombin receptor peptide SFLLRNP, thrombin Tokushima, Thromboxane A2, thromboxane B2, Thyminose, thymol, thymoquinone, Thyrotropin, Ticlopidine, Tilidine, tipranavir, tirilazad, titanium alloy (TiA16V4), TMC-95A, Tmndga, TMSI, Tobrex, tocotrienols, tofisopam, tolrestat, Tolterodine, toluene, TOLUENE-DITHIOL, topiramate, Topotecan, Toremifene, Tosylarginine Methyl Ester, Tosyllysine Chloromethyl Ketone, Tosylphenylalanyl Chloromethyl Ketone, TPN+, Tracer, Tramadol, trans-resveratrol, trastuzumab, Trazodone, Tremode, Tremorine, Tretinoin, Triad, Triamcinolone, triazolam, triazoles, tributylstannane, trichostatins, Triclosan, triethylamine, Trifluoperazine, trimethylaminocarboxyldihydroboran, trioctyl phosphine oxide, Triolein, tripterine, triptolide, triterpenoids, troglitazone, Troleandomycin, TTNPB, tubocapsanolide A, Tunicamycin, tyrphostin AG 1478, tyrphostin AG-490, tyrphostin AG17, U 0126, Ubizol, Ufur, UK 157147, Uprima, uranyl acetate, urethane, Urex, urinastatin, Urso, USAN, valerenic acid, valspodar, venlafaxine, Verapamil, verlukast, vesnarinone, Viagra, Vigil, vincristine, vinflunine, vinorelbine, vinpocetine, violacein, Vira-A, voriconazole, vorozole, VX680, Warfarin, WAY-169916, Win 55212-2, withaferin A, WLN: QR BG, WLN: RVR, WLN: ZSWR, xanthohumol, Xaxa, Xylit, Y 27632, yristate, Z 338, zafirlukast, Zalcitabine, zardaverine, ZD 9331, Zearalenone, Zeldox, zerumbone, Zidovudine, zileuton, Zocor, zopiclone, Zymosan, Trospium chloride, Valproic Acid. These compounds interact with newly identified key regulators of pain sensation and nociception. Mechanistically the inventive treatments involve the modulation of the genes and gene function or interaction with the gene products, in particular proteins, of the genes listed in table 1 or the human orthologues of the Drosophila genes described in Neely et al., 2010, or preferably the human genes listed in table 1.
According to the investigation described herein it was found that these compounds modify at least one gene or gene product thereof selected from the CACNA2D3 (gene for calcium channel subunit alpha-2-delta-3), PIK3CG, or any one of the human genes of table 1, column 2, or any of the human orthologues of the Drosophila genes described in Neely et al., 2010, or any drosophila gene of table 1 column 3, in particular preferred any one of CG10033, CG10095, CG10142, CG10153, CG10158, CG10186, CG10186, CG10228, CG10265, CG1031, CG10332, CG10332, CG10481, CG10537, CG10550, CG1058, CG10583, CG10603, CG10603, CG10612, CG10641, CG10667, CG10686, CG10689, CG10689, CG10691, CG10706, CG10711, CG10728, CG10746, CG10800, CG10823, CG1086, CG10882, CG10932, CG10936, CG10954, CG10988, CG1100, CG1100, CG1101, CG11033, CG11081, CG11183, CG1119, CG11280, CG1130, CG11352, CG11456, CG11508, CG1152, CG11555, CG11577, CG11586, CG11590, CG11592, CG11594, CG11637, CG11637, CG11638, CG11642, CG11715, CG1180, CG1180, CG11820, CG11857, CG11865, CG11878, CG11893, CG11895, CG1193, CG11930, CG11942, CG11967, CG11992, CG12004, CG12030, CG12035, CG12052, CG12079, CG12082, CG12093, CG12131, CG12135, CG12199, CG12209, CG12235, CG12269, CG12290, CG12334, CG12373, CG12559, CG12637, CG1264, CG12641, CG12641, CG12645, CG12663, CG12749, CG12796, CG12797, CG12831, CG12878, CG12932, CG12938, CG12954, CG12975, CG13035, CG13047, CG13061, CG13069, CG13074, CG13096, CG13110, CG13130, CG13130, CG13162, CG13194, CG13196, CG13196, CG13243, CG13308, CG13319, CG13403, CG13559, CG13575, CG13623, CG1371, CG1387, CG13998, CG14028, CG1406, CG14065, CG14086, CG14214, CG14217, CG14240, CG14252, CG14274, CG14351, CG14362, CG14374, CG14374, CG14376, CG14506, CG14514, CG14590, CG14659, CG14710, CG14750, CG14755, CG14804, CG14818, CG14940, CG14952, CG14980, CG15059, CG15120, CG15153, CG15167, CG15254, CG15307, CG15321, CG15324, CG15427, CG15570, CG15604, CG15604, CG15884, CG16778, CG1683, CG16840, CG16852, CG16854, CG16873, CG16899, CG16932, CG16975, CG17003, CG17027, CG1709, CG17137, CG17146, CG17150, CG17189, CG17234, CG1725, CG17255, CG17266, CG17293, CG17295, CG17521, CG1759, CG17612, CG17673, CG17697, CG17943, CG1800, CG1804, CG18069, CG18088, CG18130, CG18249, CG18332, CG18332, CG18350, CG18350, CG18350, CG18350, CG18372, CG1845, CG18480, CG18624, CG18624, CG18666, CG1915, CG1921, CG1921, CG1966, CG1968, CG1982, CG2038, CG2060, CG2079, CG2100, CG2109, CG2128, CG2158, CG2161, CG2257, CG2257, CG2286, CG2346, CG2371, CG2371, CG2503, CG2522, CG2747, CG2848, CG2848, CG2872, CG2872, CG2901, CG3000, CG30004, CG30004, CG30005, CG30039, CG30050, CG30073, CG30291, CG30342, CG30383, CG30384, CG30404, CG3083, CG3105, CG31065, CG31068, CG31110, CG31267, CG31299, CG31300, CG31623, CG31713, CG31716, CG31718, CG3181, CG3184, CG31841, CG31842, CG31876, CG31886, CG31908, CG31936, CG31955, CG31962, CG32016, CG32025, CG32045, CG32057, CG32121, CG3213, CG32148, CG32150, CG32176, CG32193, CG32219, CG32227, CG3224, CG32278, CG32296, CG32296, CG32313, CG32333, CG32346, CG3241, CG32531, CG32533, CG32540, CG32604, CG32614, CG32678, CG32678, CG32678, CG32678, CG3269, CG32698, CG3270, CG32703, CG32736, CG32779, CG32779, CG32779, CG32792, CG3291, CG3295, CG3298, CG33002, CG33106, CG33106, CG33106, CG33106, CG33106, CG33106, CG33128, CG33135, CG33147, CG33149, CG33166, CG33202, CG33261, CG33275, CG33275, CG3330, CG33346, CG33350, CG3344, CG33484, CG33500, CG33500, CG3351, CG33512, CG33512, CG33530, CG33547, CG33547, CG33653, CG33980, CG34059, CG34140, CG34140, CG34159, CG3421, CG34339, CG34341, CG34364, CG34383, CG34400, CG34401, CG34401, CG34416, CG3474, CG3520, CG3569, CG3581, CG3604, CG3613, CG3619, CG3619, CG3619, CG3707, CG3711, CG3717, CG3735, CG3905, CG3943, CG3949, CG3955, CG3981, CG4013, CG4040, CG4083, CG4094, CG4109, CG4217, CG42250, CG4247, CG4247, CG4260, CG4279, CG4279, CG4351, CG4365, CG4396, CG4459, CG4477, CG4502, CG4550, CG4560, CG4584, CG4587, CG4612, CG4633, CG4633, CG4648, CG4655, CG4673, CG4692, CG4698, CG4742, CG4775, CG4795, CG4798, CG4799, CG4806, CG4807, CG4830, CG4875, CG4875, CG4887, CG4946, CG4975, CG4977, CG5003, CG5012, CG5012, CG5013, CG5014, CG5014, CG5121, CG5134, CG5160, CG5179, CG5183, CG5198, CG5201, CG5219, CG5219, CG5261, CG5287, CG5330, CG5405, CG5411, CG5473, CG5499, CG5516, CG5519, CG5565, CG5580, CG5611, CG5643, CG5644, CG5703, CG5723, CG5725, CG5725, CG5727, CG5757, CG5788, CG5800, CG5818, CG5819, CG5821, CG5842, CG5884, CG5889, CG5890, CG5902, CG5934, CG5940, CG5949, CG5969, CG5977, CG5986, CG6006, CG6098, CG6136, CG6143, CG6177, CG6210, CG6249, CG6340, CG6395, CG6457, CG6496, CG6536, CG6549, CG6553, CG6571, CG6575, CG6582, CG6583, CG6605, CG6620, CG6637, CG6673, CG6703, CG6721, CG6724, CG6822, CG6824, CG6930, CG6930, CG6946, CG6948, CG6963, CG6971, CG6971, CG6972, CG6987, CG6998, CG7006, CG7007, CG7007, CG7010, CG7015, CG7025, CG7059, CG7081, CG7099, CG7100, CG7109, CG7129, CG7145, CG7160, CG7175, CG7175, CG7187, CG7194, CG7211, CG7223, CG7225, CG7292, CG7311, CG7342, CG7358, CG7371, CG7376, CG7422, CG7430, CG7443, CG7467, CG7494, CG7494, CG7497, CG7507, CG7556, CG7583, CG7636, CG7664, CG7708, CG7708, CG7712, CG7728, CG7730, CG7800, CG7800, CG7811, CG7816, CG7856, CG7873, CG7946, CG7957, CG8005, CG8008, CG8009, CG8014, CG8014, CG8029, CG8039, CG8048, CG8107, CG8110, CG8114, CG8203, CG8233, CG8288, CG8325, CG8326, CG8394, CG8432, CG8436, CG8440, CG8487, CG8520, CG8625, CG8631, CG8651, CG8732, CG8764, CG8849, CG8912, CG8914, CG8985, CG8985, CG9022, CG9022, CG9032, CG9067, CG9102, CG9160, CG9172, CG9231, CG9280, CG9311, CG9323, CG9350, CG9388, CG9447, CG9453, CG9460, CG9519, CG9537, CG9548, CG9603, CG9636, CG9636, CG9650, CG9696, CG9739, CG9742, CG9753, CG9753, CG9825, CG9825, CG9901, CG9901, CG9948, as well as their orthologues, in particular human orthologues. Furthermore preferred genes (or gene targets) for the inventive treatment are selected from CG10882, CG10033, CG10095, CG10096, CG10096, CG10098, CG10142, CG10153, CG10158, CG10186, CG10186, CG10200, CG10228, CG1031, CG10315, CG10332, CG10332, CG10481, CG10540, CG10550, CG1058, CG10583, CG10603, CG10603, CG10612, CG10641, CG10667, CG10689, CG10691, CG10711, CG10728, CG10746, CG10754, CG10800, CG10823, CG1086, CG10872, CG10932, CG10936, CG10954, CG10988, CG10992, CG1100, CG1100, CG1101, CG11033, CG11081, CG11081, CG11183, CG1119, CG11280, CG11339, CG11419, CG11456, CG11508, CG11512, CG1152, CG11555, CG11577, CG11586, CG11590, CG11592, CG11637, CG11637, CG11638, CG11715, CG1180, CG1180, CG11820, CG11857, CG11865, CG11878, CG11893, CG11895, CG1193, CG11942, CG11953, CG11967, CG11992, CG12004, CG12030, CG12035, CG12079, CG12082, CG12082, CG12083, CG12131, CG12135, CG12209, CG12235, CG12334, CG12373, CG12532, CG12637, CG12645, CG12663, CG12785, CG12796, CG12797, CG12831, CG12915, CG12927, CG12932, CG12938, CG12954, CG12975, CG13035, CG13047, CG13069, CG13074, CG13096, CG13110, CG13162, CG13196, CG13243, CG13308, CG13319, CG13388, CG13403, CG13534, CG13548, CG13623, CG1371, CG1375, CG13777, CG13788, CG13802, CG13802, CG1387, CG13922, CG13998, CG14028, CG1406, CG14075, CG14086, CG14198, CG14214, CG14217, CG14240, CG14252, CG14255, CG14274, CG14351, CG14353, CG14365, CG14374, CG14374, CG14376, CG14429, CG14442, CG14506, CG14514, CG14707, CG14707, CG14750, CG14804, CG14818, CG14940, CG14980, CG15071, CG15120, CG15167, CG15238, CG15241, CG15254, CG15321, CG15324, CG15427, CG15433, CG15570, CG15604, CG15604, CG15884, CG16725, CG16775, CG16778, CG16852, CG16854, CG16873, CG16899, CG16932, CG17003, CG17027, CG1709, CG17137, CG17146, CG17150, CG17189, CG17203, CG17234, CG1725, CG17266, CG17293, CG17295, CG17386, CG17521, CG17650, CG17673, CG17697, CG17943, CG1800, CG18026, CG1804, CG18069, CG18088, CG18130, CG18213, CG18249, CG18332, CG18332, CG18350, CG18350, CG18350, CG18350, CG18372, CG1847, CG18480, CG18557, CG18624, CG18624, CG18666, CG18671, CG18671, CG18771, CG18816, CG18816, CG18833, CG1915, CG1922, CG1966, CG1968, CG1982, CG2038, CG2052, CG2060, CG2100, CG2109, CG2128, CG2151, CG2158, CG2161, CG2257, CG2257, CG2286, CG2309, CG2346, CG2371, CG2371, CG2503, CG2522, CG2685, CG2698, CG2713, CG2747, CG2848, CG2848, CG2848, CG2872, CG2872, CG3000, CG30005, CG30025, CG30025, CG30025, CG30025, CG30039, CG30050, CG30073, CG30113, CG30186, CG30291, CG30352, CG30383, CG30384, CG30404, CG30427, CG30474, CG3083, CG3105, CG31065, CG31067, CG31067, CG31068, CG31103, CG31110, CG31170, CG31183, CG31267, CG31299, CG31300, CG31309, CG31364, CG31406, CG31623, CG31654, CG31713, CG31718, CG3181, CG3184, CG31841, CG31842, CG31876, CG31893, CG31908, CG31936, CG31955, CG31962, CG32006, CG32016, CG32025, CG32057, CG3213, CG32131, CG32148, CG32150, CG32176, CG32219, CG32227, CG3224, CG32278, CG32283, CG32313, CG32333, CG32381, CG3240, CG3240, CG3241, CG32467, CG32478, CG32531, CG32614, CG32678, CG32678, CG32678, CG32678, CG3269, CG32779, CG32792, CG3291, CG3298, CG33002, CG3330, CG33346, CG3344, CG33530, CG3421, CG3520, CG3581, CG3604, CG3612, CG3613, CG3619, CG3619, CG3707, CG3711, CG3717, CG3717, CG3733, CG3735, CG3905, CG3943, CG3949, CG3955, CG3955, CG3981, CG3996, CG4073, CG4083, CG4109, CG4110, CG4217, CG4247, CG4247, CG4279, CG4279, CG4351, CG4365, CG4396, CG4453, CG4459, CG4477, CG4550, CG4560, CG4581, CG4584, CG4587, CG4609, CG4612, CG4633, CG4633, CG4648, CG4655, CG4673, CG4698, CG4742, CG4772, CG4775, CG4795, CG4798, CG4799, CG4806, CG4830, CG4863, CG4875, CG4887, CG4946, CG4975, CG4977, CG4994, CG5003, CG5012, CG5012, CG5013, CG5014, CG5014, CG5121, CG5160, CG5179, CG5183, CG5198, CG5201, CG5219, CG5219, CG5254, CG5261, CG5287, CG5330, CG5380, CG5411, CG5473, CG5499, CG5507, CG5516, CG5519, CG5541, CG5565, CG5580, CG5611, CG5625, CG5643, CG5644, CG5703, CG5711, CG5714, CG5723, CG5725, CG5725, CG5727, CG5751, CG5757, CG5788, CG5818, CG5819, CG5820, CG5821, CG5842, CG5884, CG5889, CG5890, CG5902, CG5934, CG5940, CG5949, CG5969, CG5977, CG5986, CG5989, CG6006, CG6006, CG6027, CG6066, CG6098, CG6136, CG6143, CG6177, CG6210, CG6249, CG6294, CG6340, CG6375, CG6457, CG6496, CG6553, CG6571, CG6582, CG6583, CG6605, CG6620, CG6637, CG6673, CG6703, CG6721, CG6724, CG6822, CG6852, CG6881, CG6901, CG6930, CG6930, CG6946, CG6948, CG6963, CG6971, CG6971, CG6972, CG6987, CG6998, CG7006, CG7007, CG7007, CG7010, CG7015, CG7042, CG7042, CG7059, CG7100, CG7109, CG7129, CG7145, CG7160, CG7172, CG7175, CG7175, CG7187, CG7194, CG7211, CG7223, CG7225, CG7307, CG7311, CG7342, CG7358, CG7371, CG7376, CG7422, CG7430, CG7436, CG7443, CG7462, CG7467, CG7494, CG7494, CG7513, CG7520, CG7556, CG7580, CG7583, CG7636, CG7664, CG7693, CG7708, CG7708, CG7712, CG7726, CG7728, CG7730, CG7778, CG7800, CG7800, CG7811, CG7816, CG7856, CG7873, CG7946, CG7957, CG8005, CG8008, CG8009, CG8014, CG8014, CG8029, CG8039, CG8039, CG8048, CG8107, CG8110, CG8114, CG8137, CG8203, CG8233, CG8288, CG8325, CG8326, CG8394, CG8432, CG8436, CG8440, CG8487, CG8520, CG8625, CG8631, CG8651, CG8663, CG8732, CG8764, CG8771, CG8849, CG8912, CG8914, CG9022, CG9022, CG9032, CG9067, CG9102, CG9160, CG9172, CG9231, CG9280, CG9288, CG9305, CG9311, CG9323, CG9343, CG9350, CG9388, CG9447, CG9453, CG9460, CG9519, CG9548, CG9588, CG9603, CG9633, CG9636, CG9636, CG9650, CG9678, CG9696, CG9696, CG9720, CG9742, CG9753, CG9753, CG9825, CG9825, CG9901, CG9901, CG9948, CG9948, CG9983, as well as their orthologues, in particular human orthologues (such as described in Neely et al., 2010, incorporated herein by reference). These genes are referred herein as “pain genes”. Preferred genes are selected from CG10095, CG10096, CG10098, CG10158, CG10481, CG11033, CG11456, CG11577, CG11586, CG11590, CG11592, CG11820, CG11967, CG12004, CG12334, CG12785, CG12797, CG13096, CG13162, CG13623, CG1371, CG14351, CG14442, CG14514, CG14980, CG16725, CG16854, CG1804, CG18088, CG18130, CG18213, CG18249, CG18480, CG1968, CG2052, CG2747, CG30005, CG31103, CG31267, CG31955, CG3213, CG32150, CG3224, CG32792, CG33346, CG3996, CG4110, CG4351, CG4477, CG4946, CG5516, CG5565, CG5819, CG5969, CG5986, CG6136, CG6294, CG6340, CG6553, CG6583, CG6637, CG6724, CG6852, CG6901, CG7006, CG7042, CG7175, CG7358, CG7376, CG7556, CG7728, CG7800, CG8233, CG8325, CG8436, CG8771, CG9067, CG9288, CG9636, CG9650. These genes, as well as their orthologue counterparts, in particular human orthologs (Neely et al., 2010), or their respective gene products are preferred targets for therapy according to the present invention. According to the present invention function of at least one of these genes is modified by the inventive compounds, in particular the small molecules given in table 1. In preferred embodiments the compound modulates at least two, three, four, five or six or more of these genes (or orthologues). Further compounds suitable to modulate gene function include the administration of therapeutic proteins or nucleic acids, such as transgenes or inhibitory nucleic acids (RNAi molecules, siRNA, antisense RNA or DNA). Such interfering nucleic acids bind messages of the genes leading to degradation and reduced gene expression. Preferred therapeutic proteins include the gene products of these genes (as agonists) or antibodies which specifically bind these proteins (as antagonists, but also as agonists if protein activity is increased—such as by binding and blocking an inhibitor binding site). The inventive compounds can act as either agonist by increasing the gene function (via mRNA regulation or interaction with the protein) of a protein in the enzymatic pathway of any one of the above listed genes or an antagonist in said pathways. The antagonizing or activating (agonist) activity of the compounds acts preferably on the identified pain genes (including their gene product) themselves or on a binding partner thereof. With the inventive methods it is possible to suppress pain or, alternatively to increase pain, e.g. to treat hyposensitivities. Depending on the goal an antagonist or agonist of the gene targets may be used. In preferred embodiments antagonists of the pain genes are used.
The subject to be treated according to the present invention can be any non-human animal or a human. Preferably the subject is a mammal, in particular preferred embodiments a human.
According to the present invention pain and conditions associated with pain, e.g. itching or depression, can be treated or prevented, in particular in the meaning of a prophylactic administration. “Preventing” or “prevention” herein does not require absolute success in the sense of an absolute prevention of pain but indicates a reduced risk of developing a disease or painful condition, or developing pain with reduced severity. Likewise, “treatment” shall not be construed as an absolute cure, but may also relate to amelioration or suppression of pain or pain associated conditions.
Pain and pain associated conditions and diseases to be treated according to the present invention can include acute pain, chronic pain, somatogenic pain, neuropathic pain, psychogenic pain, heat induced pain, physical pain and nociception in general, or hyperalgesia. In particular embodiments the pain is selected from neuropathic pain, inflammatory pain, nociceptive pain, rheumatic pain, headache, low back pain, pelvic pain, myofascial pain, vascular pain, migraine, wound associated pain, inflammatory pain, arthritic pain, diabetic pain, pain from cancer or somatic visceral pain, all in both acute and chronic forms. The pain can also be related to phantom pain, pain from a part of the body that has been lost or from which the brain no longer receives physical signals.
Pain can be generally classified to two broad categories, acute and chronic. The treatment of any acute or chronic pain is subject matter of the present invention. Acute pain is usually associated with a specific cause such as a specific injury and is often sharp and severe. Acute pain begins suddenly and is not persistent. Chronic pain is long-term pain, with a typical duration of more than three months leading to significant psychological and emotional problems. Chronic pain is generally associated with clinical conditions characterised by chronic and/or degenerative lesions. Common examples of chronic pain are neuropathic pain (e.g. painful diabetic neuropathy, post-herpetic neuralgia), rheumatoid arthritis, osteoarthritis, fibromyalgia, back pain, headache, carpal tunnel syndrome, cancer pain, and chronic post-surgical pain. Pain can also be divided into a number of different subtypes according to differing pathophysiology, including nociceptive, inflammatory and neuropathic pain. Also some types of pain can be classified in multiple categories, for example pain associated with cancer can have a nociceptive and neuropathic component. Nociceptive pain consists of somatic pain (musculo-skeletal pain) and visceral pain (pain associated with the viscera, which encompass the organs of the abdominal cavity). Common causes of somatic pain include cancer metastasis such as to the bone and postsurgical pain from a surgical incision in addition to musculo-skeletal disorders such as dystrophinopathy, myalgia and polymyositis. Nociceptive pain also includes tissue injury-induced pain and inflammatory pain such as that associated with arthritis. Another type of inflammatory pain is visceral pain which includes pain associated with gastrointestinal disorders (GI) such as functional bowel disorder (FBD) and inflammatory bowel disease (IBD). Further examples of visceral pain include the pain associated with dysmenorrhea, cystitis and pancreatis and pelvic pain. Additional pain types include dysfunctional pain such as fibromyalgia, Temporomandibular Joint Disorder (TMJ), Irritable bowel syndrome (IBS) and musculo-skeletal pain). Neuropathic pain is caused by damage to the peripheral or central nervous system. Examples of central neuropathic pain include pain from spinal cord injury, multiple sclerosis, strokes and fibromyalgia. Diabetes and related metabolic disorders are a common cause of peripheral neuropathic pain (diabetic neuropathy). Some of the human conditions and pathologies characterised by the presence of neuropathic pain include, but are not limited to, cancer (cancer neuropathy), HIV neuropathy, Parkinson's disease, epilepsy, immunodeficiency, post-herpetic syndromes, trauma, ischaemia, sciatica, multiple sclerosis, peripheral neuropathy, trigeminal neuralgia, back pain, phantom limb pain, carpal tunnel syndrome, central post-stroke pain and pain associated with chronic alcoholism, hypothyroidism, uraemia, spinal cord injury, and vitamin deficiency. Preferably the pain is neuropathic pain, such as trigeminal neuralgia, such as post-herpetic neuralgia, such as painful diabetic neuropathy, such as painful diabetic peripheral neuropathy, such as diabetic polyneuropathy, such as sciatic pain, such as radiculopathy, such as radicular pain or such as non-inflammatory neuropathic pain. Pain may be selected from fibromyalgia, postoperative pain, trigeminal neuralgia, post-herpetic neuralgia, painful diabetic neuropathy, painful diabetic peripheral neuropathy, diabetic polyneuropathy, sciatic pain, radiculopathy, radicular pain, lumbar pain. Preferably the pain is caused by the conditions as mentioned above related to the given pain type. In particular the pain type can be the only pain type in a subject. E.g. preferably a neuropathic pain is caused by affected nerves but not caused by inflammation, i.e. neuropathic pain is the only pain in the subject and is non-inflammatory.
“About” is used to refer to certain dosages that can vary from a given value, nevertheless with the same effects as the indicated dose. In some embodiments “about” may refer to +/−20% or 10% of a given value.
Preferably the compound is administered in a dosage sufficient to treat or prevent pain or associated conditions and diseases. Administration can e.g. be a singe dose administration or a successive or repeated administration, e.g. twice a day, daily or in an interval of at least 1 day, at least 2 days, at least 3 days, at least 1 week, preferably at least 2 weeks, at least 4 weeks, at least 8 weeks or even more preferred at least 12 weeks. Preventive administrations are usually a short time before expected pain, if controllable or foreseeable—such as in scheduled surgery—e.g. up to 1 hour (h), 2 h, 3 h, 4 h, 5 h, 6 h, 8 h, 10 h, 12 h or up to 24 h or even up to 48 h beforehand, as well as any interval in between.
According to a further preferred embodiment of the present invention, the compound is provided in a pharmaceutical composition or a medicament, in particular an analgesics. The composition or medicament may comprise a pharmaceutical carrier. Pharmaceutical carrier substances serve for a better tolerance of the medicament and allow for a better solubility as well as a better bioavailability of the active substances contained in the medicament. Examples of this are emulsifiers, thickening agents, redox components, starch, alcohol solutions, polyethylene glycol or lipids. The choice of a suitable pharmaceutical carrier is highly dependent on the manner of administration. For oral administrations, liquid or solid carriers may be used, for injections, liquid final compositions are required. For cellular targeting, such as for inhibitory nucleic acids, suitable vehicles can be included such as liposomes or microsomes.
Preferably, the medicament or the compound to be used according to the invention comprises buffer substances or tonic substances. By means of a buffer, the pH of the medicament can be adjusted to physiological conditions, and moreover, pH fluctuations can be attenuated, or buffered, respectively. An example thereof is a phosphate buffer. Tonic substances serve for adjusting the osmolarity and may comprise ionic substances, such as, e.g., inorganic salts, such as NaCl, or also non-ionic substances, such as, e.g. glycerol or carbohydrates.
The inventive compound or medicament can be administered topical, enteral or parenteral, in particular preferred oral or rectal, intravenous, intraarterial, intramuscular, subcutaneous, intradermal or intraperitoneal, transdermal, transmucosal or inhalational. Preferred routes of administration of the inventive agent according to the present invention are parenteral routes, preferably intraperitoneal or intravenous administration, intravenous administration being specifically preferred. Intravenous administration can be performed e.g. via bolus injection or by continuous intravenous delivery over a longer time period (e.g. 30 min to 6 h, especially 1 to 3 h). Further routes include oral or transdermal or subcutaneous routes. In particular preferred is oral administration. For digestible agents, such as active proteins, peptides or siRNA, parenteral routes are preferred.
The medicament or the compound to be used according to the invention can be prepared to be suitable for oral or intranasal administration. These administration forms of the medicament of the present invention allow for a rapid an uncomplicated uptake of the active substances via the mucous membranes. For a nasal intake, nose drops or nose sprays are suitable. For an oral administration, solid or liquid medicaments may, e.g., be taken directly or in a dissolved or diluted state, respectively.
The medicament or compound to be used according to the invention can be prepared for an intravenous, intra-arterial, intramuscular, intravascular, systemic, intraperitoneal or subcutaneous administration. For this purpose, e.g., injections or transfusions are suitable. Administrations directly into the bloodstream have the advantage that the active substances of the medicament will be distributed in the entire body and will quickly reach the target tissue or cells, in particular the peripheral nerves, spinal cord cells or brain cells.
The compound may be administered in a effective therapeutic dose. Effective doses are in the range of dosages known for the compounds for other, non-pain related administrations. In particular, for a specific use a dosage can be determined by a simple test using drosophila or mouse test systems. Further possible therapeutic doses of the compounds for the inventive treatment can be the same dosage disclosed or approved for other therapeutic uses for each of these compounds. Example dosages are at least 0.01 mg/kg, at least 0.1 mg/kg, at least 1 mg/kg, at least 10 mg/kg and/or up to 1 mg/kg, up to 10 mg/kg, up to 100 mg/kg, up to 1 g/kg, and any dosages in between. Preferred dosage ranges are between 0.01 mg/kg and 1 g/kg, preferably between 0.1 mg/kg and 100 mg/kg.
The examples show that the inventive pain tests revealed pharmaceutical compounds that are well known to be therapeutically applicable for the treatment of human conditions and diseases. The compounds may now also be used for the treatment of pain and pain associated secondary diseases. Of course the full list of compounds according to table 1 provides new therapeutic concepts.
The present invention also relates to a method of modulating the gene expression or gene function in a cell, wherein the gene is selected from one or more of the genes listed in table 1, in particular selected from the genes above, or an ortholog counterpart thereof, comprising administering a compound of table 1 to said cell. The cell can be a nerve cell, including pain or thermosensitive nerve cells, and/or preferably selected from spinal cord cells, brain cells or peripheral nerve cells. The cell can be of the “pain matrix” such as the thalamus, the S1 and S2 somatosensory cortex, the cingulum, amygdala, hypothalamus, or the motor cortex. The inventive administration be be for treatment, alleviation or prevention of pain or hyperalgesia in a subject.
In a further aspect the present invention relates to method of screening active compounds suitable for the treatment of pain comprising testing for modulation, including suppression or activation, preferably suppression, of gene activity of any one of the genes listed above or given in table 1. The test may comprise recombinantly expressing the gene product in a suitable host cell or cell lines, such as mammal cell lines, in particular CHO cells, contacting said cell or cell line with a candidate compound and detecting a deviation in gene function when compared to normal levels without contacting with the compound. Further tests compromising binding of the compound to the gene product (the expressed protein) and detecting binding events. Other tests include the use of animal models and testing the compounds for behavioural changes when exposed to pain, such tests are disclosed in the examples. Additional, information on optimal dosages can be obtained with these tests.
Drosophila Id
The inventive pharmaceutical compounds suitable for the treatment of pain are also known by the following synonyms, trade names and CAS designations:
(1S,2S)-2-(2-(N-((3-benzimidazol-2-yl)propyl)-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride, (1S,2S)-2-(2-(N-((3-benzimidazol-2-yl)propyl)-N-methylamino)ethyl)-6-fluoro-1,2,3,4-tetrahydro-1-isopropyl-2-naphtyl cyclopropanecarboxylate dihydrochloride, NNC 55-0396;
(5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine, (5-(2-methoxy-5-chloro-5-phenyl)furan-2-ylcarbonyl)guanidine, (5-(2-methoxy-5-chlorophenyl)furan-2-ylcarbonyl)guanidine, KR-32570;
(6S)-5,6,7,8-tetrahydrofolic acid, (6S)-5,6,7,8-TETRAHYDROFOLATE, (6S)-5,6,7,8-tetrahydrofolic acid, (6S)-5,6,7,8-tetrahydropteroylglutamate;
(T,G)-A-L, (2S)-2-amino-3-(4-hydroxyphenyl)propanoic acid; (2S)-2-aminopentanedioic acid;
(2S)-2-aminopropanoic acid; (2S)-2,6-diaminohexanoic acid, (2S)-2-aminoglutaric acid; (2S)-2-amino-3-(4-hydroxyphenyl)propionic acid; (2S)-2-aminopropionic acid; (2S)-2,6-diaminohexanoic acid, (L-Tyrosine-L-glutamic acid)-poly(DL-alanine)-poly(L-lysine);
1 alpha-hydroxyergocalciferol, 1 alpha-hydroxyergocalciferol, 1alpha(OH)2D2, 1alpha-hydroxyvitamin D2;
1-(1-cyclohexylethylamino)-4-phenylphthalazine, 1-(1-cyclohexylethylamino)-4-phenylphthalazine, MKC 963, MKC-963;
1-(2-methyl-4-methoxyphenyl)-4-((2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline, 1-(2-methyl-4-methoxyphenyl)-4-(2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline, 1-(4-methoxy-2-methylphenyl)-4-(2-hydroxyethyl)amino)-6-trifluoromethoxy-2,3-dihydropyrrolo(3,2-c)quinoline, KR 60436;
1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole, 1-(2,3-dichlorobenzoyl)-5-methoxy-2-methyl-(2-(mopholin-4-yl)ethyl)-1H-indole, GW405833;
1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-((5-(4-fluorophenyl)-3-pyridinyl)methyl)piperazine, 1-(2,3-dihydro-1,4-benzodioxin-5-yl)-4-((5-(4-fluorophenyl)-3-pyridinyl)methyl)piperazine, SLV 313, SLV-313;
1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione, 1-(6-((3-methoxyestra-1,3,5(10)-trien-17-yl)amino)hexyl)-1H-pyrrole-2,5-dione, U 73122, U-73,122;
1-adamantyl propargyl ether, 1-adamantyl propargyl ether, TAPE;
1-aminobenzotriazole, 1-aminobenzotriazole;
1-aminooxy-3-aminopropane, 1-aminooxy-3-aminopropane;
1-hydrazino-4-(3,5-dimethyl)-1-pyrazolyl-5H-pyridazino(4,5-b)indole, 1-hydrazino-4-(3,5-dimethyl)-1-pyrazolyl-5H-pyridazino(4,5-b)indole;
1-hydroxymethylmidazolam, 1-hydroxymethylmidazolam;
1-hydroxypyrene, 1-hydroxypyrene, 1-pyrenol;
1-Methyl-4-phenylpyridinium, 1 Methyl 4 phenylpyridine, 1 Methyl 4 phenylpyridinium, 1 Methyl 4 phenylpyridinium Chloride;
1-Nitropyren-8-ol, 1-Nitro-8-hydroxypyrene, 1-Nitropyren-8-ol, 1-Nitropyrene-8-ol;
1-phosphatidyl-1D-myo-inositol 3-phosphates, 1,2-Diacyl-sn-glycero-3-phospho-(1′-myo-inositol-3′-phosphate), 1-O-(3-sn-phosphatidyl)-1D-myo-inositol 3-(dihydrogen phosphate), 1-Phosphatidyl-1D-myo-inositol 3-phosphate;
1-stearoyl-2-oleoyl-sn-glycero-3-phosphocholine, 1-SOPC, 1-stearoyl-2-oleoyl lecithin, 1-stearoyl-2-oleoyl-sn-3-glycerophosphocholine;
1,1-bis(3′-indolyl)-1-(4-t-butylphenyl)methane, 1,1-bis(3′-indolyl)-1-(4-t-butylphenyl)methane, 1,1-bis(3′-indolyl)-1-(p-t-butylphenyl)methane, DIM-C-pPhtBu;
1,1-dimethylbutyl-1-deoxy-Delta(9)-THC, 1,1-dimethylbutyl-1-deoxy-Delta(9)-THC, JWH-133, JWH1333;
1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane, 1,1,1-trichloro-2-(4-hydroxyphenyl)-2-(4-methoxyphenyl)ethane, mono-OH-M;
1,2-bis(diphenylphosphino)ethane, 1,2-bis(diphenylphosphino)ethane, bis(diphenylphosphine)ethane, C(CP(c1ccccc1)c2ccccc2)P(c3ccccc3)c4ccccc4;
1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione, 1,2-di-(4-sulfamidophenyl)-4-butylpyrazolidine-3,5-dione;
1,2-diacyl-sn-glycero-3-phosphocholines, (3-sn-phosphatidyl)choline, 1,2-diacyl-sn-glycero-3-phosphocholine, 1,2-diacyl-sn-glycero-3-phosphocholines;
1,2-ethanedithiol, 1,2-ethanedithiol, 2-mercaptoethanol disulfide, BisEDT;
1,2-oleoylphosphatidylcholine, 1,2-dioleoyl glycerophosphocholine, 1,2-dioleoyl-sn-glycerol-3-ethylphosphocholine, 1,2-dioleoylglycerophosphocholine;
1,2,4-triazines, 1,2,4-triazines;
1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol, 1,25-dihydroxy-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol, 1alpha,25-dihydroxy-20S-21-(3-hydroxy-3-methylbutyl)-23-yne-26,27-hexafluorocholecalciferol, Ro 438-2582;
1,25-dihydroxyergocalciferol, 1 alpha,25-dihydroxyvitamin D2, 1,25-(OH)2D2, 1,25-dihydroxyergocalciferol;
1,25D3, (1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol, (1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol;
1,3-Dcg, (2-hydroxy-3-octanoyloxy-propyl) octanoate, (2-hydroxy-3-octanoyloxypropyl) octanoate, 1,3-Dcg;
1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole, 1,3-dihydroxy-4,4,5,5-tetramethyl-2-(4-carboxyphenyl)tetrahydroimidazole, 1,3-DTCTI, 2-(4-carboxyphenyl)-;
1,3-dipropyl-8-(3-noradamantyl)xanthine, 1,3-dipropyl-8-(3-noradamantyl)xanthine;
1,3,5-trimethylbenzene, 1,3,5-trimethylbenzene, 3,5-dimethyltoluene, Cc1cc(C)cc(C)c1;
1,7-dioxa-2,6-diaza-4,4-dioxide-4,7a-dithia-3H,5H-benzo(cd)pentalene, 1,7-dioxa-2,6-diaza-4,4-dioxide-4,7a-dithia-3H,5H-benzo(cd)pentalene, HEP-IV;
10-deoxymethynolide, 10-deoxymethynolide;
10-propargyl-10-deazaaminopterin, 10-propargyl-10-deazaaminopterin, pralatrexate;
10-undecynoic acid, 10-undecynoic acid;
10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone, 10,10-bis(4-pyridinylmethyl)-9(10H)-anthracenone, XE 991, anthracenone, XE-991;
11-cis-retinal, (2E,4Z,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenal, 11-cis-retinal, 11-cis-Retinene;
11-hydroxycannabinol, 11-hydroxycannabinol;
12-Hht, (5E,8E,10E)-12-hydroxyheptadeca-5,8,10-trienoic acid, 12-Hht, 12-hydroxy-5,8,10-heptadecatrienoic acid;
13-Lox, (9E,11E)-13-hydroxyoctadeca-9,11-dienoic acid, 13-Hodd, 13-Hode;
13-oxo-9,11-octadecadienoic acid, 13-oxo-9,11-octadecadienoic acid;
15 hete, (15 S)-15-Hydroxy-5,8,11-cis-13-trans-eicosatetraenoate, (15 S)-15-Hydroxy-5,8,11-cis-13-trans-icosatetraenoate, (15S,5Z,8Z,11Z,13E)-15-Hydroxyeicosatetraenoic acid;
15-Hydroxy-11 alpha,9 alpha-(epoxymethano)prosta-5,13-dienoic Acid, (15S)-Hydroxy-11 alpha, 9 alpha-(epoxymethano)prosta-5Z, 13E-dienoic Acid, (15S)hydroxy-9alpha,11alpha-(epoxymethano)prosta-5,13-dienoic acid, 11 alpha,9 alpha-Epoxymethano PGH2;
17-(allylamino)-17-demethoxygeldanamycin, 17-(allylamino)-17-demethoxy-geldanamycin, 17-(allylamino)-17-demethoxygeldanamycin, 17-AAG;
17alpha-ethynylestradiol, 17-Ethinyl-3,17-estradiol, 17-Ethinyl-3,17-oestradiol, 17-Ethinylestradiol;
1843U89, 1843U, 1843U89, 2-(5-(((1,2-dihydro-3-methyl-1-oxobenzo(f)quinazolin-9-yl)methyl)amino)-1-oxo-2-isoindolinyl)glutaric acid;
1D-myo-inositol 1,3,4,5-tetrakisphosphate, 1D-myo-inositol 1,3,4,5-tetrakis(dihydrogen phosphate), 1D-myo-inositol 1,3,4,5-tetrakisphosphate, D-myo-Inositol 1,3,4,5-tetrakisphosphate;
1H-indole, 1H-indole, 2,3-Benzopyrrole, c1 ccc2[nH]ccc2c1;
1H-pyrazolo(3,4-b)pyridine, 1H-pyrazolo(3,4-b)pyridine;
2 APB, ( )-2-Amino-4-phosphonobutyric acid, ( )-AP-4, 2 APB;
2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide, 2-(1-(3-dimethylaminopropyl)-5-methoxyindol-3-yl)-3-(1H-indol-3-yl)maleimide, Gö6983;
2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-3(2H)-pyridazinone, 2-(1-methyl-4-piperidinyl)-6-(2-phenylpyrazolo(1,5-a)pyridin-3-yl)-3(2H)-pyridazinone, FR194921;
2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone, 2-(2-hydroxyethylsulfanyl)-3-methyl-1,4-naphthoquinone, CPD 5, CPD-5;
2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile, 1-isopropyl-1-N-methylpropylamino-(3,4-dimethoxyphenyl)acetonitrile, 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile, 2-(3,4-dimethoxyphenyl)-5-amino-2-isopropylvaleronitrile hydrochloride;
2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole, 2-(4-amino-3-methylphenyl)-5-fluorobenzothiazole, 2-NMPh-FBzT, 5F-203;
2-(4-morpholinoanilino)-6-cyclohexylaminopurine, 2-(4-morpholinoanilino)-6-cyclohexylaminopurine, reversine;
2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one, LY 294002, LY-294002;
2-(4-toluidino)-6-naphthalenesulfonic acid, 2,6-TNS, 2-(4-toluidino)-6-naphthalenesulfonic acid, 2-(4-toluidino)-6-naphthalenesulfonic acid, monopotassium salt;
2-(cyclohexylmethylidenehydrazino)adenosine, 2-(cyclohexylmethylidenehydrazino)adenosine, Binodenoson, WRC 0470;
2-acetylthiomethyl-3-(4-methylbenzoyl)propionic acid, 2-acetylthiomethyl-3-(4-methylbenzoyl)propionic acid, esonarimod, KE 298;
2-AG, (5Z,8Z,11Z,14Z)-Eicosatetraenoic acid, 2-hydroxy-1-(hydroxymethyl)ethyl ester, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid (2-hydroxy-1-methylol-ethyl) ester, (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid [2-hydroxy-1-(hydroxymethyl)ethyl]ester;
2-amino-1-methyl-6-phenylimidazo (4,5-b)pyridine, 2-amino-1-methyl-6-phenylimidazo (4,5-b)pyridine;
2-amino-3,4-dimethylimidazo(4,5-f)quinoline, 2-amino-3,4-dimethylimidazo(4,5-f)quinoline;
2-aminoethoxydiphenyl borate, 2-aminoethoxydiphenyl borate, 2-APB compound, 2APB;
2-AP, 2-AP, 4H-1,3-Thiazin-2-amine, 5,6-dihydro-, monohydrobromide, 5,6-Dihydro-4H-1,3-thiazin-2-amine hydrobromide;
2-CADO, (2R,3R,4S,5R)-2-(6-amino-2-chloro-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-(6-amino-2-chloro-purin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, (2R,3R,4S,5R)-2-(6-amino-2-chloro-purin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;
2-chloro-5-nitrobenzanilide, 2-chloro-5-nitrobenzanilide, GW9662;
2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide, 2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynoic acid, FK 778;
2-cyanomethylthiopyridine-4-carbonitrile, 2-(cyanomethylsulfanyl)pyridine-4-carbonitrile, 2-(cyanomethylthio)isonicotinonitrile, 2-(cyanomethylthio)pyridine-4-carbonitrile;
2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole, 2-cyclopentyl-5-(5-isoquinolylsulfonyl)-6-nitro-1H-benzo(D)imidazole, compound-1;
2-DG, (2S,4R,5S,6R)-6-(hydroxymethyl)oxane-2,4,5-triol, (2S,4R,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,4,5-triol, (2S,4R,5S,6R)-6-methyloltetrahydropyran-2,4,5-triol;
2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid, 2-hydroxy-4-(2,2,3,3,3-pentafluoropropoxy)benzoic acid, UR 1505, UR-1505;
2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine, 2-hydroxyamino-1-methyl-6-phenylimidazo(4,5-b)pyridine;
2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline, 2-hydroxyamino-3-methylimidazolo(4,5-f)quinoline;
2-ME, (17beta)-2-Methoxyestra-1,3,5(10)-triene-3,17-diol, (8R,9S,13S,14S,17S)-2-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol, 1,3,5(10)-ESTRATRIEN-2,3,17-BETA-TRIOL 2-METHYL ETHER;
2-methoxyacetic acid [2-[2-[3-(1H-benzoimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl]ester, 2-methoxyacetic acid [2-[2-[3-(1H-benzoimidazol-2-yl)propyl-methyl-amino]ethyl]-6-fluoro-1-isopropyl-tetralin-2-yl]ester, d020748, mibefradil;
2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine, 2-methyl-1-((4-methyl-5-isoquinolinyl)sulfonyl)homopiperazine, dimethylfasudil, H 1152;
2-N-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine, 2-N-(4-(1-azitrifluoroethyl)benzoyl)-1,3-bis-(mannos-4-yloxy)-2-propylamine, 2-N-4-(1-azi-2,2,2-trifluoroethyl)benzoyl-1,3-bis(D-mannos-4-yloxy)-2-propylamine, ATB-BMPA;
2-Naftol, .beta.-Hydroxynaphthalene, .beta.-Monoxynaphthalene, .beta.-Naftol;
2-oxothiazolidine-4-carboxylic acid, 2-oxo-4-thiazolidine carboxylic acid, 2-oxothiazolidine-4-carboxylate, 2-oxothiazolidine-4-carboxylic acid;
2-phenyl-4-oxohydroquinoline, 2-phenyl-4-oxohydroquinoline;
2,2,2-trichloroethane-1,1-diol, 1,1,1-trichloro-2,2-dihydroxyethane, 1,1,1-trichloro-2,2-ethanediol, 2,2,2-trichloro-1,1-ethanediol;
2,2′-(hydroxynitrosohydrazono)bis-ethanamine, 1-(N-(2-aminoethyl)-N-(2-ammonioethyl)amino)diazen-1-ium-1,2-diolate, 2,2′-(hydroxynitrosohydrazono)bis-ethanamine, DETA NONOate;
2,2′-azobis(2,4-dimethylvaleronitrile), 2,2′-azobis(2,4-dimethyl)valeronitrile, 2,2′-azobis(2,4-dimethylvaleronitrile), ABDVN-2,2;
2,2′-bipyridine, 2,2′-Bipyridin, 2,2′-bipyridine, 2,2′-bipyridyl;
2,2′,4,4′-tetrachlorobiphenyl, 1,1′-Biphenyl, 2,2′,4,4′-tetrachloro-, 2,2′,4,4′-tetrachloro-1,1′-biphenyl, 2,2′,4,4′-tetrachlorobiphenyl;
2,3-bis(3′-hydroxybenzyl)butane-1,4-diol, 2,3-BHBBD, 2,3-bis(3′-hydroxybenzyl)butane-1,4-diol, 2,3-bis(3-hydroxybenzyl)butane-1,4-diol;
2,3-dihydroxyterephthalamide, 2,3-DHPA, 2,3-dihydroxyterephthalamide;
2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate, 2,3,4-tri-O-acetylarabinopyranosyl isothiocyanate;
2,4-diaminoquinazoline, 2,4-diaminoquinazoline;
2,4-thiazolidinedione, 2,4-thiazolidinedione, thiazolidinedione;
21-hydroxy-9beta,10alpha-pregna-5,7-diene-3-ol-20-one, 21-hydroxy-9beta,10alpha-pregna-5,7-diene-3-ol-20-one;
25-desacetylrifabutin, 25-desacetylrifabutin, LM 565, LM-565;
25-Hydroxycholesterol, (3BETA)-CHOLEST-5-ENE-3,25-DIOL, (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, (3S,8S,9S,10R,13R,14S,17R)-17-[(1R)-5-hydroxy-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol;
25(OH)D3, (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexan-1-ol, (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol, (1S,3Z)-3-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methyl-heptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol;
3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine, 3-((4-(4-chlorophenyl)piperazin-1-yl)methyl)-1H-pyrrolo(2,3-b)pyridine, CPMPP-3, L 745,870;
3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol, 3-(2-hydroxy-4-(1,1-dimethylheptyl)phenyl)-4-(3-hydroxypropyl)cyclohexanol, CP 55940, CP 56667;
3-(2h)-pyridazinone, 2H-pyridazin-3-one, 3 (2H)-Pyridazinone, 3(2H)-Pyridazinone;
3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide, 3-(cyclopentyloxy)-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide, 3-cyclopentyloxy-N-(3,5-dichloro-4-pyridyl)-4-methoxybenzamide, CPODPMB;
3-aminopyrazole, 3-aminopyrazole, 3-APz1;
3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one, 3-beta-(2-(diethylamino)ethoxy)androst-5-en-17-one, 3beta-(2-diethylaminoethoxy)-androst-5-en-17-one hydrochloride, U 18,666A;
3-BHA, 2(3)-tert-Butyl-4-hydroxyanisole, 2-(1,1-Dimethylethyl)-4-methoxy-phenol, 2-Butyl-4-hydroxyanisole;
3-hydroxybutanal, 3-hydroxybutanal, 3-hydroxybutyraldehyde, acetaldol;
3-hydroxyflunitrazepam, 3-hydroxyflunitrazepam;
3-Hydroxyquinine, (35,4R,6R)-6-[(S)-hydroxy-(6-methoxy-4-quinolyl)methyl]-3-vinyl-3-quinuclidinol, (3S,4R,6R)-6-[(S)-hydroxy-(6-methoxy-4-quinolyl)methyl]-3-vinyl-quinuclidin-3-ol, (4R,5S,7R)-5-ethenyl-7-[(S)-hydroxy-(6-methoxyquinolin-4-yl)methyl]-1-azabicyclo[2.2.2]octan-5-ol;
3-isobutyl-1-methyl-Xanthine, 3-isobutyl-1-methyl-Xanthine;
3-keto-desogestrel, 13-ethyl-17-hydroxy-11-methylene-18,19-dinor-17alpha-pregn-4-en-20-yn-3-one, 3-keto-desogestrel, 3-ketodesogestrel;
3-methoxy-4-aminoazobenzene, 3-methoxy-4-aminoazobenzene;
3-Methoxymorphinan, 3-Methoxymorphinan, Morphinan, 3-methoxy-;
3-Methoxyoestradiol, (17-beta)-3-Methoxyestra-1,3,5(10)-trien-17-ol, (17S)-3-methoxy-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthren-17-ol, 17-beta-Estradiol 3-methyl ether;
3-methylcholanthrene, 1,2-Dihydro-3-methylbenzWaceanthrylene, 20-MC, 20-Methylcholanthrene;
3-MI, .beta.-Methylindole, 1H-Indole, 3-methyl-, 3-methyl-1H-indole;
3,3′,4,5′-tetrahydroxystilbene, 3′-hydroxyresveratol, 3,3′,4′,5-tetrahydroxystilbene, 3,3′,4,5′-tetrahydroxy stilbene;
3,4-DCI, 1H-2-Benzopyran-1-one, 3,4-dichloro-, 3,4-DCI, 3,4-Del;
3,4,5-trihydroxybenzamidoxime, 3,4,5-trihydroxybenzamidoxime, trimidox, VF 233;
4-(3-3,4-p-menthadien-(1,8)-yl)olivetol, 4-(3-3,4-p-menthadien-(1,8)-yl)olivetol, abn-cbd, abnormal cannabidiol;
4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone, 4-(3-Butoxy-4-methoxybenzyl)-2-imidazolidinone, Ro 1724, Ro 20 1724;
4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanol, hydroxyhaloperidol, reduced haloperidol;
4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline, 4-(4-(N-benzoylamino)anilino)-6-methoxy-7-(3-(1-morpholino)propoxy)quinazoline, ZM 447439, ZM-447439;
4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole, 4-(4-fluorophenyl)-2-(4-hydroxyphenyl)-5-(4-pyridyl)imidazole, SB 202190, SB-202190;
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide, 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide, SB 431542, SB-431542;
4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine, 4-(benzodioxan-5-yl)-1-(indan-2-yl)piperazine, S 15535, S-15535;
4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone, 4-(N-methyl-N-nitrosamino)-1-(3-pyridyl)-1-butanone;
4-AP, .gamma.-Aminopyridine, 4-Aminopyridine, 4-Aminopyridine 10;
4-azidosalicylic acid, 4-AzHBA, 4-azido-2-hydroxybenzoic acid, 4-azidosalicylic acid;
4-dimethylamino-3′,4′-dimethoxychalcone, 4-dimethylamino-3′,4′-dimethoxychalcone, CH 11;
4-hydroxy-N-desmethyltamoxifen, 4-hydroxy-N-demethyltamoxifen, 4-hydroxy-N-desmethyltamoxifen, 4-hydroxy-N-desmethyltamoxifen, (Z)-isomer;
4-hydroxyacetophenone, 1-(4-hydroxyphenyl)ethanone, 4-hydroxyacetophenone, p-hydroxyacetophenone;
4-hydroxycoumarin, 4-hydroxycoumarin;
4-hydroxyestradiol-17 beta, 4-hydroxyestradiol, 4-hydroxyestradiol-17 alpha, 4-hydroxyestradiol-17 beta;
4-hydroxynon-2-enal, 4-Hydroxy-2,3-nonenal, 4-Hydroxy-2-nonenal, 4-hydroxynon-2-enal;
4-hydroxytriazolam, 4-hydroxytriazolam;
4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide, AMN107, nilotinib;
4-phenylbutyric acid, 4-phenylbutyrate, 4-phenylbutyric acid, 4-phenylbutyric acid, calcium salt;
4-sulfophenylmethallyl ether, 4-sulfophenylmethallyl ether, 4-sulfophenylmethallyl ether, sodium salt, SPME;
4,4′-DDE, 1,1′-(2,2-dichloroethene-1,1-diyl)bis(4-chlorobenzene), 1,1′-(Dichloroethenylidene)bis(4-chlorobenzene), 1,1′-(Dichloroethenylidene)bis[4-chlorobenzene];
4,4′-dipyridyl disulfide, 4,4′-dipyridine disulfide, 4,4′-dipyridyl disulfide, 4,4′-dithiodipyridine;
4,8-dimethoxy-7-hydroxyfuro(2,3-b)quinoline, 4,8-dimethoxy-7-hydroxyfuro(2,3-b)quinoline, haplopine;
4′-epidoxorubicin, (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside, 4′-Epiadriamycin, 4′-epidoxorubicin;
4′-N-benzoylstaurosporine, 4′-N-benzoyl staurosporine, 4′-N-benzoylstaurosporine, benzoylstaurosporine;
4(2′-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline, 4(2′-aminoethyl)amino-1,8-dimethylimidazo(1,2-a)quinoxaline, BMS-345541, BMS345541;
4alpha-phorbol 12,13-didecanone, 4alpha-phorbol 12,13-didecanone;
4alphaPDD, 4-.alpha.-Phorbol 12,13-didecanoate, 4-.alpha.-Phorbol didecanoate, 4-alpha-Phorbol 12,13-didecanoate;
5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid, 5-((1,2-dihydro-2-oxo-3H-indol-3-ylidene)methyl)-2,4-dimethyl-1H-pyrrole-3-propanoic acid, TSU 68, TSU-68;
5-7-oxo-zeaenol, 5-7-oxo-zeaenol, 7-oxozeaenol;
5-AC, 1,3,5-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-, 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one, 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one;
5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine, 5-acetylneuraminyl-(2-3)-galactosyl-(1-4)-(fucopyranosyl-(1-3))-N-acetylglucosamine;
5-azido-1H-indole-3-acetic acid, 5-AIAA, 5-azido-(7-3H)-indol-3-ylacetic acid, 5-azido-1H-indole-3-acetic acid;
5-HT, 1H-Indol-5-ol, 3-(2-aminoethyl)-, 3-(2-aminoethyl)-1H-indol-5-ol, 3-(2-Aminoethyl)indol-5-ol;
5-methoxy-N,N-diisopropyltryptamine, 5-MeO-DIPT, 5-methoxy-N,N-bis(1-methylethyl)-1H-indole-3-ethanamine, 5-methoxy-N,N-diisopropyltryptamine;
5-Mop, 4-methoxy-7-furo[3,2-g]chromenone, 4-Methoxy-7H-furo(3,2-g)(1)benzopyran-7-one, 4-methoxy-7H-furo[3,2-g]chromen-7-one;
5,10-methylenetetrahydrofolate, 5,10-methylene-5,6,7,8-tetrahydrofolate, 5,10-methylenetetrahydrofolate, 5,10-methylenetetrahydrofolate monohydrochloride, (L-Glu)-isomer;
5,6-dimethylxanthenoneacetic acid, 5,6-dimethyl xanthenone acetic acid, 5,6-dimethyl-9-oxo-9H-xanthene-4-acetic acid, 5,6-dimethylxanthenone-4-acetic acid;
5′-O-(((2-decanoylamino-3-phenylpropyloxycarbonyl)amino)sulfonyl)uridine, 5′-O-(((2-decanoylamino-3-phenylpropyloxycarbonyl)amino)sulfonyl)uridine, PP55;
6 beta-hydroxycortisol, 6 beta-hydroxycortisol, 6beta-hydroxycortisol;
6-Aminochrysene-1,2-dihydrodiol, (1S,2S)-6-amino-1,2-dihydrochrysene-1,2-diol, 1,2-Chrysenediol, 1,2-dihydro-6-amino-, trans-, 6-Aminochrysene-1,2-dihydrodiol;
6-chloro-2-pyridylmethyl nitrate, 6-chloro-2-pyridylmethyl nitrate;
6-deoxy-6-bromoascorbic acid, 6-bromo-6-deoxy-ascorbic acid, 6-bromo-6-deoxy-L-ascorbic acid, 6-bromo-6-deoxyascorbic acid;
6-hydroxydexamethasone, 6-hydroxydexamethasone;
6-Mercaptopurine, 1,7-Dihydro-6H-purine-6-thione, 6 Mercaptopurine, 6 Mercaptopurine Monohydrate;
6,6′-oxybis(2,2-dimethylhexanoic acid), 6,6′-oxybis(2,2-dimethylhexanoic acid), gemcabene, PD 72953;
64Gd, 64Gd, gadolinio, gadolinium;
7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine, 7-(1,1-dimethylethyl)-6-(2-ethyl-2H-1,2,4-triazol-3-ylmethoxy)-3-(2-fluorophenyl)-1,2,4-triazolo(4,3-b)pyridazine, TPA 023, TPA-023;
7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine, 7-benzylamino-6-chloro-2-piperazino-4-pyrrolidinopteridine;
7-benzyloxyquinoline, 7-benzyloxyquinoline;
7-CDL, (2S,4R)—N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)-2-tetrahydropyranyl]propyl]-1-methyl-4-propyl-2-pyrrolidinecarboxamide, (2S,4R)—N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-(methylthio)tetrahydropyran-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide, (2S,4R)—N-[2-chloro-1-[(2R,3R,4S,5R,6R)-3,4,5-trihydroxy-6-methylsulfanyl-oxan-2-yl]propyl]-1-methyl-4-propyl-pyrrolidine-2-carboxamide;
7-hydroxystaurosporine, 7-hydroxy-staurosporine, 7-hydroxystaurosporine, UCN 01;
7-ketocholesterol, 7-ketocholesterol;
7,8-BF, .alpha.-Naphthoflavone, .alpha.-Naphthylflavone, 2-phenyl-4-benzo[h]chromenone;
7,8-dihydroneopterin, 7,8-dihydro-neopterin, 7,8-dihydroneopterin;
7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol, 7′-Isothiocyanato-11-hydroxy-1′,1′-dimethylheptylhexahydrocannabinol, AM841;
7C3MT, (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-7-yl]chroman-4-one, (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxy-phenyl)-3-methylol-2,3-dihydro-1,4-benzodioxin-7-yl]chroman-4-one, (2R,3R)-3,5,7-trihydroxy-2-[(2R,3R)-2-(4-hydroxy-3-methoxyphenyl)-3-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-7-yl]-4-chromanone;
7H-Pyrrolo(2,3-d)pyrimidine, 7H-Pyrrolo(2,3-d)pyrimidine;
8-((4-bromo-2,3-dioxobutyl)thio)-adenosine 3′,5′-cyclic monophosphate, 8-((4-bromo-2,3-dioxobutyl)thio)-adenosine 3′,5′-cyclic monophosphate;
8-(2,6-dichlorophenyl)-10-methyl-3-((4-morpholin-4-ylphenyl)amino)-2,4,10-triazabicyclo(4.4.0)deca-1,3,5,7-tetraen-9-one, 8-(2,6-dichlorophenyl)-10-methyl-3-((4-morpholin-4-ylphenyl)amino)-2,4,10-triazabicyclo(4.4.0)deca-1,3,5,7-tetraen-9-one, PD0173952;
8-(3-chlorostyryl)caffeine, 8-(3-chlorostyryl)caffeine;
8-anilinonaphthalene-1-sulfonic acid, 1-(phenylamino)-8-naphthalenesulfonic acid, 1-Anilino-8-naphthalenesulfonate, 1-anilino-8-naphthalenesulfonic acid;
8-Hydroxy-2-(di-n-propylamino)tetralin, 8-Hydroxy-2-(di-n-propylamino)tetralin, 8-Hydroxy-2-(di-n-propylamino)tetralin Hydrobromide, 8-Hydroxy-2-(di-n-propylamino)tetralin Hydrobromide, (+−)-Isomer;
8-Isoprostane, (5Z,13E,15S)-9alpha,11alpha,15-trihydroxy-8beta-prosta-5,13-dien-1-oic acid, (Z)-7-[(1S,2R,3R,5S)-3,5-dihydroxy-2-[(E,3S)-3-hydroxyoct-1-enyl]cyclopentyl]hept-5-enoic acid, 8-Epi PGF-2alpha;
8,10-bis((2,2-dimethyl-1-oxopropyl)oxy)-11-methyl-1234-tetrahydro-6H-benzo(beta)quinolizin-6-one, 8,10-bis((2,2-dimethyl-1-oxopropyl)oxy)-11-methyl-1234-tetrahydro-6H-benzo(beta)quinolizin-6-one, Sch35966;
9-(4′-aminophenyl)-9H-pyrido(3,4-b)indole, 9-(4′-aminophenyl)-9H-pyrido(3,4-b)indole, amino-phenylnorharman, APNH cpd;
9-anthroic acid, 9-anthracenecarboxylic acid, 9-anthroic acid, 9-carboxyanthracene;
9-CRA, (2E,4E,6Z,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid, 9 Cis Retinoic Acid, 9-cis-RA;
9-hydroxy-risperidone, 3-(2-(4-(6-fluoro-3-(1,2-benzisoxazolyl))-1-piperidinyl)ethyl)-6,7,8,9-tetrahydro-9-hydroxy-2-methyl-4H-pyrido(1,2-a)pyrimidin-4-one, 9-hydroxy-risperidone, 9-hydroxyrisperidone;
9,10-anthraquinone, 9,10-Anthracendion, 9,10-anthracenedione, 9,10-Anthrachinon;
9H-xanthene, 10H-9-oxaanthracene, 9H-xanthene, C1c2ccccc20c3ccccc13;
A-300-I, (2E,4E,6R)-7-(4-(dimethylamino)phenyl)-N-hydroxy-4,6-dimethyl-7-oxo-2,4-heptadienamide, (2E,4E,6R)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxo-hepta-2,4-dienehydroxamic acid, (2E,4E,6R)-7-(4-dimethylaminophenyl)-4,6-dimethyl-7-oxohepta-2,4-dienehydroxamic acid;
a-ADP, (S)-1-C-(7-Amino-1H-pyrazolo(4,3-d)pyrimidin-3-yl)-1,4-anhydro-D-ribitol, 5-(trihydrogen diphosphate), 5′-Adenylphosphoric acid, 5′-ADP;
Abbott, 1,2,4-Triazolidine-3,5-dione, 1,2-bis(1-methylethyl)-, 1,2,4-Triazolidine-3,5-dione, 1,2-bis(1-methylethyl)-(9CI), 1,2,4-Triazolidine-3,5-dione, 1,2-diisopropyl-;
abciximab, abciximab, c7E3 Fab, CentoRx;
Absele, (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate, (+)-Etomidate, (d)-Etomidate;
acetamide 45, acetamide 45, acetamide-45;
Aceton, .beta.-Ketopropane, 2-Propanone, Aceton;
acetonitrile, acetonitrile, CC#N, CH3-C#N;
acetyl-11-ketoboswellic acid, 3-O-acetyl-11-keto-boswellic acid, acetyl-11-keto-beta-boswellic acid, acetyl-11-ketoboswellic acid;
acetylcholine, 2-acetyloxy-N,N,N-trimethylethanaminium, acetylcholine, ACh;
acetylvalerenolic acid, acetylvalerenolic acid;
Acolen, (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-10,13-dimethyl-3,7,12-trioxo-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]pentanoic acid, (4R)-4-[(5S,8R,9S,10S,13R,14S,17R)-3,7,12-triketo-10,13-dimethyl-1,2,4,5,6,8,9,11,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl]valeric acid, (5beta)-3,7,12-trioxocholan-24-oic acid;
ACON, (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraen-1-ol, (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraen-1-ol, (all-E)-3,7-Dimethyl-9-(2,6,6-trimethyl-1-cyclohexen-1-yl)-2,4,6,8-nonatetraen-1-ol;
ACT D, Err: 508, 10,10′-[(2-Amino-4,6-dimethyl-3-oxo-3H-phenoxazine-1,9-Diyl)bis(carbonylimino)]bis-[dodecahydro-6,13-diisopropyl-2,5,9-trimethyl-1H-Pyrrolo-(2,1-1)(1,4,7,10,13)oxatetra-azacyclohexadecine]-1,4,7,11,14, 1H-Pyrrolo(2,1-1)-(1,4,7,10,13)oxatetraazacyclohexadecine;
actinium, 89Ac, actinio, actinium;
Actosin, 2-methoxy-2-methyl-4-phenyl-3,4-dihydropyrano[5,6-c]chromen-5-one, 2H,5H-Pyrano(3,2-c)(1)benzopyran-5-one, 3,4-dihydro-2-methoxy-2-methyl-4-phenyl-, 2H,5H-Pyrano[3,2-c][1]benzopyran-5-one, 3,4-dihydro-2-methoxy-2-methyl-4-phenyl-;
adalimumab, Abbott brand of adalimumab, adalimumab, D2E7 antibody;
Adalin, (.alpha.-Bromo-.alpha.-ethylbutyryl)carbamide, (.alpha.-Bromo-.alpha.-ethylbutyryl)urea, (2-Brom-2-ethylbutyryl)harnstoff;
Adanon, (+)-Methadone, (+−)-Methadone, (−)-(R)-6-(Dimethylamino)-4,4-diphenyl-3-heptanone;
Adfeed, (−)-(2R)-2-(2-fluorobiphenyl-4-yl)propanoic acid, (−)-Flurbiprofen, (2R)-2-(2-Fluoro-1,1′-biphenyl-4-yl)propanoic acid;
adinazolam, adinazolam;
Adofeed, (C3-C24) Fatty acids, 2-arylpropanoic acid, 2-Arylpropionate;
Adrenor, (−)-Norepinephrine, (−)-(R)-Norepinephrine, (−)-alpha-(Aminomethyl)protocatechuyl alcohol;
Adrin, (+)-3,4-dihydroxy-alpha-((methylamino)methyl)benzyl alcohol, (+)-adrenaline, (−)-Adrenaline;
AEBSF, 4-(2-Aminoethyl)benzenesulfonyl fluoride, 4-(2-Aminoethyl)benzenesulfonylfluoride, 4-beta-Aminoethylbenzolsulfofluoride;
Aeromax, (+−)-4-Hydroxy-alpha′-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-m-xylene-alpha,alpha′-diol, (+−)-4-Hydroxy-alpha1-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-1,3-benzenedimethanol, 1,3-Benzenedimethanol, 4-hydroxy-alpha(sup 1)-(((6-(4-phenylbutoxy)hexyl)amino)methyl)-, (+−)-;
afloqualone, afloqualone;
AGMATINE, (4-Aminobutyl) guanidine, (4-AMINOBUTYL)GUANIDINE, (4-Aminobutyl)guanidinium sulphate;
AIDSVAX, AIDSVAX, ALVAC-HIV, vCP1521;
ajoene, 4,5,9-trithiadodeca-1,6,11-triene 9-oxide, ajoene;
ajulemic acid, ajulemic acid;
alachlor, 2-chloro-N-(2,6-diethylphenyl)-N-(methoxymethyl)acetamide, alachlor;
Aladerm, 5-amino-4-keto-valeric acid, 5-amino-4-oxo-pentanoic acid, 5-Amino-4-oxopentanoate;
alaninate, 2-aminopropanoate, alaninate, alanine anion;
Alat, 1,4-Dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester, 2,6-Dimethyl-3,5-dicarbomethoxy-4-(2-nitrophenyl)-1,4-dihydropyridine, 2,6-dimethyl-4-(2-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid dimethyl ester;
Alcolo, 1-Hydroxy-1-methylethyl, 1-Methylethanol, 1-Methylethyl alcohol;
Aldara, (1-isobutylimidazo[4,5-c]quinolin-4-yl)amine, 1-(2-Methylpropyl)-1H-imidazole[4,5-c]quinoline-4-amine, 1-(2-methylpropyl)-1H-imidazo[4,5-c]quinolin-4-amine;
ALDO, .gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone, 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine, 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-;
Aldrich, 1,3-di-O-methylpyrogallol, 1,3-dimethoxy-2-hydroxybenzene, 1,3-dimethyl pyrogallate;
alemtuzumab, alemtuzumab, Berlex brand of alemtuzumab, Campath;
Alfarol, (1S,3R,5Z)-5-[(2E)-2-[(1R,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol, (1S,3R,5Z)-5-[(2E)-2-[(1R,7aR)-1-[(1R)-1,5-dimethylhexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol, (1S,3R,5Z)-5-[(2E)-2-[(1R,7aR)-7a-methyl-1-[(2R)-6-methylheptan-2-yl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol;
aliskiren, 2(S),4(S),5(S),7(S)—N-(2-carbamoyl-2-methylpropyl)-5-amino-4-hydroxy-2,7-diisopropyl-8-(4-methoxy-3-(3-methoxypropoxy)phenyl)octanamid hemifumarate, aliskiren, CGP 060536B;
Alli, (−)-Tetrahydrolipstatin, (−)-Tetrahydrolipstatin, (2S)-2-formamido-4-methyl-valeric acid [(1S)-1-[[(2S,3S)-3-hexyl-4-keto-oxetan-2-yl]methyl]dodecyl]ester;
ALLN, (2S)-2-[(2S)-2-acetamido-4-methylpentanamido]-N-[(1S)-1-formylpentyl]-4-methylpentanamide, (2S)-2-[[(2S)-2-acetamido-4-methyl-1-oxopentyl]amino]-N-[(1S)-1-formylpentyl]-4-methylpentanamide, (2S)-2-[[(2S)-2-acetamido-4-methyl-pentanoyl]amino]-4-methyl-N-[(2S)-1-oxohexan-2-yl]pentanamide;
alloxazine, Alloxazin, alloxazine, benzo[g]pteridine-2,4(1H,3H)-dione;
allyl isothiocyanate, allyl isothiocyanate;
almokalant, almokalant;
aloesin, aloesin;
Alprenolol, 1-(o-Allylphenoxy)-3-(isopropylamino)-2-propanol, Alfeprol, Alpheprol;
Am 80, 4-((5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)carbamoyl)benzoic acid, Am 80, AM-80;
amino-polyethyleneoxide-sulfonate, amino-polyethyleneoxide-sulfonate, NH2-PEO-SO3, PEO-SO3;
aminoflavone, 5-amino-2-(4-amino-3-fluorophenyl)-6,8-difluoro-7-methyl-4H-1-benzopyran-4-one, aminoflavone, NSC 686288;
Amiodarone, (2-butyl-1-benzofuran-3-yl)(4-{[2-(diethylamino)ethyl]oxy}-3,5-diiodophenyl)methanone, (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodo-phenyl]methanone, (2-butyl-1-benzofuran-3-yl)-[4-(2-diethylaminoethoxy)-3,5-diiodophenyl]methanone;
amprenavir, 141 W94, Agenerase, amprenavir;
Amrinone, 5-Amino-(3,4′-bipyridine)-6(1H)-one, Amrinon, Amrinone;
amsonic acid, 4,4′-diacetamido-2,2′-stilbene disulfonate, 4,4-diaminostilbene-2,2′-disulfonic acid, amsonic acid;
Anaboleen, (5a,17b)-17-Hydroxyandrostan-3-one, (5alpha,17beta)-17-hydroxyandrostan-3-one, (5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one;
anacardic acid, 6-(8(Z),11(Z),14-pentadecatrienyl)salicylic acid, 6-(8,11,14-pentadecatrienyl)salicylic acid, 6-nonadecyl salicylic acid;
Anandamide, (5Z,8Z,11Z,14Z)— N-(2-Hydroxyethyl)-5,8,11,14-eicosatetraenamide, (5Z,8Z,11Z,14Z)—N-(2-hydroxyethyl)-5,8,11,14-eicosatetraenamide, (5Z,8Z,11Z,14Z)—N-(2-hydroxyethyl)icosa-5,8,11,14-tetraenamide;
Anco, (−)-Ibuprofen, (+−)-2-(p-isobutylphenyl)propionic acid, (+−)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid;
Andrographis, (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5,8a-dimethyl-2-methylene-5-methylol-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one, (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-decalinyl]ethylidene]-4-hydroxy-2-tetrahydrofuranone, (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one;
Androtine, (3 alpha,5 alpha)-3-hydroxyandrostan-17-one, (3R,5 S,8R,9S,10S,13 S,14S)-3-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one, 3-alpha-Hydroxy-17-androstanone;
Aneol, (+−)-3-Benzoyl-alpha-methylbenzeneacetic acid, 19583 RP, 2-(3-benzoylphenyl)propanoic acid;
Ang II, (3S)-3-amino-4-[[(1S)-1-[[(1S)-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-2-[(2S)-2-[[(1S)-1-(benzyl)-2-hydroxy-2-keto-ethyl]carbamoyl]pyrrolidin-1-yl]-1-(3H-imidazol-4-ylmethyl)-2-keto-ethyl]carbamoyl]-2-methyl-butyl]amino]-1-(4-hydroxybenzyl)-2-keto-ethyl]carbamoyl], (3S)-3-amino-4-[[(1S)-4-guanidino-1-[[(1S)-1-[[(1S)-2-[[(1S,2S)-1-[[(1S)-2-[(2S)-2-[[(1S)-2-hydroxy-2-oxo-1-(phenylmethyl)ethyl]carbamoyl]pyrrolidin-1-yl]-1-(3H-imidazol-4-ylmethyl)-2-oxo-ethyl]carbamoyl]-2-methyl-butyl]amino]-1-[(4-hydroxyphenyl)methyl]-, (3S)-3-amino-4-[[(1S)-4-guanidino-1-[[[(1S)-1-[[[(1S)-2-[[(1S,2S)-1-[[[(1S)-2-[(2S)-2-[[[(1S)-2-hydroxy-2-oxo-1-(phenylmethyl)ethyl]amino]-oxomethyl]-1-pyrrolidinyl]-1-(3H-imidazol-4-ylmethyl)-2-oxoethyl]amino]-oxomethyl]-2-methylbutyl]amino]-1-[(4-hydrox;
anthra(1,9-cd)pyrazol-6(2H)-one, anthra(1,9-cd)pyrazol-6(2H)-one, SP600125;
anthracene, anthracene, Anthrazen, c1ccc2cc3ccccc3cc2c1;
anthralin, 1,8-dihydroxy-9(10H)-anthracenone, 1,8-dihydroxy-9-anthrone, 1,8-dihydroxyanthracen-9(10H)-one;
anthrone, 9(10H)-anthracenone, 9,10-dihydro-9-oxoanthracene, anthracen-9(10H)-one;
antibiotic G 418, antibiotic G 418;
antibiotic H107, antibiotic H107, H 107;
APDC, 1-Pyrrolidinecarbodithioic acid, 1-Pyrrolidinecarbodithioic acid & Z-100, Ammonium pyrrolidine dithiocarbamate;
Aphidicolin, Aphidicolin, Aphidicolin, (3-S-(3alpha,4beta,4abeta,6aalpha,8alpha,9alpha,11aalpha,11balpha))-Isomer, ICI 69653;
Aphloiol, 1,3,6,7-tetrahydroxy-2-[(3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)-2-tetrahydropyranyl]-9-xanthenone, 1,3,6,7-tetrahydroxy-2-[(3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]xanthen-9-one, 1,3,6,7-tetrahydroxy-2-[(3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]xanthen-9-one;
apicidin, apicidin, apicidin C, cyclo(N—O-methyl-tryptophyl-isoleucyl-pipecolinyl-2-amino-8-oxodecanoyl);
Apigenin, 2-(p-hydroxyphenyl)-5,7-dihydroxychromone, 4′,5,7-Trihydroxyflavone, 4′,5,7-Trihydroxyflavone;
apocynin, 1-(4-hydroxy-3-methoxyphenyl)ethan-1-one, 4′-hydroxy-3′-methoxyacetophenone, Acetovanillone;
aprepitant, (2R)-(1R)-3,5-bis(trifluoromethylphenyl)ethoxy)-(3S)-(4-fluoro)phenyl-4-(3-(5-oxo-1H,4H-1,2,4-triazole)methyl-morpholine, aprepitant, Emend;
APRL, 1-ethyl-2-acetyl-sn-glycero-3-phosphocholine, 1-O-Alkyl-2-acetyl-sn-glycero-3-phophocholine, 1-O-Alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine;
AQ4N, 1,4-bis-((2-(dimethylamino)ethyl)amino)-5,8-dihydroxyanthracene-9,10-dione, 1,4-bis-((2-(dimethylamino-N-oxide)ethyl)amino)-5,8-dihydroxyanthracene-9,10-dione, AQ4N;
arabinogalactan, arabinogalactan;
Aralen, (−)-Chloroquine, (+)-Chloroquine, (+)-N4-(7-Chloro-4-quinolinyl)-N1,N1-diethyl-1,4-pentanediamine;
Arasine, 1H-Imidazole-4-carboxamide, 5-amino-1-beta-D-ribofuranosyl-, 5-Amino-1-.beta.-D-ribofuranosyl-1H-imidazole-4-carboxamide, 5-Amino-1-beta-D-ribofuranosyl-1H-imidazole-4-carboxamide;
Areca, Areca, Areca catechu, Betel Nut;
Areether, 109716-83-8 (UNSPECIFIED 12 POSITION), 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, 10-ethoxydecahydro-3,6,9-trimethyl-, (3S-(3alpha,5alpha,6alpha,8aalpha,9beta,10beta,12beta,12aalpha))-, 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-ethoxy-3,6,9-trimethyl-, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-;
argatroban, 4-methyl-1-(N(2)-(3-methyl-1,2,3,4-tetrahydro-8-quinolinesulfonyl)-L-arginyl)-2-piperidinecarboxylic acid, Acova, argatroban;
aripiprazole, 7-(4-(4-(2,3-dichlorophenyl)-1-piperazinyl)butyloxy)-3,4-dihydro-2(1H)-quinolinone, Abilify, aripiprazole;
Aron, 2-Carboxyethyl acrylate oligomers, 2-Propenoic acid, 2-Propenoic acid, homopolymer;
Artein, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(2R,4R)-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl(S)-2-methyl-butyrate, (15-(1alpha(R),3alpha,7beta,8beta(2S,4S),8abeta))-(1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthyl) 2-methylbutanoate, (15-(1alpha(R*),3alpha,7beta,8beta(2S*,4S*),8abeta))-2-Methylbutanoic acid 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester;
Artra, .alpha.-Hydroquinone, .beta.-Quinol, 1,4-Benzenediol;
arvanil, arvanil;
asiatic acid, asiatic acid;
asiaticoside, asiaticoside;
Asmax, 1,3-Dimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine, 1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione, 1,3-dimethyl-7H-purine-2,6-dione;
Asmol, (+−)-Albuterol, (+−)-alpha(sup 1)-(((1,1-Dimethylethyl)amino)methyl)-4-hydroxy-1,3-benzenedimethanol, (+−)-Salbutamol;
ASTA, (+−)-Cyclophosphamide, (+−)-N,N-Bis(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorin-2-amine 2-oxide, (−)-Cyclophosphamide;
astatine, 85At, Astat, astate;
atazanavir, 3,12-bis(1,1-dimethylethyl)-8-hydroxy-4,11-dioxo-9-(phenylmethyl)-6-((4-(2-pyridinyl)phenyl)methyl)-2,5,6,10,13-pentaazatetradecanedioic acid dimethyl ester, atazanavir, atazanavir sulfate;
ATL 146e, 4-(3-(6-amino-9-(5-ethylcarbamoyl-3,4-dihydroxytetrahydrofuran-2-yl)-9H-purin-2-yl)prop-2-ynyl)cyclohexanecarboxylic acid methyl ester, ATL 146e, ATL-146e;
Atorel, .beta.-D-Ribofuranoside, hypoxanthine-9, .beta.-Inosine, 6H-Purin-6-one, 9-.beta.-D-arabinofuranosyl-1,9-dihydro-;
atorvastatin, atorvastatin, atorvastatin calcium, atorvastatin, calcium salt;
Atovaquone, 2-(4-(4′-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone, 2-(trans-4-(4-chlorophenyl)cyclohexyl)-3-hydroxy-1,4-naphthoquinone, 566C;
ATRA, (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethyl-1-cyclohexenyl)nona-2,4,6,8-tetraenoic acid, (2E,4E,6E,8E)-3,7-dimethyl-9-(2,6,6-trimethylcyclohex-1-en-1-yl)nona-2,4,6,8-tetraenoic acid, (2E,4E,6E,8E)-3,7-Dimethyl-9-(2,6,6-trimethylcyclohex-1-enyl)nona-2,4,6,8-tetraenoic acid;
AuTM, (1,2-dicarboxyethylthio)gold, 1,2-dicarboxyethanethiolatogold(I), 1,2-dicarboxyethylsulfanylgold;
auxin, (indol-3-yl)acetate, 1H-indol-3-ylacetate, 2-(1H-indol-3-yl)acetate;
avasimibe, 2,6-bis(1-methylethyl)phenyl((2,4,6-tris(1-methylethyl)phenyl)acetyl)sulfamate, avasimibe, CI 1011;
avicularin, avicularin;
Axsain, (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide, (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide, (E)-8-Methyl-N-vanillyl-6-nonenamide;
azacyclonol, azacyclonol;
Azadc, 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-D-erythro-pentofuranosyl)-, 2′-Deoxy-5-azacytidine, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one;
azamulin, azamulin;
azaspirane, antiprimod, atiprimod, azaspirane;
azelaic acid, 1,7-dicarboxyheptane, 1,7-Heptanedicarboxylic acid, 1,9-nonanedioic acid;
azelastine, 4-((4-chlorophenyl)methyl)-2-(hexahydro-1-methyl-1H-azepin-4-yl)-1(2H)-phthalazinone HCl, 4-(p-chlorobenzyl)-2-(N-methylperhydroazepinyl-(4))-1-(2H)-phthalazinone, A 5610;
azelnidipine, 3-(1-diphenylmethylazetidin-3-yl)-5-isopropyl-2-amino-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate, azelnidipine, CS 905;
azido ruthenium, azido ruthenium;
Azobisisobutyramidinium dichloride, 2,2′-Azobis(2-amidinopropane)dihydrochloride, 2,2′-Azobis(2-amidinopropane)hydrochloride, 2,2′-Azobis(2-methylpropionamidine)dihydrochloride;
Azole, (4H)-1,2,4-Triazol-3-amine, .DELTA.2-1,2,4-Triazoline, 5-imino-, 1,2,4-Triazol-3-amine;
Azophen, .beta.-Antipyrine, 1,2-Dihydro-1,5-dimethyl-2-phenyl-3H-pyrazol-3-one, 1,5-dimethyl-2-phenyl-1,2-dihydro-3H-pyrazol-3-one;
Azor, 4H-(1,2,4)Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-, 4H-s-Triazolo(4,3-a)(1,4)benzodiazepine, 8-chloro-1-methyl-6-phenyl-, 4H-[1,2,4]Triazolo[4,3-a][1,4]benzodiazepine, 8-chloro-1-methyl-6-phenyl-;
BA (VAN), 1,1′-(Oxybis(methylene))bisbenzene, 1,1′-[oxybis(methylene)]dibenzene, 1,1-(Oxybis(methylene))bisbenzene;
Ba 0108E, Ba 0108E, Barium chloride, Barium chloride (BaC12);
bacitracin, bacitracin, bacitracins;
bacterial lysate, bacterial immunostimulant, bacterial lysate, Broncho-Vaxom;
bafilomycin A1, bafilomycin A1;
Bagren, (5′alpha)-2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)-3′,6′,18-trioxoergotaman, (5′alpha)-2-bromo-12′-hydroxy-2′-(1-methylethyl)-5′-(2-methylpropyl)ergotaman-3′,6′,18-trione, (5′alpha)-2-bromo-12′-hydroxy-5′-(2-methylpropyl)-2′-(propan-2-yl)-3′,6′,18-trioxoergotaman;
baicalein, 5,6,7-trihydroxy-2-phenyl-4-chromenone, 5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one;
Barbiturate, 1,2,3,4,5,6-Hexahydro-2,4,6-pyrimidinetrione, 1,3-diazinane-2,4,6-trione, 2,4,6(1H,3H,5H)-Pyrimidinetrione;
Barnidipine, (+)-(3′S,4S)-1-Benzyl-3-pyrrolidinyl methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-[(3S)-1-(benzyl)pyrrolidin-3-yl]O5-methyl ester, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-methyl O3-[(3S)-1-(phenylmethyl)-3-pyrrolidinyl]ester;
BAY 11-7085, 3-((4-(1,1-dimethylethyl)phenyl)sulfonyl)-2-propenenitrile, BAY 11-7083, BAY 11-7085;
BB-K8, (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-(3-amino-3-deoxy-alpha-D-glucopyranosyloxy)-4-(6-amino-6-deoxy-alpha-D-glucopyranosyloxy)-3-hydroxycyclohexyl]-2-hydroxybutanamide, (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxy-oxan-2-yl]oxy-3-hydroxy-cyclohexyl]-2-hydroxy-butanamide, (2S)-4-amino-N-[(1R,2S,3S,4R,5S)-5-amino-2-[(2S,3R,4S,5S,6R)-4-amino-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4-[(2R,3R,4S,5S,6R)-6-(aminomethyl)-3,4,5-trihydroxyoxan-2-yl]oxy-3-hydroxycyclohexyl]-2-hydroxybutanamide;
BCNU, 1,3-Bis(.beta.-chloroethyl)-1-nitrosourea, 1,3-bis(2-chloroethyl)-1-nitroso-urea, 1,3-Bis(2-chloroethyl)-1-nitrosourea;
Belt, (1alpha,2alpha,3aalpha,4beta,7beta,7aalpha)-1,2,4,5,6,7,8,8-Octachloro-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-indene, (1alpha,2beta,3aalpha,4beta,7beta,7aalpha)-1,2,4,5,6,7,8,8-Octachloro-2,3,3a,4,7,7a-hexahydro-4,7-methano-1H-indene, .gamma.-Chlordan;
benazepril, Beecham brand of benazepril hydrochloride, benazapril, benazepril;
bendamustine, bendamustin, bendamustine, bendamustine hydrochloride;
Benidipine, (+−)-(R*)-3-((R*)-1-Benzyl-3-piperidyl) methyl 1,4-dihydro-2,6-dimethyl-4-(m-nitrophenyl)-3,5-pyridinedicarboxylate, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O3-[(3R)-1-(benzyl)-3-piperidyl]O5-methyl ester, 2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3,5-dicarboxylic acid O5-methyl O3-[(3R)-1-(phenylmethyl)-3-piperidinyl]ester;
benzamidine, benzamidine, benzenecarboximidamide, phenylamidine;
benzimidazolide, benzimidazol-1-ide, benzimidazolide, bim;
benzydamine N-oxide, benzydamine N-oxide;
benzylamine, (Aminomethyl)benzene, (Phenylmethyl)amine, 1-phenylmethanamine;
benzyloxycarbonylleucyl-leucyl-leucine aldehyde, benzyloxycarbonylleucyl-leucyl-leucine aldehyde;
benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone, Ac-DEVD-CMK, Ac-ZVAD-FMK, benzyloxycarbonylvalyl-alanyl-aspartyl fluoromethyl ketone;
beractant, Abbott brand of beractant, beractant, Ross brand of beractant;
berberine, 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-[methylenebis(oxy)]berbinium, 9,10-dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetradehydroberbinium, 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium;
bergamottin, 5-geranoxypsoralen, 8-geranyloxypsoralen, bergamottin;
bergaptol, 4-hydroxy-7H-furo[3,2-g]chromen-7-one, 5-Hydroxyfuranocoumarin, bergaptol;
beta-glycerophosphoric acid, 2-glycerophosphoric acid, beta-glycerol phosphate, beta-glycerophosphate;
beta-lapachone, beta-lapachone;
beta-Naphthoflavone, 5,6-Benzoflavone, beta Naphthoflavone, beta-Naphthoflavone;
beta-propiolactone, 1,3-propiolactone, 2-oxetanone, 3-hydroxypropionic acid beta-lactone;
betulinic acid, betulic acid, betulinic acid;
bexarotene, 3-methyl-TTNEB, 4-(1-(3,5,5,8,8-pentamethyl-5,6,7,8-tetrahydro-2-naphthyl)ethenyl)benzoic acid, bexarotene;
BG 9928, 3-(4-(2,6-dioxo-1,3-dipropyl-2,3,6,7-tetrahydro-1H-purin-8-yl)-bicyclo(2.2.2)oct-1-yl)propionic acid, BG 9928, BG-9928;
biapigenin, bi-apigenin, biapigenin;
biphenyl-4-ol, 4-biphenylol, 4-diphenylol, 4-Hydroxybiphenyl;
BIRB 796, 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3(4-(2-morpholin-4-yl-ethoxy)naph-thalen-1-yl)urea, BIRB 796, BIRB796;
bisindolylmaleimide I, 2-(1-(3-dimethylaminopropyl)indol-3-yl)-3-(indol-3-yl)maleimide, 3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, BIS-1 cpd;
bisindolylmaleimide III, 3-[1-(3-aminopropyl)-1H-indol-3-yl]-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione, bis-(III) indolyl-maleimide, bisindolylmaleimide III;
bisperoxovanadium, bisperoxovanadium, bpV vanadium compound;
Bisphenol A-Glycidyl Methacrylate, 2-Propenoic acid, 2-methyl-, (1-methylethylidene)bis(4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)) ester, homopolymer, Adaptic, Bis GMA;
bizelesin, bizelesin, U-78779;
Bla-S, (2R,3R,6S)-3-[[(3S)-3-amino-5-(carbamimidoyl-methyl-amino)pentanoyl]amino]-6-(4-amino-2-oxo-pyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid, (2R,3R,6S)-3-[[(3S)-3-amino-5-(carbamimidoyl-methylamino)-1-oxopentyl]amino]-6-(4-amino-2-oxo-1-pyrimidinyl)-3,6-dihydro-2H-pyran-2-carboxylic acid, (2R,3R,6S)-3-[[(3S)-3-amino-5-(carbamimidoyl-methylamino)pentanoyl]amino]-6-(4-amino-2-oxopyrimidin-1-yl)-3,6-dihydro-2H-pyran-2-carboxylic acid;
Blow, (−)-Cocaine, (1R,2R,3S,5S)-2-(methoxycarbonyl)tropan-3-yl benzoate, (1R,2R,3S,5S)-2-Methoxycarbonyltropan-3-yl benzoate;
BM 41.440, 1-Hexadecylmercapto-2-methoxymethyl-3-propyl phosphoric acid monocholine ester, 1-Hexadecylthio-2-methoxymethyl-rac-glycero-3-phosphocholine, 3,5-Dioxa-9-thia-4-phosphapentacosan-1-aminium, 4-hydroxy-7-(methoxymethyl)-N,N,N-trimethyl-, (2S-(1(R*(R*)),2alpha,3abeta,7abeta))-;
BMS204352, (5-chloro-2-methoxyphenyl)-1,3-dihydro-3-fluoro-6-(trifluoromethyl)-2H-indol-2-one, BMS 204352, BMS-204352;
Boltin, (7beta,8xi,9beta,13alpha,14beta,17alpha)-17-ethynyl-17-hydroxy-7-methylestr-5(10)-en-3-one, (7R,8R,9S,13S,14S,17R)-17-ethynyl-17-hydroxy-7,13-dimethyl-1,2,4,6,7,8,9,11,12,14,15,16-dodecahydrocyclopenta[a]phenanthren-3-one, Boltin;
Bonopen, (2S,5R,6R)-6-((2R)-2-Methylenamino-2-phenylacetamido-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo(3.2.0)heptan-2-carbonsaeure, (alpha-(Methyleneamino)benzyl)penicillin, 3,3-Dimethyl-6-(2-(methyleneamino)-2-phenylacetamidol-7-oxo-4-thia-1-azabicyclo(3.2.0)heptane-2-carboxylic acid;
boron, Bor, boracium, bore;
Borrelia-burgdorferi, Borrelia-burgdorferi;
bortezomib, bortezomib, PS 341, PS-341;
bosentan, 4-t-butyl-N-(6-(2-hydroxyethoxy)-5-(2-methoxyphenoxy)-2,2′-bipyrimidin-4-yl)benzenesulfonamide, Actelion brand of bosentan monohydrate, bosentan;
bosutinib, 4-((2,4-dichloro-5-methoxyphenyl)amino)-6-methoxy-7-(3-(4-methyl-1-piperazinyl)propoxy)-3-quinolinecarbonitrile, 4-[(2,4-dichloro-5-methoxyphenyl)amino]-6-methoxy-7-[3-(4-methylpiperazin-1-yl)propoxy]quinoline-3-carbonitrile, bosutinib;
botrocetin, botrocetin;
BPDE, (+)-7beta,8alpha-Dihydroxy-9alpha,10alpha-oxy-7,8,9,10-tetrahydrobenzo(a)pyrene, (+−)-(E)-7,8-Dihydroxy-9,10-epoxy-7,8,9,10-tetrahydrobenzo(a)pyrene, (+−)-anti-BPDE;
Brake, 1-Methyl-3-phenyl-5-(3-(trifluoromethyl)phenyl)-4(1H)-pyridinone, 1-Methyl-3-phenyl-5-(3-(trifluoromethyl)phenyl)-4-pyridone, 1-Methyl-3-phenyl-5-(alpha,alpha,alpha-trifluoro-m-tolyl)-4-pyridone;
bredinin, bredinin;
bromo-cis-stilbene, bromo-cis-stilbene;
brucine, brucine;
bryostatin 1, bryostatin 1;
bufalin, bufalin, bufalin, (3alpha,5beta)-isomer;
bufuralol, bufuralol, bufuralol, (DL)-(+−)-isomer, bufuralol, hydrochloride;
BuOH, 1-butanol, 1-Butyl alcohol, 1-Hydroxybutane;
Bupivacaine, 1-Butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide, Abbott Brand of Bupivacaine Hydrochloride, Astra Brand of Bupivacaine Hydrochloride;
BUPROPION, (−)-2-(tert-Butylamino)-3′-chloropropiophenone, (−)-2-(tert-Butylamino)-3′-chlorpropiophenon, (+−)-1-(3-chlorophenyl)-2-((1,1-dimethylethyl)amino)-1-propanone;
Butyrate, 1-Butyric acid, 1-Propanecarboxylic acid, 2-butanoate;
butyrolactone I, alpha-oxo-beta-(4-hydroxyphenyl)-gamma-(4-hydroxy-m-3,3-dimethylallylbenzyl)-gamma-methoxycarbonyl-gamma-butyrolactone, butyrolactone I;
C 1027, C 1027, C-1027, C1027 chromophore;
CACP, azanide; dichloroplatinum, CACP, cis Pt II;
Calcijex, (1R,5Z)-5-[(2E)-2-[(1R,7aR)-1-(5-hydroxy-1,5-dimethyl-hexyl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol, (1R,5Z)-5-[(2E)-2-[(1R,7aR)-1-(5-hydroxy-1,5-dimethylhexyl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol, (1R,5Z)-5-[(2E)-2-[(1R,7aR)-1-(6-hydroxy-6-methyl-heptan-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol;
calphostin C, calphostin C;
Calyculin, Calyculin, Calyculin A, Calyculin A from Discodermia calyx;
Canef, Canef, Cranoc, Fluindostainin sodium;
cangrelor, AR C69931MX, AR-C69931MX, cangrelor;
Cannabis, Bhang, Cannabis, Cannabis indica;
CAPE, (E)-3-(3,4-dihydroxyphenyl)acrylic acid 2-phenylethyl ester, (E)-3-(3,4-dihydroxyphenyl)prop-2-enoic acid 2-phenylethyl ester, 2-phenylethyl(E)-3-(3,4-dihydroxyphenyl)prop-2-enoate;
capsaicinoids, capsaicinoids;
capsazepine, capsazepine;
carbapenem, (5R)-1-azabicyclo[3.2.0]hept-2-en-7-one, 2,3-didehydro-1-carbapenam, carbapenem;
carbobenzoxy-leucyl-leucyl-norvalinal, benzyloxycarbonyl-leucyl-leucyl-norvalinal, carbobenzoxy-leucyl-leucyl-norvalinal, carbobenzoxyl-leucinyl-leucinyl-norvalinal-H;
carebastine, carebastine;
carrageenans, Carrageenan, carrageenans, carrageenin;
carvacrol, carvacrol;
carvedilol, Atlana Pharma brand of carvedilol, BM 14190, BM-14190;
caspofungin, Cancidas, caspofungin, caspofungin acetate;
casticin, 3′,5-dihydroxy-3,4′,6,7-tetramethoxyflavone, casticin, vitexicarpin;
catechins, catechin, catechins;
Cbdca, (SP-4-2)-diammine[cyclobutane-1,1-dicarboxylato(2-)-kappa(2)O,O′]platinum, 1,1-Cyclobutanedicarboxylate diammine platinum(II), ammonia; cyclobutane-1,1-dicarboxylic acid;
platinum(+2) cation;
CCPA, (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)-9-purinyl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol, (2R,3R,4S,5R)-2-[2-chloro-6-(cyclopentylamino)purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;
CD 437, 6-(3-(1-adamantyl)-4-hydroxyphenyl)-2-naphthalenecarboxylic acid, AHPN, CD 437;
celecoxib, 4-(5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide, Celebrex, celecoxib;
cephalomannine, cephalomannine, taxol B;
cephalosporins, cephalosporins;
cepharanthine, cepharanthin, cepharanthine;
cerebrolysin, cerebrolysin, cerebrolysine, FPF 1070;
cerivastatin, 6-Heptenoic acid, 7-(4-(4-fluorophenyl)-5-(methoxymethyl)-2,6-bis(1-methylethyl)-3-pyridinyl)-3,5-dihydroxy-, monosodium salt, (S—(R*,S*-(E)))-, 7-(4-(4-fluorophenyl)-2,6-diisopropyl-5-(methoxymethyl)pyrid-3-yl)-3,5-dihydroxy-6-heptenoate sodium salt, Bay w 6228;
Cetomacrogol, alpha-Hexadecyl-omega-Hydroxypoly(oxy-1,2-Ethanediyl), Brij 52, Brij 56;
cetrorelix, ASTA Medica brand of cetrorelix acetate, cetrorelix, cetrorelix acetate;
cetuximab, C225, cetuximab, Erbitux;
CGP 12177, 4-(3-tert-butylamino-2-hydroxypropoxy)benzimidazol-2-one, 4-(3-tert-butylamino-2-hydroxypropoxy)benzimidazol-2-one hydrochloride, (+−)-isomer, 4-(3-tert-butylamino-2-hydroxypropoxy)benzimidazol-2-one, (+−)-isomer;
CGS 15943A, (1,2,4)Triazolo(1,5-c)quinazolin-5-amine, 9-chloro-2-(2-furanyl)-, 9-Chloro-2-(2-furanyl)-(1,2,4)triazolo(1,5-c)quinazolin-5-amine, 9-Chloro-2-(2-furanyl)-[1,2,4]triazolo[1,5-c]quinazolin-5-amine;
CGS 21680, 2-(4-(2-carboxyethyl)phenethylamino)-5′-N-ethylcarboxamidoadenosine, Benzenepropanoic acid, 4-(2-((6-amino-9-(N-ethyl-beta-D-ribofuranuronamidosyl)-9H-purin-2-yl)amino)ethyl)-, CGS 21680;
CH-THF, 2-[[4-(3-amino-1-keto-5,6,6a,7-tetrahydro-4H-imidazo[3,4-f]pteridin-10-ium-8-yl)benzoyl]amino]glutaric acid, 2-[[4-(3-amino-1-oxo-5,6,6a,7-tetrahydro-4H-imidazo[3,4-f]pteridin-10-ium-8-yl)benzoyl]amino]pentanedioic acid, 2-[[4-(3-amino-1-oxo-5,6,6a,7-tetrahydro-4H-imidazo[3,4-f]pteridin-10-ium-8-yl)phenyl]carbonylamino]pentanedioic acid;
CH2CHO, Acetaldehyd, Acetaldehyde, Acetaldehyde (natural);
CHAPS, 3-((3-Cholamidopropyl)dimethylammonio)-1-propanesulfonate, 3-((3-Cholamidopropyl)dimethylammonium)-1-propanesulfonate, 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate;
Chinine, (−)-Quinine, (5-ethenyl-1-azabicyclo[2.2.2]octan-7-yl)-(6-methoxyquinolin-4-yl)methanol, (6-methoxy-4-quinolyl)-(5-vinyl-2-quinuclidinyl)methanol;
chlorophenyl-ethane, chlorophenyl-ethane;
chlorophyllin, chlorophyllin, chlorophyllin a, chlorophyllin copper complex;
chlorophyllypt, Chlorophyllipt, chlorophyllypt;
chlorpromazine, 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethyl-1-propanamine, 3-(2-chloro-10H-phenothiazin-10-yl)-N,N-dimethylpropan-1-amine, 3-(2-chlorophenothiazin-10-yl)-N,N-dimethyl-propan-1-amine;
Cholestanol, 5 alpha Cholestan 3 alpha ol, 5 alpha Cholestan 3 beta ol, 5 alpha-Cholestan-3 alpha-ol;
CHOLINE, (2-Hydroxyethyl)trimethylammonium, (2-Hydroxyethyl)trimethylammonium chloride, (beta-hydroxyethyl)trimethylammonium;
Chonsurid, (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxy-oxan-4-yl]oxy-3,4,5-trihydroxy-oxane-2-carboxylic acid, (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxy-tetrahydropyran-4-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid, (2S,3S,4S,5R,6R)-6-[(2R,3R,4R,5R,6R)-3-acetamido-2,5-dihydroxy-6-sulfooxyoxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid;
chromophore, chromophore, chromophores;
Chrysin, 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-, 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-(9CI), 5,7-dihydroxy-2-phenyl-4-chromenone;
chymostatin, chymostatin;
cicaprost, 13,14-didehydro-16,20-dimethyl-3-oxa-18,18,19,19-tetradehydro-6-carbaprostaglandin I2,5-(7-hydroxy-6-(3-hydroxy-4-methylnona-1,6-diynyl)-bicyclo(3.3.0)octan-3-yliden)-3-oxapentanoic acid, cicaprost;
cifostodine, cifostodine;
ciglitazone, 5-(4-(1-methylcyclohexylmethoxy)benzyl)thiazolidine-2,4-dione, ADD 3878, ADD-3878;
cilostazol, 6-(4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy)-3,4-dihydro-2(1H)-quinolinone, cilostazol, OPC 13013;
cinacalcet, alpha-methyl-N-(3-(3-(trifluoromethyl)phenyl)propyl)-1-naphthalenemethanamine, (alphaR)-hydrochloride, AMG 073, AMG073;
cinitapride, Almirall brand of cinitapride tartrate, Blaston, Cidine;
cinnamic aldehyde, 3-phenylprop-2-enaldehyde, beta-phenylacrolein, cinnamaldehyde;
cionin, Asn-Tyr(SO3)-Tyr(SO3)-Gly-Trp-Met-Asp-Phe-NH2, cionin;
Cipol N, (R—(R*,R*-(E)))-Cyclic(L-alanyl-D-alanyl-N-methyl-L-leucyl-N-methyl-L-leucyl-N-methyl-, 1,4,7,10,13,16,19,22,25,28,31-undecaazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-, 30-ethyl-33-[(Z,1S,2R)-1-hydroxy-2-methyl-hex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23,26,29,32-undecone;
Ciprol, 2-(4-(2,2-Dichlorocyclopropyl)phenoxy)2-methylpropanoic acid, 2-(p-(2,2-Dichlorocyclopropyl)phenoxy)-2-methylpropionic acid, 2-[4-(2,2-dichlorocyclopropyl)phenoxy]-2-methyl-propanoic acid;
cis-9, trans-11-conjugated linoleic acid, c9-t11-CLA, cis-9, trans-11-conjugated linoleic acid;
Citox, .alpha.,.alpha.-Bis(p-chlorophenyl)-.beta.,.beta.,.beta.-trichlorethane, 1,1′-(2,2,2-trichloroethane-1,1-diyl)bis(4-chlorobenzene), 1,1′-(2,2,2-Trichloroethylidene)bis(4-chlorobenzene);
CITRULLINE, (2S)-2-amino-5-(aminocarbonylamino)pentanoic acid, (2S)-2-amino-5-(carbamoylamino)pentanoic acid, (2S)-2-amino-5-ureido-pentanoic acid;
clebopride, clebopride, clebopride fumarate (1:1), clebopride maleate;
clevidipine, butyroxymethyl methyl 4-(2′,3′-dichlorophenyl)-2,6-dimethyl-1,4-dihydropyridine-3,5-dicarboxylate, clevidipine;
clobazam, clobazam;
clofarabine, 2-chloro-2′-arabino-fluoro-2′-deoxyadenosine, 2-chloro-2′-fluoroarabino-2′-deoxyadenosine, 2-chloro-9-(2-deoxy-2-fluoro-beta-D-arbinofuranosyl)adenine;
Clofibric Acid, 2-(4-Chlorophenoxy)-2-methylpropionic Acid, Clofibric Acid, Clofibrinic Acid;
clopidogrel, clopidogrel, clopidogrel bisulfate, clopidogrel, (+)(S)-isomer;
clotiazepam, clotiazepam;
clozapine N-oxide, clozapine N-oxide;
CNI 1493, CNI 1493, CNI-1493, N,N′-bis(3,5-diacetylphenyl)decanediamide tetrakis(amidinohydrazone)tetrahydrochloride;
Co 2-1970, 1-[(3S,5S,8R,9S,10S,13S,14S,17S)-3-hydroxy-10,13-dimethyl-3-(trifluoromethyl)-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-17-yl]ethanone, 3alpha-Hydroxy-3beta-(trifluoromethyl)-5alpha-pregnan-20-one, 3alpha-Hydroxy-3beta-trifluoromethyl-5alpha-pregnan-20-one;
Coagulin, antigens, cd142, blood coagulation factor iii, cd142 antigens;
compactin, 6-demethylmevinolin, compactin, CS 500;
CONT, 1-(.beta.-Ethylol)-2-methyl-5-nitro-3-azapyrrole, 1-(.beta.-Hydroxyethyl)-2-methyl-5-nitroimidazole, 1-(2-Hydroxy-1-ethyl)-2-methyl-5-nitroimidazole;
Cotrim, 3-(p-Aminophenylsulfonamido)-5-methylisoxazole, 3-(para-Aminophenylsulphonamido)-5-methylisoxazole, 3-Sulfanilamido-5-methylisoxazole;
coumarin, 1,2-Benzopyrone, 2-Propenoic acid, 3-(2-hydroxyphenyl)-, d-lactone, 2H-1-Benzopyran-2-one;
Crestor, calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonyl-amino)-6-propan-2-yl-pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoate, calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-2-(methyl-methylsulfonylamino)-6-propan-2-ylpyrimidin-5-yl]-3,5-dihydroxyhept-6-enoate, calcium (E,3R,5S)-7-[4-(4-fluorophenyl)-6-isopropyl-2-(mesyl-methyl-amino)pyrimidin-5-yl]-3,5-dihydroxy-hept-6-enoate;
Crodacid, 1-Tridecanecarboxylic acid, C14 fatty acid, CH3-[CH2]12-COOH;
Crypt-2,2,2,13,16,21,24-Hexaoxa-1,10-diazabicyclo-(8,8,8)-hexacosane, 2,2,2-Cryptand, 4,7,13,16,21,24-Hexaoxa-1,10-diazabicyclo(8.8.8)hexacosane;
cryptdin 3, cryptdin 3, cryptdin-3;
cryptotanshinone, cryptotanshinone;
cryptoxanthin, beta-caroten-3-ol, beta-cryptoxanthin, cryptoxanthin;
CUBE, (−)-cis-Rotenone, (−)-Rotenone, (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-alpha-isopropenyl-8,9-dimethoxy-;
CVT 3146, (1-(9-(3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl)-6-aminopurin-2-yl)pyrazol-4-yl)-N-methylcarboxamide, CVT 3146, CVT-3146;
cyanidin 3-rutinoside, cyanidin 3-rutinoside;
cyanidin-3-glucoside, cyanidin-3-glucoside;
cyanoginosin-LA, cyanoginosin-LA, cyanogynosin-LA, microcystin LA;
cyclohexyl carbamic acid 3′-carbamoylbiphenyl-3-yl ester, cyclohexyl carbamic acid 3′-carbamoylbiphenyl-3-yl ester, URB 597, URB-597;
cyclohexyl-methyl, cyclohexyl-methyl;
cyclopamine, cyclopamine;
Cyclopentenone, 1-cyclopent-2-enone, 2-Cyclopenten-1-one, 2-Cyclopenten-1-one (8CI)(9CI);
cyclopiazonic acid, cyclopiazonic acid;
Cyproterone Acetate, Androcur, Cyproterone Acetate, Cyproterone Acetate, (1 alpha,2 alpha)-Isomer;
cystathionine, 2-amino-4-[(2-amino-2-carboxyethyl)sulfanyl]butanoic acid, cystathionine, DL-Allocystathionine;
cysteamine, 2-amino-1-ethanethiol, 2-aminoethanethiol, beta-Aminoethanethiol;
cysteinyl-leukotriene, Cys-LT, cysteinyl-leukotriene;
cytochalasin B, cytochalasin B;
cytochalasin E, cytochalasin E;
DA 8159, 5-(2-propyloxy-5-(1-methyl-2-pyrollidinylethylamidosulfonyl)phenyl)-1-methyl-3-propyl-1,6-dihydro-7H-pyrazolo (4,3-d) pyrimidine-7-one, DA 8159, DA-8159;
Dacarbazine, 5-(3,3-Dimethyl-1-triazeno)imidazole-4-carboxamide, Biocarbazine, Dacarbazine;
DADSO, 2-Propene-1-sulfinic acid, thio-, S-allyl ester, 2-Propene-1-sulfinothioic acid S-2-propenyl ester, 2-Propene-1-sulfinothioic acid, S-2-propenyl ester (9CI);
daidzein, daidzein, diadzein;
danaproid, danaparoid, danaproid, danaproid sodium;
Daral, 3-[(2E)-2-[1-(5,6-dimethylhept-3-en-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexan-1-ol, 3-[(2E)-2-[1-(5,6-dimethylhept-3-en-2-yl)-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexan-1-ol, 3-[(2E)-2-[7a-methyl-1-(1,4,5-trimethylhex-2-enyl)-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-1-cyclohexanol;
Darifenacin, 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)acetamide, 2-[(3S)-1-[2-(2,3-dihydro-1-benzofuran-5-yl)ethyl]pyrrolidin-3-yl]-2,2-di(phenyl)ethanamide, 2-[(3S)-1-[2-(2,3-dihydrobenzofuran-5-yl)ethyl]-3-pyrrolidinyl]-2,2-di(phenyl)acetamide;
darunavir, darunavir, darunavir ethanolate, Prezista;
dasatinib, (18F)—N-(2-chloro-6-methylphenyl)-2-(6-(4-(2-hydroxyethyl)piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide, BMS 354825, BMS-354825;
Dayfen, 1-Methyl-4-piperidyl benzhydryl ether, 132-18-3 (HCL), 4-(Benzhydryloxy)-1-methylpiperidine;
DBPC, (2,5-Cyclohexadiene-1,4-diylidene)-dimalononitrile, 1-Hydroxy-4-methyl-2,6-di-tert-butylbenzene, 2,6-Bis(1,1-dimethylethyl)-4-methylphenol;
DDE, 1,1-Dichloro-2,2-bis(4′-chlorophenyl)ethylene, 1-chloro-4-[2,2-dichloro-1-(4-chlorophenyl)ethenyl]benzene, 4,4′-DDE;
decursin, decursin, decursinol;
Deethylamiodarone, (2-butyl-1-benzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodo-phenyl]methanone, (2-butyl-1-benzofuran-3-yl)-[4-(2-ethylaminoethoxy)-3,5-diiodophenyl]methanone, (2-Butyl-3-benzofuranyl)(4-(2-(ethylamino)ethoxy)-3,5-diiodophenyl)methanone;
deferiprone, 1,2-dimethyl-3-hydroxy-4-pyridinone, 1,2-dimethyl-3-hydroxypyrid-4-one, 1,2-dimethyl-3-hydroxypyridin-4-one;
deguelin, deguelin;
dehydroaripiprazole, dehydroaripiprazole;
dehydroxymethylepoxyquinomicin, dehydroxymethylepoxyquinomicin, DHMEQ cpd;
delta8-THC, (−)-.delta.-(sup8)-trans-Tetrahydrocannabinol, (−)-.DELTA.6-Tetrahydrocannabinol, (−)-.DELTA.8-Tetrahydrocannabinol;
denbinobin, 5-hydroxy-3,7-dimethoxy-1,4-phenanthraquinone, denbinobin;
denileukin diftitox, DAB(389)-IL-2, DAB(389)-interleukin 2, DAB(389)IL-2;
denopamine, (3,4-dimethoxyphenethylaminomethyl)-4-hydroxybenzyl alcohol, 1-(p-hydroxyphenyl)-2-((3,4-dimethoxyphenethyl)amino)ethanol, denopamine;
Depas, 4-(2-chlorophenyl)-2-ethyl-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 4-(o-Chlorophenyl)-2-ethyl-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine, 4H-s-Triazolo(3,4-c)thieno(2,3-e)(1,4)-diazepine, 6-(o-chlorophenyl)-8-ethyl-1-methyl-;
deramciclane, 2-phenyl-2-(dimethylaminoethoxy)-1,7,7-trimethylbicyclo(2.2.1)heptane hemifumarate, deramciclane, deramciclane, (1R,2S,4R)-isomer;
desethylchloroquine, deethylchloroquine, desethylchloroquine, desethylchloroquine dihydrochloride;
desflurane, Baxter Anaesthesia brand of desflurane, Baxter brand of desflurane, desflurane;
desisobutyrylciclesonide, desisobutyryl-ciclesonide, desisobutyrylciclesonide;
desmethylazelastine, desmethylazelastine;
Desmethyldeprenyl, (1-methyl-2-phenyl-ethyl)-propargyl-amine, 1-Phenyl-2-(N-2-propynyl)aminopropane, alpha-Methyl-N-2-propynylbenzeneethanamine;
dexloxiglumide, dexloxiglumide;
dFdC, 122111-03-9 (HYDROCHLORIDE), 2′,2′-DiF-dC, 2′,2′-DIFLUORODEOXYCYTIDINE;
DFMO, .alpha.-DFMO HCl, 2,5-diamino-2-(difluoromethyl)pentanoic acid, 2,5-diamino-2-(difluoromethyl)valeric acid;
DHEA, (+)-Dehydroisoandrosterone, (3-beta)-3-Hydroxyandrost-5-en-17-one, (3beta)-3-hydroxyandrost-5-en-17-one;
DHLA, ( )-6,8-Dimercaptooctanoic acid, ( )-Dihydrolipoic acid, 6,8-bis-sulfanyloctanoic acid;
di-(1-isoquinolinyl)-di-(pyridyl-2)butane, di-(1-isoquinolinyl)-di-(pyridyl-2)butane, S-147;
Diaben, 1-butyl-3-(4-methylphenyl)sulfonyl-urea, 1-butyl-3-(4-methylphenyl)sulfonylurea, 1-Butyl-3-(4-methylphenylsulfonyl)urea;
Diacomit, (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethyl-pent-1-en-3-ol, (E)-1-(1,3-benzodioxol-5-yl)-4,4-dimethylpent-1-en-3-ol, 1-(1,3-Benzodioxol-5-yl)-4,4-dimethyl-1-penten-3-ol;
diadenosine tetraphosphate, diadenosine tetraphosphate;
Dial, 1,4-Pentanediamine, N4-(6-chloro-2-methoxy-9-acridinyl)-N1,N1-diethyl-, 2-Methoxy-6-chloro-9-diethylaminopentylaminoacridine, 3-Chloro-7-methoxy-9-(1-methyl-4-diethylaminobutylamino)acridine;
DIAN, .beta.,.beta.′-Bis(p-hydroxyphenyl)propane, .beta.-Di-(p-hydroxyphenyl)propane, 2,2-(4,4′-Dihydroxydiphenyl)propane;
diarsenic trioxide, Arsenic trioxide, arsenic(III) oxide, As203;
diethyl maleate, diethyl maleate;
Digicor, 4-[(3S,5R,8R,9S,10S,13R,14S,17S)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-4-hydroxy-6-methyl-oxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradeca, 4-[(3S,5R,8R,9S,10S,13R,14S,17S)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-4-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,4-[(3S,5R,8R,9S,10S,13R,14S,17S)-3-[(2R,4S,5S,6R)-5-[(2S,4S,5S,6R)-5-[(2S,4S,5S,6R)-4,5-dihydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-4-hydroxy-6-methyloxan-2-yl]oxy-14-hydroxy-10,13-dimethyl-1,2,3,4,5,6,7,8,9,11,12,15,16,17-tetradecahyd;
Digitin, .beta.-D-Galactopyranoside, (2.alpha.,3.beta.,5.alpha.,15.beta.,25R)-2,15-dihydroxyspirostan-3-yl O-.beta.-D-glucopyranosyl-(1.fwdarw.3)-O-.beta.-D-galactopyranosyl-(1.fwdarw.2)-O-[.beta.-D-xylopyranosyl-(1.fwdarw.3)]-O-.beta.-D-glucopyranosyl-(1.fwdarw.4, Digitin, Digitogenin, glycoside;
Digoxin, AWD.pharma Brand of Digoxin, Bertek Brand of Digoxin, Digacin;
Dihydroqinghaosu, 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)—, 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R-(3alpha,5abeta,6beta,8abeta,9alpha,10alpha,12beta,12aR*))-, Dihydroartemisinin;
diisopropyl fluorophosphate, bis(propan-2-yl) fluorophosphate, Diisopropoxyphosphoryl fluoride, diisopropyl fluorophosphate;
dillapiol, dillapiol;
Dimethadione, 5,5-Dimethyl-2,4-oxazolidinedione, 5,5-Dimethyloxazolidine-2,4-dione, Dimethadione;
dimethyl fumarate, dimethyl fumarate, dimethylfumarate, Fumaderm;
dimethyl-hydrazide, dimethyl-hydrazide;
dimethylamino-purine, dimethylamino-purine;
dimuonium, (mu(+)e(−))2, dimuonium, Mu2;
dinitrophenol, dinitrophenol;
Dinoprostone, Dinoprostone, PGE2, PGE2 alpha;
dioxirane, dioxirane;
Dipalmitoyl, 1,2-Di-O-palmitoyl-3-sn-glyceryl-O-phosphoric acid, 1,2-dihexadecanoyl-sn-glycero-3-phosphate, 1,2-Dipalmitoyl-3-sn-phosphatidic acid;
diphenylalanine, diphenylalanine;
diphenyleneiodonium, diphenylene iodonium, diphenyleneiodium chloride, diphenyleneiodonium;
discodermolide, discodermolide;
diuretic, diuretic, diuretics;
Diuron, 3-(3,4-Dichlorophenyl)-1,1-dimethylurea, DCMU, Diuron;
divinyl benzene, divinyl benzene;
dl-Ipr, (+)-Isoprenaline, (+)-Isoproterenol, (+−)-Isoprenaline;
DMGG, 1,1-Dimethyl biguanide, 1,1-Dimethylbiguanide, 1115-70-4 (HCL);
DMPX, 1H-Purine-2,6-dione, 3,7-dihydro-3,7-dimethyl-1-(2-propynyl)-, 3,7-Dimethyl-1-(2-propynyl)xanthine, 3,7-dimethyl-1-prop-2-ynyl-purine-2,6-dione;
DMSO, (CH3)2SO, (DMSO), (methanesulfinyl)methane;
Doconexent, (4Z,7Z,10Z,13Z,16Z,19Z)-4,7,10,13,16,19-Docosahexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)-docosa-4,7,10,13,16,19-hexaenoic acid, (4Z,7Z,10Z,13Z,16Z,19Z)-Docosahexaenoic acid;
dodecyl-phosphocholine, dodecyl-phosphocholine;
dodecyloctaethyleneglycol monoether, dodecyloctaethyleneglycol monoether;
DOTA, 1,4,7,10-Dota, 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid, 1,4,7,10-Tetraazacyclododecane-1,4,7,10-tetraacetic acid;
Doxazosin, 1 (4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-((2,3-dihydro-1,4-benzodioxin-2-yl)carbonyl)piperazine, Alfamedin, Aliud Brand of Doxazosin Mesylate;
Doxycycline, alpha 6 Deoxyoxytetracycline, alpha-6-Deoxyoxytetracycline, BMY 28689;
DPCPX, 1,3-Dipropyl-8-cyclopentylxanthine, 1,3-Dpcpx, 1H-Purine-2,6-dione, 8-cyclopentyl-3,7-dihydro-1,3-dipropyl-;
Droxia, 1-HYDROXYUREA, Biosupressin, Carbamohydroxamic acid;
DTMC, 1,1-bis(4-chlorophenyl)-2,2,2-trichloroethanol, 1,1-Bis(chlorophenyl)-2,2,2-trichloroethanol, 1,1-bis(p-chlorophenyl)-2,2,2-trichloroethanol;
dulcin, dulcin, p-ethoxyphenylurea, phenetolcarbamide;
Dxms, (11beta,16alpha)-9-Fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, (11beta,16beta)-9-fluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione, (3H)-Dexamethasone;
Dynatra, (3H)-Dopamine, .alpha.-(3,4-Dihydroxyphenyl)-.beta.-aminoethane, .Beta.-(3,4-Dihydroxyphenyl)ethylamine hydrochloride;
E 10, E 10, E-10, N-(2-aminoethyl)-N-(2-(octylamino)ethyl)glycine monohydrochloride, mixt. with N,N-bis(2-(octylamino)ethyl)glycine monohydrochloride;
E-MIX 80, .gamma.-Tocopherol, 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)-6-chromanol, 2,7,8-trimethyl-2-(4,8,12-trimethyltridecyl)chroman-6-ol;
E.O., 1,2-Epoxyethane, Alpha,beta-oxidoethane, alpha-Hydro-omega-hydroxypoly(oxy(methyl-1,2-ethanediyl)), (chloromethyl)oxirane polymer;
EACA, .epsilon. S, .epsilon.-Aminocaproic acid, .epsilon.-Aminohexanoic acid;
ebastine, 4-diphenylmethoxy-1-(3-(4-tert-butylbenzoyl)propyl)piperidine, Almirall brand of ebastine, Bactil;
ebrotidine, 4-bromo-N-(((2-(((-((diaminomethylene)amino)-4-thiazolyl)methyl)thio)ethyl)amino)methylene)benzenesulfonamide, ebrotidine;
Econ, ( )-alpha-Tocopherol, (+)-alpha-Tocopherol acetate, (+)-alpha-Tocopheryl acetate;
econazole, 1-(2,4-Dichloro-beta-((p-chlorobenzyl)oxy)phenethyl)imidazole, 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole, C1c1ccc(COC(Cn2ccnc2)c3ccc(C1)cc3C1)cc1;
ecteinascidin 743, ecteinascidin 743, ET 743, ET-743;
Edex, (11alpha,13E,15S)-11,15-dihydroxy-9-oxoprost-13-en-1-oic acid, (11alpha,13E,15S)-11,15-Dihydroxy-9-oxoprost-13-enoic acid, (13E)-(15S)-11alpha,15-Dihydroxy-9-oxoprost-13-enoate;
efavirenz, 6-chloro-4-cyclopropylethynyl-4-trifluoromethyl-1,4-dihydro-2H-3,1-benzoxazin-2-one, Bristol-Myers Squibb brand of efavirenz, DMP 266;
EGCg, (−)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate, (−)-cis-3,3′,4′,5,5′,7-Hexahydroxy-flavane-3-gallate, (−)-Epigallocatechin gallate;
EGTA, (Ethylenebis(oxyethylenenitrilo))tetraacetic acid, 1,2-Bis(2-aminoethoxyethane)-N,N,N′,N′-tetraacetic acid, 1,2-Bis(2-dicarboxymethylaminoethoxy)ethane;
eletriptan, 3-(1-methyl-2-pyrrolidinylmethyl)-5-(2-(phenylsulfonyl)ethyl)-1H-indole hydrobromide, eletriptan, eletriptan hydrobromide;
Elicide, Elicide, Estivin, Ethylmercurithiosalicylate sodium;
Empecid, (2-Chlorophenyl)diphenyl-1-imidazolylmethane, (Chlorotrityl)imidazole, 1-((2-Chlorophenyl)diphenylmethyl)-1H-imidazole;
endomorphin 1, (Dmtl)endomorphin-1, endomorphin 1, endomorphin-1;
enflurane, 2-chloro-1,1,2-trifluoroethyl difluoromethyl ether, 2-chloro-1-(difluoromethoxy)-1,1,2-trifluoroethane, Alyrane;
enone, enone;
entacapone, 2-cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide, Comtan, Comtess;
Entex, 4-Methylmercapto-3-methylphenyl dimethyl thiophosphate, Bay-Bassa, Baycid;
enzastaurin, enzastaurin, LY317615.HCl;
EPC-K(1), ascorbic acid-2-(3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1-benzopyran-6-yl hydrogen phosphate), EPC-K, EPC-K(1);
EPEG, (−)-Etoposide, (5R,5aR,8aR,9S)-9-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[5,6-d][1,3]dioxin-6-yl]oxy]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-isobenzofurano[6,5-f][1,3]benzodioxol-6-one, (5R,5aR,8aR,9S)-9-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[5,6-d][1,3]dioxin-6-yl]oxy]-5-(4-hydroxy-3,5-dimethoxyphenyl)-5a,8,8a,9-tetrahydro-5H-isobenzofurano[6,5-f][1,3]benzodioxol-6-one;
EPIB, .alpha.-(p-Chlorophenoxy)isobutyric acid, ethyl ester, .alpha.-p-Chlorophenoxyisobutyryl ethyl ester, 19 more names available;
epibatidine, epibatidine;
Epicar, (+)-pilocarpine, (35,4R)-3-ethyl-4-[(1-methyl-1H-imidazol-5-yl)methyl]dihydrofuran-2(3H)-one, (35,4R)-3-ethyl-4-[(3-methyl-4-imidazolyl)methyl]-2-tetrahydrofuranone;
epoxybergamottin, epoxybergamottin;
epsilon-viniferin, epsilon-viniferin;
erastin, erastin;
ergosterol-5,8-peroxide, 3-hydroxy-5,7-epidioxyergosta-6,22-diene, 5,8-epidioxyergosta-6,22-dien-3-ol, ergosterol endoperoxide;
erlotinib, CP 358,774, CP 358774, CP-358,774;
erucin, erucin;
Eryc, 6-(4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, 6-(4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-dione, 6-(4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl)oxy-14-ethyl-7,12,13-trihydroxy-4-(5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl)oxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-quinone;
erythritol anhydride, erythritol anhydride;
esterbut-3, esterbut-3;
Estriol, 16 alpha Hydroxy Estradiol, 16 Epiestriol, 16 Hydroxyestradiol;
ET18-Ome, ( )-ET-18-OCH3, ( )-ET-18-OMe, (2-methoxy-3-octadecoxy-propyl) 2-trimethylammonioethyl phosphate;
Etfc cpd, 2H-1-Benzopyran-2-one, 7-ethoxy-4-(trifluoromethyl)-, 7-ethoxy-4-(trifluoromethyl)-2-chromenone, 7-Ethoxy-4-(trifluoromethyl)-2H-1-benzypyran-2-one;
Ethynodiol Diacetate, (3 beta, 17 alpha)-19-Norpregn-4-en-20-yne-3,17 diol Diacetate, Continuin, Ethyndiol Diacetate;
Eticol, Chinorta, Chinorto, diethyl(4-nitrophenyl)phosphate;
Etidronic Acid, (1-hydroxyethylene)diphosphonic acid, (1-hydroxyethylene)diphosphonic acid, Tetrapotassium Salt, 1,1-hydroxyethylenediphosphonate;
Etoposide, alpha-D-Glucopyranosyl Isomer Etoposide, Baxter Brand of Etoposide, Baxter Oncology Brand of Etoposide;
etoricoxib, Arcoxia, etoricoxib, L-791456;
etravirine, etravirine, R165335, TMC 125;
Eufor, (+) or (−)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine, (+) or (−)-N-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine, (+−)-N-Methyl-3-phenyl-3-((alpha,alpha,alpha-trifluoro-p-tolyl)oxy)propylamine;
Eugenol, 1,3,4-Eugenol, 1-Hydroxy-2-methoxy-4-allylbenzene, 1-Hydroxy-2-methoxy-4-prop-2-enylbenzene;
eupatilin, eupatilin;
everolimus, 40-O-(2-hydroxyethyl)-rapamycin, Certican, everolimus;
Evex, (+)-3,17beta-Estradiol, (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol, (17beta)-estra-1(10),2,4-triene-3,17-diol;
Evodin, (4aS,6aR,8aR,8bR,9aS,12R,12aS,14aR,14bR)-12-(3-furyl)-6,6,8a,12a-tetramethyldecahydro-3H-oxireno[d]pyrano[4′,3′:3,3a][2]benzofuro[5,4-f]isochromene-3,8,10(6H,9aH)-trione, 7,16-Dioxo-7,16-dideoxylimondiol, Citrolimonin;
exenatide, AC 2993, AC 2993 LAR, Byetta;
Extina, (+−)-cis-1-Acetyl-4-(p-((2-(2,4-dichlorophenyl)-2-(imidazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazine, (−)-Ketoconazole, (2S,4R)-ketoconazole;
Ezerin, (3aS,8aR)-1,3a,8-trimethyl-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indol-5-yl methylcarbamate, (3aS-cis)-1,2,3,3a,8,8a-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)indol-5-ol methylcarbamate (ester), 1,2,3,3abeta,8abeta-Hexahydro-1,3a,8-trimethylpyrrolo(2,3-b)-indol-5-yl methylcarbamate;
ezetimib, ezetimib;
Facet, 3,7-Dichloro-8-quinolinecarboxylic acid, 3,7-Dichloroquinoline-8-carboxylic acid, 8-Quinolinecarboxylic acid, 3,7-dichloro-;
Facid, (2S)-2-[[4-[(2-amino-4-keto-1H-pteridin-6-yl)methylamino]benzoyl]amino]glutaric acid, (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]benzoyl]amino]pentanedioic acid, (2S)-2-[[4-[(2-amino-4-oxo-1H-pteridin-6-yl)methylamino]phenyl]carbonylamino]pentanedioic acid;
facile, facile;
FAMP, 2-F-ara-AMP, 2-Fluoro-9-(5-O-phosphono-beta-D-arabinofuranosyl)-9H-purin-6-amine, 2-Fluoro-ARA AMP;
Farnesyl-PP, (2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl trihydrogen diphosphate, (2E,6E)-Farnesyl diphosphate, (2E,6E)-Farnesyl pyrophosphate;
farnesylthiosalicylic acid, farnesylthiosalicylic acid, S-farnesylthiosalicylic acid, S-trans,transfarnesylthiosalicylic acid;
febuxostat, 2-(3-cyano-4-isobutoxyphenyl)-4-methyl-5-thiazolecarboxylic acid, febuxostat, TEI 6720;
felbamate, 2-phenyl-1,3-propanediol dicarbamate, ADD-03055, Essex brand of felbamate;
fenitrothion, fenitrothion, MEP, O,O-dimethyl O-(3-methyl-4-nitrophenyl)thiophosphate;
fenofibric acid, 2-(4-(4′-chlorophenoxy)phenoxy)propionic acid, fenofibric acid, fenofibric acid potassium salt;
Fenretinide, 13-cis-Isomer Fenretinide, 4 Hydroxyphenylretinamide, 4-HPR;
ferulic acid, 4-hydroxy-3-methoxycinnamic acid, 8,8′-diferulic acid, ferulic acid;
fingolimod, 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol hydrochloride, fingolimod, fingolimod hydrochloride;
fipronil, 5-amino-1-[2,6-dichloro-4-(trifluoromethyl)phenyl]-4-[(trifluoromethyl)sulfinyl]-1H-pyrazole-3-carbonitrile, fipronil;
fisetin, 2-(3,4-Dihydroxyphenyl)-3,7-dihydroxy-4H-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,7-dihydroxy-4H-chromen-4-one, 3,3′,4′,7-Tetrahydroxyflavone;
Flanin F, 1H-Purin-6-amine, flavin dinucleotide, 1H-Purin-6-amine, flavine dinucleotide, Adenine-flavin dinucleotide;
Flavon, 2-Phenyl-.gamma.-benzopyrone, 2-Phenyl-4-benzopyron, 2-phenyl-4-chromenone;
flavonols, a flavonol, flavonols;
flavopiridol, (−)cis-5,7-dihydroxy-2-(2-chlorophenyl)-8-(4-(3-hydroxy-1-methyl)piperidinyl)-4H-1-benzopyran-4-one, flavopiridol, HMR 1275;
Flavyl, 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N,N-dimethyl-, 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N,N-dimethyl-, 10,11-Dihydro-5-(gamma-dimethylaminopropylidene)-5H-dibenzo(a,d)cycloheptene;
FLCZ, .alpha.-(2,4-Difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-1H-1,2,4-triazole-1-ethanol, 1H-1,2,4-Triazole-1-ethanol, .alpha.-(2,4-difluorophenyl)-.alpha.-(1H-1,2,4-triazol-1-ylmethyl)-, 1H-1,2,4-Triazole-1-ethanol, alpha-(2,4-difluorophenyl)-alpha-(1H-1,2,4-triazol-1-ylmethyl)-;
flufenamic acid, 2-[3-(trifluoromethyl)anilino]benzoic acid, 2-[[3-(TRIFLUOROMETHYL)PHENYL]AMINO]BENZOIC ACID, 3′-trifluoromethyldiphenylamine-2-carboxylic acid;
Flunitrazepam, 1A Brand of Flunitrazepam, betapharm Brand of Flunitrazepam, ct Arzneimittel Brand of Flunitrazepam;
fluorexon, fluorexon;
Fluorouracil, 5 Fluorouracil, 5 Fluorouracil biosyn, 5 FU Lederle;
fluvoxamine, (1E)-5-methoxy-1-[4-(trifluoromethyl)phenyl]pentan-1-one O-(2-aminoethyl)oxime, fluvoxamine;
fondaparinux, Arixtra, fondaparinux, fondaparinux sodium;
Format, 2-Pyridine carboxylic acid, 3,6-dichloro-, 2-Pyridinecarboxylic acid, 3,6-dichloro-, 3,6-Dichloro-2-pyridinecarboxylic acid;
fosamprenavir, (3-(((4-aminophenyl)sulfonyl)(2-methylpropyl)amino)-1-(phenylmethyl)-2-(phosphonooxy)propyl)carbamic acid C-(tetrahydro-3-furanyl) ester, fos-amprenavir, fosamprenavir;
fraxin, fraxin;
fucoidan, fucan sulfate, fucan sulfate Hor-1, fucoidan;
fulvestrant, 7-(9-(4,4,5,5,5-pentafluoropentylsulfinyl)nonyl)estra-1,3,5(10)-triene-3,17-diol, AstraZeneca brand of fulvestrant, Faslodex;
fumagillin, (2E,4E,6E,8E)-10-({(3R,4S,5S,6R)-5-methoxy-4-[(2R,3R)-2-methyl-3-(3-methylbut-2-en-1-yl)oxiran-2-yl]-1-oxaspiro[2.5]oct-6-yl}oxy)-10-oxodeca-2,4,6,8-tetraenoic acid, 2,4,6,8-decatetraenedioic acid, 4-(1,2-epoxy-1,5-dimethyl-4-hexenyl)-5-methoxy-1-oxaspiro(2,5)oct-6-yl ester, Fugillin;
furafylline, furafylline;
Furamon, (2-Furylmethyl)trimethylammonium iodide, 2-Furanmethanaminium, N,N,N-trimethyl-, iodide, 2-Furanmethanaminium, N,N,N-trimethyl-, iodide (9CI);
gadolinium, 64Gd, gadolinio, gadolinium;
Gadolinium DTPA, Berlex Brand of Gadopentetate Dimeglumine, Gadolinium Diethylenetriaminepenta acetic Acid, Gadolinium Diethylenetriaminepenta-acetic Acid;
galactocerebroside, galactocerebroside;
galactomannan, galactomannan;
galangin, 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-4H-chromen-4-one, 3,5,7-Trihydroxyflavone;
galaturonate, (2R,3S,4S,5R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid, (2R,3S,4S,5S,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid, (2S,3R,4S,5R,6R)-3,4,5,6-tetrahydroxyoxane-2-carboxylic acid;
gallic acid, 3,4,5-trihydroxybenzoic acid, gallic acid, Pyrogallol-5-carboxylic acid;
Gallogen, (1)Benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,3,7,8-tetrahydroxy-, 2,3,7,8-Tetrahydroxy(l)benzopyrano(5,4,3-cde)(1)benzopyran-5,10-dione, 2,3,7,8-Tetrahydroxy(l)benzopyrano(5,4,3-cde)-(1)benzopyran-5,10-dione;
gambierol, gambierol;
Gambogic acid, Gambogic acid;
gamma-butyric-acid, gamma-butyric-acid;
gastrin 17, gastrin 17;
gatifloxacin, 1-cyclopropyl-1,4-dihydro-6-fluoro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinolinecarboxylic acid, AM 1155, AM-1155;
gefitinib, 4-(3′-chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, COc1cc2ncnc(Nc3ccc(F)c(Cl)c3)c2cc1OCCCN4CCOCC4, gefitinib;
Geldanamycin, 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9,13-dihydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, 9-carbamate (8CI), 2-azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-[(aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, (4E,6Z,8S,9S,10E,12S,13R,14S,16R)—, 2-Azabicyclo[16.3.1]docosa-4,6,10,18,21-pentaene-3,20,22-trione, 9-[(aminocarbonyl)oxy]-13-hydroxy-8,14,19-trimethoxy-4,10,12,16-tetramethyl-, [8S-(4E,6Z,8R*,9R*,10E,12R*,13S*,14R*,16S*)]-;
gemtuzumab, CMA 676, CMA-676, gemtuzumab;
gepirone, gepirone;
geraniol, (2E)-3,7-dimethyl-2,6-octadien-1-ol, (2E)-3,7-dimethylocta-2,6-dien-1-ol, (E)-3,7-dimethyl-2,6-octadien-1-ol;
geranylcoumarin, geranylcoumarin;
Gestodene, 13-ethyl-17-hydroxy-18,19-dinor-17 alpha-pregna-4,15-dien-20-yn-3-one, 17-alpha-ethinyl-13-ethyl-17 beta-hydroxy-4,15-gonadien-3-one, Gestoden;
gingerol, (6)-gingerol, 6-gingerol, gingerol;
ginsenoside Rd, ginsenoside Rd, ginsenoside-Rd;
ginsenoside Rf, ginsenoside Rf;
ginsenoside Rg1, ginsenoside Rg1, ginsenoside-Rg(1), sanchinoside C(1);
ginsenoside Rh2, ginsenoside Rh2;
GLCa, (2S,3R,4S,5R)-3,4,5-trihydroxy-6-keto-pipecolinic acid, (2S,3R,4S,5R)-3,4,5-trihydroxy-6-oxo-2-piperidinecarboxylic acid, (2S,3R,4S,5R)-3,4,5-trihydroxy-6-oxo-piperidine-2-carboxylic acid;
Glumin, (2S)-2,5-diamino-5-keto-valeric acid, (2S)-2,5-diamino-5-oxo-pentanoic acid, (2S)-2,5-diamino-5-oxopentanoic acid;
GnRH, cystorelin, dirigestran, factrel;
gossypol, gossypol;
GR 79236X, (2S,3S,4S,5R)-2-[6-[(2-hydroxycyclopentyl)amino]-9-purinyl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2S,3S,4S,5R)-2-[6-[(2-hydroxycyclopentyl)amino]purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol, (2S,3S,4S,5R)-2-[6-[(2-hydroxycyclopentyl)amino]purin-9-yl]-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;
gramicidin S,1,10-anhydro(L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithine), Cyclo(L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl-L-valyl-L-ornithyl-L-leucyl-D-phenylalanyl-L-prolyl), Gramicidin C;
Granisetron, 1-Methyl-N-(endo-9-Methyl-9-Azabicyclo(3.3.1)non-3-yl)-1H-Indazole-3-Carboxamide, BRL 43694, BRL 43694A;
Grofo, Bonidel, Brodan, Chloropyrifos solution;
Guggulsterone, (17E)-Pregna-4,17(20)-diene-3,16-dione, (17E)-pregna-4,17-diene-3,16-dione, (8R,9S,10R,13S,14S,17E)-17-ethylidene-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15-decahydrocyclopenta[a]phenanthrene-3,16-dione;
Halan, (R)-2-Bromo-2-chloro-1,1,1-trifluoroethane, 1,1,1-Trifluoro-2-bromo-2-chloroethane, 1,1,1-Trifluoro-2-chloro-2-bromoethane;
halofuginone, 7-bromo-6-chlorofebrifugine, halofuginone, halofunginone;
harmine, harmine;
Harzol, (3beta)-stigmast-5-en-3-ol, (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol, (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,4R)-4-ethyl-1,5-dimethylhexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol;
hassium, 108Hs, hahnium, hassio;
HDMTX, ( )Amethopterin, (+)-Amethopterin, 2-[[4-[(2,4-diaminopteridin-6-yl)methyl-methyl-amino]benzoyl]amino]glutaric acid;
Hectorol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5R)-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(E,1R,4R)-1,4,5-trimethylhex-2-enyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol;
helenalin, helenalin;
herbimycin, geldanamycin, 17-demethoxy-15-methoxy-11-O-methyl-, (15R)—, herbimycin, herbimycin A;
hesperadin, hesperadin;
HESPERETIN, 3′,5,7-Trihydroxy-4′-methoxyflavanone, 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)—, 5,7,3′-Trihydroxy-4′-methoxyflavanone;
hexarelin, hexarelin;
Hgln, (+−)-Glutamine, (2R)-2,5-diamino-5-oxopentanoic acid, .gamma.-Glutamine;
himbacine, himbacine, NSC-23969, NSC23969;
Hocus, (−)(5.alpha.,6.alpha.)-7,8-Didehydro-4,5-epoxy-17-methylmorphinan-3,6-diol, (−)-Heroin hydrochloride, (−)-Morphine;
honokiol, honokiol;
Horner, (+)-(5Z,7E)-26,26,26,27,27,27-Hexafluoro-9,10-secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-(trifluoromethyl)hexyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-7a-methyl-1-[(1R)-6,6,6-trifluoro-5-hydroxy-1-methyl-5-(trifluoromethyl)hexyl]-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol;
HU 211, 1,1-dimethylheptyl-11-hydroxytetrahydrocannabinol, 1,1-dimethylheptyl-7-hydroxy-delta(6)-tetrahydrocannabinol, 11-hydroxy-delta(8)-tetrahydrocannabinol-dimethylheptyl;
HyateC, antihemophilic factor, blood coagulation factor viii, coagulation factor viii;
Hydoxin, 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine, 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine, 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine;
hydride, hydride, hydrogen anion;
hydroxycotinine, 1-methyl-3-hydroxy-5-(3-pyridyl)-2-pyrrolidinone, 3′-hydroxycotinine, hydroxycotinine;
hydroxylamine, dihydridohydroxidonitrogen, H2NHO, HYDROXYAMINE;
Hyhorin, Conestoral, Conjugated Estrogens, Conjugated estrogens: sodium estrone sulfate;
Hypaque, 3,5-diacetamido-2,4,6-triiodo-benzoic acid; sodium, 3,5-diacetamido-2,4,6-triiodobenzoic acid; sodium, Diatrizoate;
hyperforin, hyperforin, octahydrohyperforin, tetrahydrohyperforin;
hypericin, hypericin, mono-(123I)iodohypericin;
Hypericum-perforatum, Hypericum-perforatum;
hypochlorous acid, Chlor(I)-saeure, chloranol, HClO;
iberin, iberin;
IBMX, 1-methyl-3-(2-methylpropyl)-3,7-dihydro-1H-purine-2,6-dione, 1-methyl-3-(2-methylpropyl)-3,9-dihydro-1H-purine-2,6-dione, 1-methyl-3-(2-methylpropyl)-7H-purine-2,6-dione;
ibopamine, Escandine, ibopamine, ibopamine hydrochloride;
ibudilast, 3-isobutyryl-2-isopropylpyrazolo(1,5-a)pyridine, ibudilast, KC 404;
icariin, icariin;
icaritin, icaritin;
icilin, AG-3-5 compound, icilin;
ilimaquinone, ilimaquinone;
Imadyl, (+−)-6-Chloro-alpha-methylcarbazole-2-acetic acid, (.+−.)-6-Chloro-.alpha.-methylcarbazole-2-acetic acid, 2-(6-Chloro-9H-carbazol-2-yl)propanoic acid;
imatinib, CGP 57148, CGP-57148, CGP57148B;
imidafenacin, imidafenacin, KRP 197, KRP-197;
imidazo-pyridine, imidazo-pyridine;
imidazolidin-2-one, 1,3-ethyleneurea, 2-imidazolidinone, 2-imidazolidone;
imidazolidin-one, imidazolidin-one;
imidazolidine, C1CNCN1, imidazolidine;
imidazolyl-disulfide, imidazolyl-disulfide;
Imizin, 10,11-Dihydro-N,N-dimethyl-5H-dibenz[b,f]azepine-5-propanamine hydrochloride, 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethyl-propan-1-amine hydrochloride, 3-(5,6-dihydrobenzo[b][1]benzazepin-11-yl)-N,N-dimethylpropan-1-amine hydrochloride;
Impulsin, Anandamide (16:0), Hexadecanamide, N-(2-hydroxyethyl)-, Hydroxyethylpalmitamide;
Imutex, 1,3-Diaza-2,4-cyclopentadiene, 1,3-Diaza-2,4-cyclopentadiene-, 1,3-Diazole;
indiplon, indiplon, NBI 34060;
indirubin, indigo red, indirubin;
indole-3-acetic acid, 1H-indol-3-ylacetic acid, 2-(indol-3-yl)ethanoic acid, 3-Indolylessigsaeure;
indole-3-methanol, 1H-indol-3-ylmethanol, 3-hydroxymethylindole, 3-indolylcarbinol;
indolin-2-one, 3Z-3-((1H-pyrrol-2-yl)-methylidene)-1-(1-piperidinylmethyl)-1,3-2H-indol-2-one, indolin-2-one, tetrahydroindolinone;
indolin-one, indolin-one;
infliximab, Centocor brand of infliximab, Essex brand of infliximab, infliximab;
inhibin B, inhibin B;
INOmax, Amidogen, oxo-, INOmax, Mononitrogen monoxide;
inositol-1,3,4,5-tetrakisphosphate, inositol-1,3,4,5-tetrakisphosphate;
inulin, (1,2-beta-D-fructosyl)n, (2,1-beta-D-Fructosyl)n, (2->1)-beta-D-fructofuranan;
iodomethane, CH3I, Iodmethan, iodomethane;
iodoresiniferatoxin, I-RTX cpd, iodo-resiniferatoxin, iodoresiniferatoxin;
ionophore, ionophore, ionophores;
IPADE, 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-, 1H-Purin-6-amine, N-(3-methyl-2-butenyl)-(9CI), 3-methylbut-2-enyl-(7H-purin-6-yl)amine;
IPOMEANOL, 1-(3-Furanyl)-4-hydroxy-1-pentanone, 1-(3-Furyl)-4-hydroxy-1-pentanone, 1-(3-Furyl)-4-hydroxy-4-pentanone;
Iressa, (3-chloro-4-fluoro-phenyl)-[7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-yl]amine, 4-(3′-Chloro-4′-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline, 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-;
irinotecan, 7-ethyl-10-hydroxycamptothecin, ALIRI cpd, Camptosar;
irisolidone, irisolidone;
Isatin, 1H-Indole-2,3-dione, 2,3-Diketoindoline, 2,3-Dioxo-2,3-dihydroindole;
isaxonine, isaxonine, isopropylamino-2-pyrimidine phosphate, N-isopropyl-amino-2-pyrimidine orthophosphate;
isoamylol, 1-HYDROXY-3-METHYLBUTANE, 3-methyl-1-butanol, 3-methylbutan-1-ol;
isobutyl-methyl-Xanthine, isobutyl-methyl-Xanthine;
Isodonol, (1S,4AR,5S,6S,14S)-1,5,6,14-tetrahydroxy-4,4-dimethyl-8-methylenedecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one, Isodonol, Oridonin;
isoflavone, 3-phenyl-4H-1-benzopyran-4-one, 3-phenyl-4H-chromen-4-one, 3-Phenylchromone;
isoflurane, 1-chloro-2,2,2-trifluoroethyl difluoromethyl ether, 2-chloro-2-difluoromethoxy-1,1,1-trifluoroethane, Aerrane;
Isol, ( )-2-Methyl-2,4-pentanediol, (+−)-2-Methyl-2,4-pentanediol, (4r)-2-Methylpentane-2,4-Diol;
Isoliquiritigenin, (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one, (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one, (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one;
isometronidazole, isometronidazole;
isoprenoids, isoprenoid, isoprenoids;
Isopropyl Thiogalactoside, IPTG, Isopropyl 1 Thio beta D galactopyranoside, Isopropyl 1-Thio-beta-D-galactopyranoside;
isosilybin A, isosilybin A, isosilybin B;
isothiocyanates, isothiocyanates;
Isotretinoin, 13 cis Retinoic Acid, 13-cis-Retinoic Acid, Accutane;
istradefylline, 8-(2-(3,4-dimethoxyphenyl)ethenyl)-1,3-diethyl-3,7-dihydro-7-methyl-1H-purine-2,6-dione, istradefylline, KW 6002;
ivabradine, 7,8-dimethoxy-3-(3-(((4,5-dimethoxybenzocyclobutan-1-yl)methyl)methylamino)propyl)-1,3,4,5-tetrahydro-2H-benzazepin-2-one, ivabradine, S 16257;
ixabepilone, BMS 247550, BMS-247550, BMS247550;
jadomycin B, (1S,3aS)-1-[(2S)-butan-2-yl]-7-hydroxy-1,3a,5-trimethyl-2,8,13-trioxo-1,2,8,13-tetrahydro-3aH-benzo[b][1,3]oxazolo[3,2-f]phenanthridin-12-yl 2,6-dideoxy-alpha-L-ribo-hexopyranoside, jadomycin B;
Jexin, (+) Tubocurarine, (+)-Tubocurarine, 13H-4,6:21,24-Dietheno-8,12-metheno-1H-pyrido(3′,2′:14,15)(1,11)dioxacycloeicosino(2,3,4-ij)isoquinolinium, 2,3,13a,14,15,16,25,25a-octahydro-9,19-dihydroxy-18,29-dimethoxy-1,14,14-trimethyl-, (13aR,25aS)—;
JHW 015,1-propyl-2-methyl-3-(1-naphthoyl)indole, JHW 015, JHW-015;
K-PAM, 2-Propenamide, 2-Propenamide, homopolymer, 2-Propeneamide;
kaempferol, 3,4′,5,7-Tetrahydroxyflavone, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one, 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4′-Trihydroxyflavonol;
kaempferol-3-O-(2,3,4-tri-O-acetyl-alpha-1-rhamnopyranoside), kaempferol-3-O-(2,3,4-tri-O-acetyl-alpha-1-rhamnopyranoside), KTARP cpd;
KAFA, 1-Acetamido-4-ethoxybenzene, 1-Acetyl-p-phenetidin, 4′ -Ethoxyacetanilide;
Kaken, (1S-(1alpha(S*),3alpha,5beta))-4-(2-(3,5-Dimethyl-2-oxo-cyclohexyl))-2-hydroxyethyl-2,6-piperidinedione, .beta.-[2-(3,5-Dimethyl-2-oxocyclohexyl)-2-hydroxyethyl]glutarimide, 2,6-Piperidinedione, 4-(2-(3,5-dimethyl-2-oxocyclohexyl)-2-hydroxyethyl)-, (1S-(1alpha(S*),3alpha,5beta))-;
Kamalin, (E)-1-(6-((3-Acetyl-2,4,6-trihydroxy-5-methylphenyl)methyl)-5,7-dihydroxy-2,2-dimethyl-2H-1-benzopyran-8-yl)-3-phenyl-2-propen-1-one, (E)-1-[6-(3-acetyl-2,4,6-trihydroxy-5-methyl-benzyl)-5,7-dihydroxy-2,2-dimethyl-chromen-8-yl]-3-phenyl-prop-2-en-1-one, (E)-1-[6-[(3-acetyl-2,4,6-trihydroxy-5-methyl-phenyl)methyl]-5,7-dihydroxy-2,2-dimethyl-chromen-8-yl]-3-phenyl-prop-2-en-1-one;
Kathon 886, Kathon 886, Kathon 886 biocide, Kathon biocide;
KB 141, KB 141, KB-141, KB141 cpd;
Kemi, (+−)-Propranolol, (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol, (2S)-1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol;
kenpaullone, 1-azakenpaullone, 9-bromo-7,12-dihydroindolo(3,2-d)(1)benzazepin-6(5H)-one, kenpaullone;
Ketamine, 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone, Calipsol, Calypsol;
Keto-pgfl alpha, Keto-pgfl alpha;
ketoglutarate, .alpha.-Ketoglutaric acid, .alpha.-Oxoglutaric acid, 2-ketoglutarate;
Kipca, 1,4-naphthalenedione, 2-methyl-, 1,4-Naphthalenedione, 2-methyl-, radical ion(1-), 1,4-Naphthoquinone, 2-methyl-;
KMD 3213, 1-(3-hydroxypropyl)-5-(2-(2-(2-(2,2,2-trifluoroethoxy)phenoxy)ethylamino)propyl)indoline-7-carboxamide, KMD 3213, KMD-3213;
KMTB, 2-keto-4-(methylthio)butyric acid, 2-Keto-4-methylthiobutanoic acid, 2-keto-4-methylthiobutyrate;
Kojic acid, 2-(Hydroxymethyl)-5-hydroxy-4H-pyran-4-one, 2-Hydroxymethyl-5-hydroxy-gamma-pyrone, 4H-Pyran-4-one, 5-hydroxy-2-(hydroxymethyl)-;
KR-31543, (2S,3R,4S)-6-amino-4-(N-(4-chlorophenyl)-N-(2-methyl-2H-tetrazol-5-ylmethyl)amino)-3,4-dihydro-2-dimethoxymethyl-3-hydroxy-2-methyl-2H-1-benzopyran, KR-31543;
L 740,093, 1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-1-methyl-2-oxo-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea, 1-[(3R)-5-(3-azabicyclo[3.2.2]nonan-3-yl)-2-keto-1-methyl-3H-1,4-benzodiazepin-3-yl]-3-(3-methylphenyl)urea, L 740,093;
L-696,474, 1H-Cycloundec[d]isoindol-1-one, 15-(acetyloxy)-2,3,3a,4,5,6,6a,9,10,11,12,15-dodecahydro-6-hydroxy-4,10,12-trimethyl-5-methylene-3-(phenylmethyl)-,(3R*,3aS*,4R*,6R*,6aS*,7E,10R*,12R*,13E,15S*,15aS*), Cytochalasin, L-696,474;
L-T3, (2S)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propanoic acid, (2S)-2-amino-3-[4-(4-hydroxy-3-iodo-phenoxy)-3,5-diiodo-phenyl]propionic acid, (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid;
LAAM, (−)-6-(Dimethylamino)-4,4-diphenyl-3-heptanol acetate (ester), (−)-alpha-Acetylmethadol, (1S,4S)-4-(dimethylamino)-1-ethyl-2,2-diphenylpentyl acetate;
lacidipine, Boehringer Ingelheim Brand of Lacidipine, Caldine, GlaxoSmithKline Brand of Lacidipine;
lactacystin, lactacystin;
lactisole, lactisole;
lamotrigine, 3,5-diamino-6-(2,3-dichlorophenyl)-as-triazine, BW-430C, Crisomet;
Lanol, (−)-Cholesterol, (3beta)-cholest-5-en-3-ol, (3H)-Cholesterol;
lansoprazole, 2-(((3-methyl-4-(2,2,2-trifluoroethoxy)-2-pyridyl)methyl)sulfinyl)-1H-benzimidazole, Abbot Brand of Lansoprazole, AG 1749;
lapatinib, GW 572016, lapatinib, N-(3-chloro-4-(3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine;
laquinimod, laquinimod;
latrunculin A, latrunculin A;
latrunculin B, LAT-B, latrunculin B;
lavendustin A, lavendustin A;
leflunomide, Arava, Aventis Behring Brand of Leflunomide, Aventis Brand of Leflunomide;
lenalidomide, 2,6-Piperidinedione, 3-(4-amino-1,3-dihydro-1-oxo-2H-isoindol-2-yl)-, 3-(4-Amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione, CC 5013;
Lendorm, 2-Bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine, 2-bromo-4-(2-chlorophenyl)-9-methyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine, 2-Bromo-4-(o-chlorophenyl)-9-methyl-6H-thieno(3,2-f)-s-triazolo(4,3-a)(1,4)diazepine;
leptomycin B, leptomycin B;
leukotrienes, leucotriene, leucotrienes, Leukotrien;
Leupeptin, (2S)—N-[(2S)-2-acetamido-4-methyl-1-oxopentyl]-2-[(1-formyl-4-guanidinobutyl)amino]-4-methylpentanamide, (2S)—N-[(2S)-2-acetamido-4-methyl-pentanoyl]-2-[(1-formyl-4-guanidino-butyl)amino]-4-methyl-pentanamide, (2S)—N-[(2S)-2-acetamido-4-methyl-pentanoyl]-2-[(1-formyl-4-guanidino-butyl)amino]-4-methyl-valeramide;
Levitra, 2-(2-Ethoxy-5-(4-ethylpiperazin-1-yl-1-sulfonyl)phenyl)-5-methyl-7-propyl-3H-imidazo(5,1-f)(1,2,4)triazin-4-one, 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonyl-phenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one, 2-[2-ethoxy-5-(4-ethylpiperazin-1-yl)sulfonylphenyl]-5-methyl-7-propyl-1H-imidazo[5,1-f][1,2,4]triazin-4-one;
levobupivacaine, Abbott Brand of Levobupivacaine Hydrochloride, Chirocaine, levobupivacaine;
levugen, (2R,3S,4S,5R)-2,5-bis(hydroxymethyl)oxolane-2,3,4-triol, 2,5-bis(hydroxymethyl)oxolane-2,3,4-triol, 2,5-bis(hydroxymethyl)tetrahydrofuran-2,3,4-triol;
liarozole, liarozole;
lilopristone, 98,73, lilopristone, ZK 98.734;
Lipoate, (+)-alpha-Lipoic acid, (R)-( )-1,2-Dithiolane-3-pentanoic acid, (R)-(+)-Lipoate;
lipoteichoic acid, lipoteichoic acid;
lissamine rhodamine B, lissamine rhodamine B;
lithocholic acid, (3alpha,5beta)-3-hydroxycholan-24-oic acid, 3alpha-hydroxy-5beta-cholan-24-oic acid, 3alpha-hydroxy-5beta-cholanic acid;
LMWH, 6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-oxan-2-yl)oxy-6-(hydroxymethyl)-3-(sulfoamino)-4-sulfooxy-oxan-2-yl]oxy-4-hydroxy-5-sulfooxy-oxane-2-carboxylic acid, 6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)oxan-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxyoxan-2-yl)oxy-6-(hydroxymethyl)-3-(sulfoamino)-4-sulfooxyoxan-2-yl]oxy-4-hydroxy-5-sulfooxyoxane-2-carboxylic acid, 6-[5-acetamido-4,6-dihydroxy-2-(sulfooxymethyl)tetrahydropyran-3-yl]oxy-3-[5-(6-carboxy-4,5-dihydroxy-3-sulfooxy-tetrahydropyran-2-yl)oxy-6-(hydroxymethyl)-3-(sulfoamino)-4-sulfooxy-tetrahydropyran-2-yl]oxy-4-hydroxy-5-sulfooxy-tetrahydropyran-2-carboxyli;
LNAC, (2R)-2-acetamido-3-mercapto-propionic acid, (2R)-2-acetamido-3-mercaptopropanoic acid, (2R)-2-Acetamido-3-sulfanyl-propanoic acid;
lonafarnib, 4-(2-(4-(8-chloro-3,10-dibromo-6,11-dihydro-5H-benzo-(5,6)-cyclohepta(1,2-b)-pyridin-11(R)-yl)-1-piperidinyl)-2-oxo-ethyl)-1-piperidinecarboxamide, lonafarnib, SCH 66336;
lopinavir, A-157378.0, ABT 378, ABT-378;
Loratadine, 4-(8-Chloro-5,6-dihydro-11H-benzo (5,6)cyclohepta(1,2-b)pyridin-11-ylidene)-1-piperidinecarboxylic Acid Ethyl Ester, Alavert, Claritin;
Lorex, DEA No. 2783, Imidazo(1,2-a)pyridine-3-acetamide, N,N,6-trimethyl-2-(4-methylphenyl)-, Lorex;
lorglumide, lorglumide;
Losartan, 2-Butyl-4-chloro-1-((2′-(1H-etrazol-5-yl) (1,1′-biphenyl)-4-yl)methyl)-1H-imidazole-5-methanol, Cozaar, DuP 753;
Lovan, ( )-N-Methyl-gamma[4-(trifluoromethyl)phenoxy]benzenepropanamine hydrochloride, (+−)-Methyl-gamma-(4-(trifluoromethyl)phenoxy)benzenepropanamine hydrochloride, (+−)-N-Methyl-3-phenyl-3-(4-(trifluoromethyl)phenoxy)propylamine hydrochloride;
loxiglumide, loxiglumide;
lupeol, lup-20(29)-en-3-ol, lup-20(29)-en-3beta-ol, lup-20(29)-ene-3alpha-ol;
luteolin, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one;
LY 117018, 6-hydroxy-2-(4-hydroxyphenyl)benzo(b)thien-3-yl4-(2-(1-pyrrolidinyl)ethoxy) phenyl ketone, Lilly 117018, LY 117018;
LY 293111, 2-(2-propyl-3-(3-(2-ethyl-4-(4-fluorophenyl)-5-hydroxyphenoxy)propoxy)phenoxy)benzoic acid, LY 293111, LY-293111;
LYCOPENE, (6Z,8E,10E,12E,14E,16E,18Z,20E,22Z,24E,26Z)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene, .psi.,.psi.-Carotene, 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-octamethyl-, (all-E)-;
lysophosphatidic acid, 1-O-oleyllysophosphatidic acid, 1-oleoyl-lysophosphatidic acid, LPA (lysophosphatidic acid);
lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine, lysyl-arginyl-alanyl-lysyl-alanyl-lysyl-threonyl-threonyl-lysyl-lysyl-arginine;
M&B22948, 1,4-Dihydro-5-(2-propoxyphenyl)-1,2,3-triazolo(4,5-d)pyrimidin-7-one, 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo(4,5-d)pyrimidin-7-one, 1,4-Dihydro-5-(2-propoxyphenyl)-7H-1,2,3-triazolo[4,5-d]pyrimidine-7-one;
Malix, 1,2,3,4,7,7-Hexachlorobicyclo(2.2.1)hepten-5,6-bioxymethylenesulfite, 1,4,5,6,7,7-Hexachloro-5-norbornene-2,3-dimethanol cyclic sulfite, 1,4,5,6,7,7-Hexachloro-8,9,10-trinorborn-5-en-2,3-ylenedimethyl sulphite;
manidipine, 2-(4-diphenylmethyl-1-piperazinyl)ethyl methyl-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylate, CV 4093, CV-4093;
manumycin, manumycin, manumycin A, UCFI-C;
maraviroc, 4,4-difluoro-N-((1S)-3-(exo-3-(3-isopropyl-5-methyl-4H-1,2,4-triazol-4-yl)-8-azabicyclo(3.2.1)oct-8-yl)-1-phenylpropyl)cyclohexanecarboxamide, maraviroc, Pfizer Brand of maraviroc;
Matrine, (+)-Matrine, .alpha.-Matrine, Matrene, (+)-;
MCYST-LR, (5R,8S,11R,12S,15S,18S,19S,22R)-15-(3-guanidinopropyl)-8-isobutyl-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenyl-hepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylene-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic, (5R,8S,11R,12S,15S,18S,19S,22R)-15-(3-guanidinopropyl)-8-isobutyl-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylene-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic, (5R,8S,11R,12S,15S,18S,19S,22R)-15-(3-guanidinopropyl)-8-isobutyl-3,6,9,13,16,20,25-heptaketo-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenyl-hepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylene-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxyli;
mead ethanolamide, 5,8,11-eicosatrienoyl ethanolamide(Z,Z,Z)—, mead ethanolamide;
MeAsO(OH)2, Arsonic acid, methyl-, DSMA (JMAF), MeAsO(OH)2;
Mebumal, 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-(1-methylbutyl)-, 5-ethyl-2-hydroxy-5-(1-methylbutyl)pyrimidine-4,6(1H,5H)-dione, 5-Ethyl-5-(1-methylbutyl)-2,4,6(1H,3H,5H)-pyrimidinetrione;
Mechlorethamine, Bis(2-chloroethyl)methylamine, Caryolysine, Chlorethazine;
Medroxyprogesterone 17-Acetate, (6 alpha)-17-(Acetoxy)-6-methylpregn-4-ene-3,20-dione, 6 alpha Methyl 17alpha hydroxyprogesterone Acetate, 6-alpha-Methyl-17alpha-hydroxyprogesterone Acetate;
Megalomicin, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2R,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyl-oxan-2-yl]oxy-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl]oxy-7-[(2S,4R,6S)-4-dimethylamino-5-hydroxy-6-methyl-oxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-3,5,7,9, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2R,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-7-[(2S,4R,6S)-4-dimethylamino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-4-[(2R,4R,5S,6S)-4,5-dihydroxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-7-[(2S,4R,6S)-4-dimethylamino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy;
Melatol, 5-Methoxy-N-acetyltryptamine, Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-(9CI), Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-;
meletin, 117-39-5 (NEUTRAL), 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-4-chromenone;
melitten, D008555, melitten, melittin;
meloxicam, Abbott brand of meloxicam, Almirall brand of meloxicam, Boehringer Ingelheim brand of meloxicam;
Melphalan, 4-(Bis(2-chloroethyl)amino)phenylalanine, Alkeran, L-PAM;
Memantine, 1,3-Dimethyl-5-aminoadamantane, 1-Amino-3,5-dimethyladamantane, Axura;
menadiol, 2-methyl-1,4-naphthohydroquinone, 2-methyl-1,4-naphthoquinol, dihydrovitamin K3;
Menhaden oil, Menhaden oil;
menthofuran, menthofuran;
mesalamine, 3-carboxy-4-hydroxyaniline, 5-amino-2-hydroxybenzoic acid, 5-Aminosalicylic acid;
Mesaton, (−)-m-Hydroxy-alpha-(methylaminomethyl)benzyl alcohol, (R)-2-Hydroxy-2-(3-hydroxyphenyl)-N-methylethylamine, 3-[(1R)-1-hydroxy-2-(methylamino)ethyl]phenol;
Meth, (+)-methylamphetamine, (+)-(s)-deoxyephedrine, (+)-(s)-n-alpha-dimethylphenethylamine;
methanandamide, methanandamide;
methanethiosulfonate ethylammonium, 2-aminoethylmethanethiosulfonate, AEMTS cpd, methanethiosulfonate ethylamine;
Methimazole, 1 Methyl 2 mercaptoimidazole, 1-Methyl-2-mercaptoimidazole, Eli Lilly Brand of Methimazole;
methionyl-leucyl-phenylalanine, methionyl-leucyl-phenylalanine;
Methorphan, (−)-3-Methoxy-N-methylmorphinan, 3-methoxy-17-methylmorphinan, 3-METHOXY-N-METHYLMORPHINAN, (−)-;
methoxyamine, methoxyamine;
methoxychlor, 1,1′-(2,2,2-trichloroethane-1,1-diyl)bis(4-methoxybenzene), 1,1,1-trichloro-2,2-bis(p-anisyl)ethane, 1,1,1-trichloro-2,2-bis(p-methoxyphenyl)ethane;
methoxymorphinan, methoxymorphinan;
methyl chloroformate, methyl chloroformate;
Methyl glycine, (Methoxycarbonyl)methylamine, 2-aminoacetic acid methyl ester, Glycine methyl ester;
Methyl paraben, Methyl paraben;
methyl salicylate, 3M brand of methyl salicylate, esparma brand of methyl salicylate, Hevert brand of methyl salicylate;
methyl tryptophan, 2-Amino-3-(1H-indol-3-yl)-propionic acid methyl ester, 2-amino-3-(1H-indol-3-yl)propanoic acid methyl ester, 2-amino-3-(1H-indol-3-yl)propionic acid methyl ester;
methyl-dopa, methyl-dopa;
methyl-phosphorothioate, methyl-phosphorothioate;
methyl-Pyridinium, methyl-Pyridinium;
methylamine, aminomethane, methylamine, methylamine bisulfite;
methylenetetrahydrofolates, methylenetetrahydrofolate, methylenetetrahydrofolates;
methylglyoxal, 1,2-propanedione, 2-Ketopropionaldehyde, 2-oxopropanal;
methylnaltrexone, 17-(cyclopropylmethyl)-4,5-epoxy-3,14-dihydroxymorphinanium-6-one, methylnaltrexone hydrobromide, methylnaltrexone;
methyloxidanyl, CH3-O(.), methoxy, methoxy radical;
methylparaben, 4-hydroxybenzoic acid methyl ester, methyl p-hydroxybenzoate, methylparaben;
methylphosphate, methyl phosphate disodium salt, hexahydrate, methylphosphate, methylphosphate diammonium salt;
methylxanthines, methylxanthines;
Metoclopramide, 4 Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide, Cerucal, Maxolon;
Metopiron, 1,2-Di-3-pyridyl-2-methyl-1-propanone, 1-Propanone, 1,2-di-3-pyridyl-2-methyl-, 1-Propanone, 2-methyl-1,2-di-3-pyridinyl-;
Metribolone, 17 BETA HYDROXY 17 ALPHA METHYLESTRA 4 9 11 TRIEN 3 ONE, 17 beta-Hydroxy-17 alpha-methylestra-4,9,11-trien-3-one, Methyltrienolone;
mevalonic acid, 3,5-dihydroxy-3-methylpentanoic acid, mevalonic acid;
micafungin, FK 463, FK-463, FK463;
miconazole, 1-(2,4-Dichloro-beta-((2,4-dichlorobenzyl)oxy)phenethyl)imidazole, 1-[2-(2,4-dichlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl]-1H-imidazole, Clciccc(COC(Cn2ccnc2)c3ccc(C1)cc3C1)c(C1)c1;
Mictonorm, (1-methyl-4-piperidyl) 2,2-diphenyl-2-propoxy-acetate hydrochloride, (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxy-ethanoate hydrochloride, (1-methylpiperidin-4-yl) 2,2-diphenyl-2-propoxyacetate hydrochloride;
MIII, 6-Methyl-5,7-dimethylthiopyrrolo[1,2-a]1,4-diazine, 7-methyl-6,8-bis(methylsulfanyl)pyrrolo[1,2-a]pyrazine, 7-Methyl-6,8-bis(methylthio)pyrrolo(1,2-a)pyrazine;
mirtazapine, (N-methyl-11C)mirtazapine, 6-azamianserin, Celltech brand of mirtazapine;
Mit-C, 7-Amino-9.alpha.-methoxymitosane, Ametycin, Ametycine;
mithramycin, (1S)-5-deoxy-1-C-[(2S,3S)-7-{[2,6-dideoxy-3-O-(2,6-dideoxy-beta-D-arabino-hexopyranosyl)-beta-D-arabino-hexopyranosyl]oxy}-3-{[2,6-dideoxy-3-C-methyl-beta-D-ribo-hexopyranosyl-(1->3)-2,6-dideoxy-beta-D-arabino-hexopyranosyl-(1->3)-2,6-dideoxy-beta-Darabi, aureolic acid, Mithracin;
mizolastine, Allphar brand of mizolastine, Galderma brand of mizolastine, Mistalin;
MLN8054, 4-((9-chloro-7-(2,6-difluorophenyl)-5H-pyrimidol(5,4-d)(2)benzazepin-2-yl)amino)benzoic acid, MLN8054;
mofarotene, 4-((2-(p-((E)-2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthyl)propenyl)phenoxy)ethyl))morpholine, arotinoid Ro 40-8757, mofarotene;
mono-N-demethyladinazolam, mono-N-demethyladinazolam;
mono(2-ethylhexyl) phthalate, (2-ethylhexyl) hydrogen phthalate, 1,2-benzenedicarboxylic acid, mono(2-ethylhexyl) ester, 2-(2-ethylhexyloxycarbonyl)benzoic acid;
monoethylglycinexylidide, ethylglycylxylidide, L 86, L-86;
monomethylarsonic acid, disodium methanearsonate, methanearsonic acid, methylarsonate;
monoterpenes, monoterpene, monoterpenes;
monuron, 1,1-Dimethyl-3-(p-chlorophenyl)urea, 3-(4-chlorophenyl)-1,1-dimethylurea, 3-(p-Chlorophenyl)-1,1-dimethylurea;
morpholine, C1COCCN1, morpholine, Tetrahydro-1,4-oxazine;
morusin, morusin;
motexafin gadolinium, (PB-7-11-233′2′4)-bis(acetato-kappaO)(9,10-diethyl-20,21-bis(2-(2-(2-methoxyethoxy)ethoxy)ethoxy)-4,15-dimethyl-8,11-imino-3,6:16,13-dinitrilo-1,18-benzodiazacycloeicosine-5,14-dipropanolato-kappaN(1),kappaN(18),kappaN(23),kappaN(24),kappaN(25))gadolinium, bis(acetato-kappaO){3,3′-[4,5-diethyl-16,17-bis {2-[2-(2-methoxyethoxy)ethoxy]ethoxy}-10,23-dimethyl-13,20,25,26,27-pentaazapentacyclo[20.2.1.1(3,6).1(8,11).0(14,19)]heptacosa-1,3,5,7,9,11(26),12,14,16,18,20,22(25),23-tridecaene-9,24-diyl-kappa(5)N(13),N(2, gadolinium texaphyrin;
moxifloxacin, 1-cyclopropyl-7-(2,8-diazabicyclo(4.3.0)non-8-yl)-6-fluoro-8-methoxy-1,4-dihydro-4-oxo-3-quinolinecarboxylic acid, Actira, Avalox;
mutalipocin II, ML-II, mutalipocin II;
mycophenolic acid, mycophenolic acid;
Mycose, .alpha.,.alpha.-Trehalose, .alpha.-D-Glucopyranoside, .alpha.-D-glucopyranosyl, .alpha.-D-Trehalose;
Myocol, (2R,3R,4S,5R)-2-(6-amino-9-purinyl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol, (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, (2R,3R,4S,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)tetrahydrofuran-3,4-diol;
myricetin, 3,3′,4′,5,5′,7-Hexahydroxyflavone, 3,5,7,3′,4′,5′-Hexahydroxyflavone, 3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-chromen-4-one;
myxothiazol, myxothiazol;
N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide, N-(2-cyclohexyloxy-4-nitrophenyl)methanesulfonamide, NS 398, NS-398;
N-(2-hydroxypropyl)methacrylamide, N-(2-hydroxypropyl)methacrylamide;
N-(3-(4-chlorophenyl)-2-(3-cyanophenyl)-1-methylpropyl)-2-methyl-2-((5-(trifluoromethyl)pyridin-2-yl)oxy)propanamide, MK 0364, MK-0364, MK0364;
N-(3-methoxyphenyl)-4-chlorocinnamanilide, N-(3-methoxyphenyl)-4-chlorocinnamanilide, SB 366791, SB366791;
N-(3-oxododecanoyl)homoserine lactone, 3-oxo-C12-HSL, 3-oxo-C8-HSL, 30-C12-HSL;
N-(4-(6-(4-(1-(4-fluorophenyl)ethyl)piperazin-1-yl)pyrimidin-4-yloxy)benzo(d)thiazol-2-yl)acetamide, AMG 628, AMG-628, AMG628;
N-(4-(6-(4-trifluoromethylphenyl)pyrimidin-4-yloxy)benzothiazol-2-yl)acetamide, AMG 517, AMG-517, AMG517;
N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine, KR-33028, N-(4-cyano-benzo(b)thiophene-2-carbonyl)guanidine;
N-(5-(((5-(1,1-dimethylethyl)-2-oxazolyl)methyl)thio)-2-thiazolyl)-4-piperidinecarboxamide, BMS 387032, BMS-387032, BMS387032;
N-acetylcysteine lysinate, L-NAC, N-acetylcysteine L-lysinate, N-acetylcysteine lysinate;
n-acetylmuramyl-1-alanyl-d-isoglutamine, 4-[2-[2-(3-acetylamino-2,5-dihydroxy-6-methyloltetrahydropyran-4-yl)oxypropanoylamino]propanoylamino]-5-amino-5-oxo-pentanoic acid, 4-[2-[2-[3-acetylamino-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxypropanoylamino]propanoylamino]-5-amino-5-oxo-pentanoic acid, 4-[2-[2-[3-acetylamino-2,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-4-yl]oxy-1-oxo-propyl]amino-1-oxo-propyl]amino-5-amino-5-oxo-pentanoic acid;
N-acetylneuraminic acid, 5-Acetamido-3,5-dideoxy-D-glycero-D-galacto-2-nonulosonic acid, 5-acetamido-3,5-dideoxy-D-glycero-D-galacto-non-2-ulopyranosonic acid, N-acetylneuraminic acid;
N-desmethylclobazam, demethylclobazam, N-desmethylclobazam, norclobazam;
N-ethylmaleimide, 1-ethyl-1H-pyrrole-2,5-dione, Ethylmaleimide, N-ethylmaleimide;
N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide, MS-PPOH, N-methylsulfonyl-6-(2-propargyloxyphenyl)hexanamide;
N-phenyl-1-naphthylamine, 1-anilinonaphthalene, 1-N-phenylnaphthylamine, N-phenyl-1-naphthylamine;
N,N,N′,N′-tetramethylethylenediamine, CN(C)CCN(C)C, N,N,N′,N′-tetramethyl-1,2-ethanediamine, N,N,N′,N′-tetramethylethane-1,2-diamine;
N(6)-cyclohexyl-2-O-methyladenosine, N(6)-cyclohexyl-2-O-methyladenosine, SDZ WAG-994, SDZ-WAG-994;
N(6)-cyclopentyladenosine, N(6)-cyclopentyladenosine;
N3-IQ, (3-methylpyrido[3,2-e]benzimidazol-2-yl)amine, 2-Amino-3-methyl-3H-imidazo(4,5-f)quinoline, 2-Amino-3-methylimidazo(4,5-f)-quinoline;
naftifine, N-cinnamyl-N-methyl-1-naphthalenemethylamine hydrochloride, naftifin, naftifine;
nal-NH2, nal-NH2;
nanchangmycin, nanchangmycin;
naratriptan, N-methyl-2-(3-(1-methylpiperiden-4-yl)indole-5-yl)ethanesulfonamide, N-methyl-2-[3-(1-methyl-4-piperidyl)-1H-indol-5-yl]-ethanesulfonamide, N-methyl-2-[3-(1-methylpiperidin-4-yl)-1H-indol-5-yl]ethanesulfonamide;
narbonolide, narbonolide;
NARIGENIN, ( )-Naringenin; 4?,5,7-Trihydroxyflavanone; H-1-benzopyran-4-one, ( )-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one, ( )-Naringenin;
Nasol, (+−)-Ephedrine, (−)-.alpha.-(1-Methylaminoethyl)benzyl alcohol, (−)-Ephedrine;
natalizumab, Antegren, natalizumab, Tysabri;
nateglinide, A 4166, A-4166, AY 4166;
Naxy, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-oxan-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-oxan-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacyclotetradecane-2,10-di, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacy, (3R,4S,5S,6R,7R,9R,11R,12R,13S,14R)-6-[(2S,3R,4S,6R)-4-dimethylamino-3-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-14-ethyl-12,13-dihydroxy-4-[(2R,4R,5S,6S)-5-hydroxy-4-methoxy-4,6-dimethyl-tetrahydropyran-2-yl]oxy-7-methoxy-3,5,7,9,11,13-hexamethyl-1-oxacy;
nebivolol, alpha,alpha′-(iminobis(methylene))bis(6-fluoro-3,4-dihydro)-2H-1-benzopyran-2-methanol, Berlin-Chemie brand of nebivolol hydrochloride, Lobivon;
Nefazodone, 1-(3-(4-(m-Chlorophenyl)-1-piperazinyl)propyl)-3-ethyl-4-(2-phenoxyethyl)-delta2-1,2,4-triazolin-5-one, 2-[3-[4-(3-Chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-2,4-dihydro-4-(2-phenoxyethyl)-3H-1,2,4-triazol-3-one, 2-[3-[4-(3-chlorophenyl)-1-piperazinyl]propyl]-5-ethyl-4-[2-(phenoxy)ethyl]-1,2,4-triazol-3-one;
nefiracetam, DM 9384, DM-9384, N-(2,6-dimethylphenyl)-2-(2-oxo-1-pyrrolidinyl)acetamide;
Neopterin, 2-Amino-6-(1,2,3-trihydroxypropyl)-4(3H)-pteridinone, Monapterin, Neopterin;
Neut, Acidosan, Baking soda, Bisodium carbonate;
NFBA, .alpha.,.alpha.,.alpha.-Trifluoro-2-methyl-4′-nitro-m-propionotoluidide, 2-Methyl-N-(4-nitro-3-[trifluoromethyl]phenyl)propanamide, 2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide;
Nialk, 1,1,2-trichloroethene, 1,1,2-trichloroethylene, 1,1-dichloro-2-chloroethylene;
nimesulide, 4′-nitro-2′-phenoxymethanesulfonanilide, N-(4-nitro-2-phenoxyphenyl)methanesulfonamide, nimesulide;
niobium, 41Nb, columbio, columbium;
nitecapone, 3-(3,4-dihydroxy-5-nitrobenzylidine)-2,4-pentanedione, nitecapone, OR 462;
nitroanilide, nitroanilide;
nitroaspirin, 2-acetoxybenzoate-2-(1-nitroxymethyl)phenyl ester, NCX 4016, NCX-4016;
NITROPYRENE, 1-Nitropyrene, 1-Nitropyrene [Nitroarenes], 1-Nitropyrene [Polycyclic aromatic compounds];
nitrosamines, N-Nitroso amines, nitrosamines;
Nitrosoanabasine, (+−)-1-Nitrosoanabasine, (+−)-3-(1-Nitroso-2-piperidinyl)pyridine, (+−)-N-Nitrosoanabasine;
Nitrosocysteine, 2-amino-3-(nitrosothio)propanoic acid, 2-amino-3-(nitrosothio)propionic acid, 2-amino-3-nitrososulfanyl-propanoic acid;
nitrosulindac, NCX 1102, NCX-1102, NCX1102;
NK 104, bis((3R,5S,6E)-7-(2-cyclopropyl-4-(4-fluorophenyl)-3-quinolyl)-3,5-dihydroxy-6-heptenoate), monocalcium salt, itavastatin, nisvastatin;
NMDA, (NMDA), 2-methylaminobutanedioic acid, 2-methylaminosuccinic acid;
NN 703, NN 703, NN-703, NN703 cpd;
Noan, 1-Methyl-5-phenyl-7-chloro-1,3-dihydro-2H-1,4-benzodiazepin-2-one, 2H-1,4-Benzodiazepin-2-one, 7-chloro-1,3-dihydro-1-methyl-5-phenyl-, 7-Chloro-1,3-Dihydro-1-Methyl-5-Phenyl-2H-1,4-Benzodiazepin-2-One;
Nobiletin, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4-chromenone, 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one;
nodularin, nodularin;
nolatrexed, 3,4-dihydro-2-amino-6-methyl-4-oxo-5-(4-pyridylthio)quinazoline dihydrochloride, AG 337, AG-337;
noralfentanil, 4-MPPP, N-(4-(methoxymethyl)-4-piperidinyl)-N-phenylpropanamide, noralfentanil;
norbuprenorphine, norbuprenorphine;
Norclozapine, 3-chloro-6-(1-piperazinyl)-5H-benzo[c][1,5]benzodiazepine, 3-chloro-6-piperazin-1-yl-5H-benzo[c][1,5]benzodiazepine, 5H-Dibenzo(b,e)(1,4)diazepine, 8-chloro-11-(1-piperazinyl)-;
Nordihydroguaiaretic Acid, 4,4′-(2,3 Dimethyl-1,4-butanediyl)bis(1,2-benzenediol), Actinex, Dihydronorguaiaretic Acid;
noreximide, K 2154, K-2154, norborn-5-ene-2,3-cis-exo-dicarboximide;
norfluoxetine, norfluoxetine;
norharman, norharman;
norketobemidone, norketobemidone;
norlaudanosoline, (R,S)-Norlaudanosoline, 1-(3,4-dihydroxybenzyl)-1,2,3,4-tetrahydroisoquinoline-6,7-diol, norlaudanosoline;
normeperidine, normeperidine, normeperidine carbonate (2:1), normeperidine hydrochloride;
Nortilidine, (1R,2S)-2-methylamino-1-phenyl-1-cyclohex-3-enecarboxylic acid ethyl ester, (1R,2S)-2-methylamino-1-phenyl-cyclohex-3-ene-1-carboxylic acid ethyl ester, 3-Cyclohexene-1-carboxylic acid, 2-(methylamino)-1-phenyl-, ethyl ester, trans-(+−)-;
norverapamil, D 591, N-demethylverapamil, norverapamil;
novobiocin, novobiocin;
NSC 366140, 9-methoxy-N,N-dimethyl-5-nitropyrazolo(3,4,5-k)acridine-2(6H)-propanamine, NSC 366140, NSC 366140, methanesulfonate salt;
NSC-134754,3-ethyl-9,10-dimethoxy-2-(1,2,3,4-tetrahydro-isoquinolin-1-ylmethyl)-1,6,7,11b-tetrahydro-4H-pyrido(2,1-a)isoquinoline, NSC-134754;
NU2058, NU2058, O(6)-cyclohexylmethylguanine;
number-one, number-one;
nutlin 3, nutlin 3, nutlin-3, nutlin-3A;
Nylon, 6-Aminohexanoic acid homopolymer, A 1030N0, Akulon;
O-(chloroacetylcarbamoyl)fumagillol, 5-methoxy-4-(2-methyl-3-(3-methyl-2-butenyl)oxiranyl)-1-oxaspiro(2,5)oct-6-yl(chloroacetyl) carbamate, AGM 1470, AGM-1470;
O-Due, .beta.-Aminoethylsulfonic acid, 1-Aminoethane-2-sulfonic acid, 2-Aminoethanesulfonic acid;
o-quinone, 1,2-Benzoquinone, 2-benzoquinone, 3,5-cyclohexadiene-1,2-dione;
obovatol, 4′,5-diallyl-2,3-dihydroxybiphenyl ether, obovatol;
OCDD, 1,2,3,4,6,7,8,9-Octachlorodibenzo(1,4)dioxin, 1,2,3,4,6,7,8,9-Octachlorodibenzo(b,e)(1,4)dioxin, 1,2,3,4,6,7,8,9-Octachlorodibenzo-p-dioxin;
octanediol, octanediol;
olanzapine, 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine, Eli Lilly brand of olanzapine, Lilly brand of olanzapine;
olefins, olefin, olefins;
oleoylethanolamide, oleoylethanolamide;
olmelin, 4′-Methoxy-5,7-dihydroxy isoflavone, 4′-Methylgenistein, 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-;
olmesartan, 4-(hydroxy-1-methylethyl)-2-propyl-1-((2′-(1H-tetrazol-5-yl)-1,1′-biphenyl-4-yl)methyl)-1H-imidazole-5-carboxylic acid, CS-088, olmesartan;
olomoucine, olomoucine;
olomoucine II, olomoucine II;
Oltipraz, 3H-1,2-DITHIOLE-3-THIONE, 4-METHYL-5-PYRAZINYL-, 4-methyl-5-(2-pyrazinyl)-3-dithiolethione, 4-Methyl-5-(pyrazinyl)-3H-1,2-dithiole-3-thione;
omalizumab, Novartis Brand of Omalizumab, omalizumab, Xolair;
omega-agatoxin, omega-agatoxin;
omega-Conotoxin GVIA, Conus geographus Toxin, Conus geographus Toxin GVIA, omega CgTX;
omega-N-Methylarginine, D-NMMA, L Monomethylarginine, L NG Monomethyl Arginine;
omeprazole sulfone, omeprazole sulfone;
onapristone, onapristone;
ONCB, 1-chloro-2-nitro-benzene, 1-Chloro-2-nitrobenzene, 1-Nitro-2-chlorobenzene;
ON04819, AE1 734, AE1-734, methyl 7-((1R,2R,3R)-3-hydroxy-2-((E)-(3S)-3-hydroxy-4-(m-methoxymethylphenyl)-1-butenyl)-5-oxocyclopentyl)-5-thiaheptanoate;
Optef, (11beta)-11,17,21-Trihydroxy-pregn-4-ene-3,20-dione, (11beta)-11,17,21-trihydroxypregn-4-ene-3,20-dione, (8S,9S,10R,11 S,13 S,14S,17R)-11,17-dihydroxy-17-(2-hydroxy-1-oxoethyl)-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one;
oroxylin A, oroxylin A;
Osten, (Ipriflavone), 3-phenyl-7-propan-2-yloxy-chromen-4-one, 3-phenyl-7-propan-2-yloxychromen-4-one;
osteum, osteum;
OSU 03012, 2-amino-N-(4-(5-(2-phenanthrenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)phenyl)acetamide, OSU 03012, OSU-03012;
OVEX, (17beta)-17-hydroxyestra-1(10),2,4-trien-3-yl benzoate, .beta.-Estradiol 3-benzoate, .beta.-Estradiol benzoate;
Ovex, (17-alpha)-19-Norpregna-1,3,5(10)-trien-20-yne-3,17,diol, (17beta)-17-ethynylestra-1(10),2,4-triene-3,17-diol, (8R,9S,13S,14S,17R)-17-ethynyl-13-methyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthrene-3,17-diol;
oxaliplatin, 1,2-diaminocyclohexane platinum oxalate, 1,2-diamminocyclohexane(trans-1)oxolatoplatinum(II), 1-OHP;
Oxarol, (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methyl-butoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methyl-butoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(1S,3aS,7aS)-1-[(1S)-1-(3-hydroxy-3-methylbutoxy)ethyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol;
oxaspirodion, oxaspirodion;
oxatomide, oxatomide;
oxcarbazepine, Desitin brand of oxcarbazepine, GP 47680, Novartis brand of oxcarbazepine;
oxotremorine M, N,N,N-trimethyl-4-(2-oxopyrrolidin-1-yl)but-2-yn-1-aminium, oxotremorine M;
Oxytrol, 2-cyclohexyl-2-hydroxy-2-phenyl-acetic acid 4-diethylaminobut-2-ynyl ester, 2-cyclohexyl-2-hydroxy-2-phenylacetic acid 4-diethylaminobut-2-ynyl ester, 4-(diethylamino)but-2-yn-1-yl cyclohexyl(hydroxy)phenylacetate;
p-ABA, 4-Aminobenzamidine, 4-Aminobenzenecarboximidamide, Benzamidine, p-amino-;
p-XSC, 1,4-bis(selenocyanatomethyl)benzene, 1,4-Phenylenebis(methylene)selenocyanate, p-XSC;
p-Xylol, 1,4-dimethylbenzene, 1,4-Dimethylbenzol, 1,4-xylene;
Paclitaxel, 7 epi Taxol, 7-epi-Taxol, Anzatax;
paeonol, 2-hydroxy-4-methoxyacetophenone, paeonol;
palladium, 46Pd, paladio, palladium;
palmitoleate, (9Z)-hexadec-9-enoate, palmitoleate;
PALMITOYL, 16-Hexadecanal, hexadecanal, N-hexadecanal;
pamidronate, (3-amino-1-hydroxypropylidene)-1,1-biphosphonate, (3-amino-1-hydroxypropylidene)-1,1-bisphosphonate, 1-hydroxy-3-aminopropane-1,1-diphosphonic acid;
panaxadiol, panaxadiol, panaxadiol, (3beta,12beta)-isomer;
panepoxydone, panepoxydone;
pantoprazole, BY 1023, BY-1023, pantoprazole;
Papite, 2-Propen-1-one, 2-propenal, 2-Propenal, homopolymer;
PAPP, 1-(2-(4-Aminophenyl)ethyl)-4-(3-trifluoromethylphenyl)piperazine, 4424443-(Trifluoromethyl)phenyl)-1-piperazinyl)ethyl)aniline hydrochloride, 4-[2-[4-[3-(trifluoromethyl)phenyl]-1-pip erazinyl]ethyl]aniline;
parecoxib, Dynastat, N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamide, N-(((5-methyl-3-phenylisoxazol-4-yl)-phenyl)sulfonyl)propanamine, sodium salt;
Parsal, 5-Amino-N-butyl-2-(2-propynyloxy)benzamide, 5-amino-N-butyl-2-prop-2-ynoxybenzamide, 5-amino-N-butyl-2-prop-2-ynoxybenzamide;
PC 314, PC 314, PC-314, PC314 cpd;
PCSO, 2-amino-3-prop-2-enylsulfinyl-propanoic acid, 2-amino-3-prop-2-enylsulfinylpropanoic acid, 3-allylsulfinyl-2-amino-propanoic acid;
PD 98059, 2-(2′-amino-3′-methoxyphenyl)oxanaphthalen-4-one, 2-(2-amino-3-methoxyphenyl)-4H-1-benzopyran-4-one, PD 098059;
pectin, pectin;
Pemetrexed, (2R)-2-[[4-[2-(2-amino-4-keto-1,7-dihydropyrrolo[4,5-e]pyrimidin-5-yl)ethyl]benzoyl]amino]glutaric acid, (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[4,5-e]pyrimidin-5-yl)ethyl]benzoyl]amino]pentanedioic acid, (2R)-2-[[4-[2-(2-amino-4-oxo-1,7-dihydropyrrolo[4,5-e]pyrimidin-5-yl)ethyl]phenyl]carbonylamino]pentanedioic acid;
Penite, Arsenite, sodium, Atlas A, Chem Pels C;
peppermint oil, peppermint oil, WS 1340, WS-1340;
Perillol, (−)-Perillyl alcohol, (−)-Perillol alcohol, (−)-Perillylalcohol;
periodate, IO4(−), periodate, tetraoxidoiodate(1-);
perospirone, 2-(4-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)butyl)hexahydro-1H-isoindole-1,3-(2H)-dione, perospirone, SM 9018;
perovskite, calcium titanium oxide, CaTiO3, perovskite;
PFPA, 2,2,3,3,3-pentafluoropropanoic acid (2,2,3,3,3-pentafluoro-1-oxopropyl) ester, 2,2,3,3,3-pentafluoropropanoyl 2,2,3,3,3-pentafluoropropanoate, 2,2,3,3,3-pentafluoropropionic acid 2,2,3,3,3-pentafluoropropanoyl ester;
phen, .beta.-Phenanthroline, 1,10-Fenanthroline, 1,10-o-Phenanthroline;
phenolate, Phenol ion, Phenol, ion(1-) (VAN), phenolate;
phenoxodiol, 7-hydroxy-3-hydroxyphenyl-1H-benzopyran, phenoxodiol;
phenyl-propionamide, phenyl-propionamide;
phenyl-Pyridinium, phenyl-Pyridinium;
pheophorbide a, (2(2)R,17S,18S)-7-ethyl-2(1),2(2),17,18-tetrahydro-2(2)-(methoxycarbonyl)-3,8,13,17-tetramethyl-2(1)-oxo-12-ethenylcyclopenta[at]porphyrin-18-propanoic acid, (3S,4S,21R)-9-ethenyl-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-3-phorbinepropanoic acid, 3-[(3S,4S,21R)-14-ethyl-21-(methoxycarbonyl)-4,8,13,18-tetramethyl-20-oxo-9-vinylphorbin-3-yl]propanoic acid;
phloretin, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)-1-propanone, 3-(4-hydroxyphenyl)-1-(2,4,6-trihydroxyphenyl)propan-1-one, phloretin;
PHOB, 2,4,6(1H,3H,5H)-Pyrimidinetrione, 5-ethyl-5-phenyl-, 5-ethyl-5-phenyl-1,3-diazinane-2,4,6-trione, 5-Ethyl-5-phenyl-2,4,6(1H,3H,5H)-pyrimidinetrione;
phorate, O,O-Diethyl S-(ethylthio)methyl phosphorodithioate, O,O-Diethyl S-ethylmercaptomethyl dithiophosphate, O,O-diethyl S-[(ethylsulfanyl)methyl]dithiophosphate;
phorbol, phorbol;
phorbol 12-phenylacetate 13-acetate 20-homovanillate, phorbol 12-phenylacetate 13-acetate 20-homovanillate;
phosphatidylethanolamines, (3-Phosphatidyl)-ethanolamine, 1,2-diacyl-sn-glycero-3-phosphoethanolamine, 1-Acyl-2-acyl-sn-glycero-3-phosphoethanolamine;
phosphatidylinositol phosphate, PtdIns(4,5)P2, phosphatidylinositol phosphate, PtdIns(4,5)P2, PtdIns(4,5)P2;
phytanic acid, 3,7,11,15-tetramethyl-hexadecanoic acid, Phytanate, phytanic acid;
picric acid, 2,4,6-trinitrophenol, picrate, picric acid;
pifithrin, 1-(4-methylphenyl)-2-(4,5,6,7-tetrahydro-2-imino-3(2H)-benzothiazolyl)ethanone hydrobromide, 2-(2-imino-4,5,6,7-tetrahydrobenzothiazol-3-yl)-1-p-tolylethanone, PFT alpha;
Pilot, 2-(4-((6-Chloro-2-quinoxalinyl)oxy)phenoxy)propanoic acid ethyl ester, 2-[4-(6-chloroquinoxalin-2-yl)oxyphenoxy]propionic acid ethyl ester, 2-[4-[(6-chloro-2-quinoxalinyl)oxy]phenoxy]propanoic acid ethyl ester;
pimecrolimus, 33-epi-chloro-33-desoxyascomycin, ASM 981, Elidel;
pioglitazone, 5-(4-(2-(5-ethyl-2-pyridyl)ethoxy)benzyl)-2,4-thiazolidinedione, Actos, AD 4833;
pipecoloxylidide, pipecoloxylidide;
piperidine, Azacyclohexane, C1CCNCC1, Hexahydropyridine;
piperine, ((1-5-(1,3)-benzodioxol-5-yl)-1-oxo-2,4-pentadienyl)piperidine, 1-piperoylpiperidine, piperine;
Pira, 1-((p-(2-(5-Chloro-o-anisamido)ethyl)phenyl)sulfonyl)-3-cyclohexylurea, 1-(p-(2-(5-Chloro-2-methoxybenzamido)ethyl)benzenesulfonyl)-3-cyclohexylurea, 5-Chloro-N-(2-(4-((((cyclohexylamino)carbonyl)amino)sulfonyl)phenyl)ethyl)-2-methoxybenzamide;
pirinixic acid, (4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio)acetic acid, 4-chloro-6-(2,3-dimethylphenyl)amino-2-pyrimidinylthioacetic acid, 4-chloro-6-(2,3-xylidinyl)-2-pyrimidinylthioacetic acid;
plumbagin, 2-methyl-5-hydroxy-1,4-naphthoquinone, 5-hydroxy-2-methyl-1,4-naphthalenedione, 5-hydroxy-2-methyl-1,4-naphthoquinone;
PMDT, 1,1,4,7,7-pentamethyldiethylenetriamine, 1,2-Ethanediamine, N-(2-(dimethylamino)ethyl)-N,N′,N′-trimethyl-, 1,2-Ethanediamine, N-[2-(dimethylamino)ethyl]-N,N′,N′-trimethyl-;
PMPA, (((1R)-2-(6-Amino-9H-purin-9-yl)-1-methylethoxy)methyl)phosphonic acid, (R)-9-(2-Phosphonomethoxypropyl)adenine, (R)-9-(2-Phosphonylmethoxypropyl)adenine;
PMSF, .alpha.-Toluenesulfonyl fluoride, alpha-TOLUENESULFONYL FLUORIDE, alpha-Toluenesulphonyl fluoride;
PNPP, (4-nitrophenoxy)phosphonic acid, (4-nitrophenyl)dihydrogen phosphate, 4-Nitrophenyl dihydrogen phosphate;
polidocanol, aethoxysclerol, aethoxysklerol, aetoxisclerol;
poly-gamma-glutamate, poly-gamma-glutamate;
ponicidin, ponicidin;
poractant alfa, Allphar brand of poractant alfa, Chiesi brand of poractant alfa, Curosurf;
posaconazole, Noxafil, posaconazole, SCH 56592;
potassium tellurate(IV), potassium tellurate(IV);
PQQ Cofactor, 2,7,9-Tricarboxy-1H-Pyrrolo-(2,3-f)Quinoline-4,5-Dione, 2,7,9-Tricarboxypyrroloquinoline Quinone, 4,5-Dihydro-4,5-Dioxo-1-H-Pyrrolo(2,3-f)Quinoline-2,7,9-Tricarboxylic Acid;
pranlukast, 8-(4 (4-phenylbutoxy)benzoyl)amino-2-(tetrazol-5′-yl)-4-oxo-4H-1-benzopyran, ONO 1078, ONO-1078;
PRDL, (11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione, (8S,9S,10R,11 S,13 S,14S,17R)-11,17-dihydroxy-17-(2-hydroxy-1-oxo ethyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one, (8S,9S,10R,11 S,13 S,14S,17R)-11,17-dihydroxy-17-(2-hydroxyacetyl)-10,13-dimethyl-7,8,9,11,12,14,15,16-octahydro-6H-cyclopenta[a]phenanthren-3-one;
Precursor mrna, Precursor mrna;
Prednisone, acis Brand of Prednisone, Apo-Prednisone, Apotex Brand of Prednisone;
pregnane, pregnane;
Pregnanolone, 3 alpha Hydroxy 5 alpha pregnan 20 one, 3 alpha Hydroxy 5 beta pregnan 20 one, 3 alpha, 5 beta-Tetrahydroprogesterone;
pregnenolone 16alpha-carbonitrile, 3beta-hydroxy-20-oxo-5-pregnene-16alpha-carbonitrile, 3beta-hydroxy-20-oxopregn-5-ene-16alpha-carbonitrile, PCN;
Pregnyl, biogonadil, choriogonadotropin, choriogonin;
preussin, (+)-preussin, L 657398, L-657,398;
Procasil, 2,3-Dihydro-6-propyl-2-thioxo-4(1H)-pyrimidinone, 2-Mercapto-4-hydroxy-6-n-propylpyrimidine, 2-Mercapto-6-propyl-4-pyrimidone;
procyanidin B2, procyanidin B2;
Prodix, (8R,9S,10R,13S,14S,17R)-17-acetyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one, (8R,9S,10R,13S,14S,17R)-17-ethanoyl-17-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1H-cyclopenta[a]phenanthren-3-one, 17-alpha-Hydroxyprogesterone;
prolactin, polymeric, BBPRL, big big prolactin, big prolactin;
Propanesulfonate, 1-Propanesulfonic acid, Ammonium propanesulfonate, propane-1-sulfonic acid;
Propofol, 2,6-Bis(1-methylethyl)phenol, 2,6-Diisopropylphenol, Abbott Brand of Propofol;
propyl pyrazole triol, PPT cpd, propyl pyrazole triol, propylpyrazole triol;
propyne, 1-propyne, allylene, CC#C;
prostratin, prostratin;
protopanaxadiol, 20(S)-protopanaxadiol, protopanaxadiol, protopanaxadiol, (3beta,12beta)-isomer;
protopanaxatriol, protopanaxatriol, protopanaxatriol, (3beta,6alpha,12beta,20R)-isomer;
PS 15, N-(3(2,4,5-trichlorophenoxy)propyloxy)-N′-(1-methylethyl)imidocarbonimidicdiamide hydrochloride, PS 15, PS-15;
Pseudohypericin, Hypericum Extract, Phenanthro(1,10,9,8-opgra)perylene-7,14-dione, 1,3,4,6,8,13-hexahydroxy-10-(hydroxymethyl)-11-methyl-, stereoisomer, Pseudohypericin;
Pseudomonas-exotoxin, Pseudomonas-exotoxin;
psychosine-3′-sulfate ester, psychosine-3′-sulfate ester;
PTBP, 1-Hydroxy-4-tert-butylbenzene, 2-tert-Butylphenol, 4-(1,1-Dimethylethyl)phenol;
pteridine, 1,3,5,8-tetraazanaphthalene, azinepurine, c1cnc2ncncc2n1;
Pterostilbene, 3′,5′-Dimethoxy-4-stilbenol, 3,5-Dimethoxy-4′ -hydroxystilbene, 3,5-Dimethoxy-4′-hydroxy-trans-stilbene;
PURAC, (+)-Lactic acid, (+−)-2-Hydroxypropanoic acid, (2R)-2-hydroxypropanoic acid;
putrescine, 1,4-Butanediamine, 1,4-butylenediamine, 1,4-DIAMINOBUTANE;
Pyra, 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N′,N′-dimethyl-N-2-pyridinyl-, 1,2-Ethanediamine, N-((4-methoxyphenyl)methyl)-N′,N′-dimethyl-N-2-pyridinyl-(9CI), 1,2-Ethanediamine, N-[(4-methoxyphenyl)methyl]-N′,N′-dimethyl-N-2-pyridinyl-;
pyranones, oxopyrans, pyranone, pyranones;
pyrazole, Pyrazol, pyrazole;
pyridazine, 1,2-diazine, ciccnncl, o-diazine;
pyrimidin-2-one beta-ribofuranoside, NSC 309132, pyrimidin-2-one beta-D-ribofuranoside, pyrimidin-2-one beta-ribofuranoside;
pyrogallol sulfonphthalein, pyrogallol sulfonphthalein;
pyrrole-2-carboxylic acid, 1H-pyrrole-2-carboxylic acid, 2-pyrrolecarboxylic acid, PCA;
pyrrolidine dithiocarbamic acid, pyrrolidine dithiocarbamic acid, Pyrrolidinedithiocarbamate;
pyrroloazepinone, pyrroloazepinone;
quercitrin, quercetin 3-O-rhamnoside, quercetin-3-L-rhamnoside, quercetrin;
quetiapine, 2-(2-(4-dibenzo (b,f)(1,4)thiazepine-11-yl-1-piperazinyl)ethoxy)ethanol, AstraZeneca Brand of Quetiapine Fumarate, Ethanol, 2-(2-(4-dibenzo(b,f)(1,4)thiazepin-11-yl-1-piperazinyl)ethoxy)-, (E)-2-butenedioate (2:1) (salt);
Quicifal, 1-Ascorbyl palmitate, 6-Hexadecanoyl-L-ascorbic acid, 6-Monopalmitoyl-L-ascorbate;
quinazoline, 1,3-benzodiazine, 1,3-diazanaphthalene, 5,6-benzopyrimidine;
quinuclidin-3′-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate, quinuclidin-3′-yl 1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monohydrochloride, quinuclidin-3′-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate, solifenacin;
quinupristin-dalfopristin, quinupristin-dalfopristin, RP 59500, RP-59500;
R-99224, (2Z)-(1-(2-cyclopropyl-1-(2-fluorophenyl)-2-oxoethyl)-4-mercapto-3-piperidinylidene), R-99224;
raltitrexed, Arkomédika brand of raltitrexed, AstraZeneca brand of raltitrexed, D 1694;
ramiprilat, ramiprilat;
RAPA, (−)-Rapamycin, (3-(4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-, (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)—;
rasagiline, 2,3-dihydro-N-2-propynyl-1H-inden-1-amine-(1R)-hydrochloride, AGN 1135, AGN-1135;
rebamipide, 2-(4-chlorobenzoylamino)-3-(2(1H)-quinolinon-4-yl)propionic acid, OPC 12759, OPC-12759;
reboxetine, 2-((2-ethoxyphenoxy)benzyl)morpholine methanesulfonate, reboxetine, reboxetine mesylate;
remifentanil, 3-(4-methoxycarbonyl-4-(1-oxopropyl)phenylamino)-1-piperidine)propanoic acid methyl ester, Abbott brand of remifentanil, GI 87084B;
renzapride, 4-amino-5-chloro-2-methoxy-N-(1-azabicyclo-(3.3.1)-non-4-yl)benzamide, BRL 24924, BRL-24924;
repaglinide, 2-ethoxy-4-(2-((3-methyl-1-(2-(1-piperidinyl)phenyl)butyl)amino)-2-oxoethyl)benzoic acid, 2-ethoxy-N-(alpha-(2-methyl-1-propyl)-2-piperidinobenzyl)-4-carbamoylmethylbenzoic acid, AG-EE 388;
resiquimod, 1-[4-amino-2-(ethoxymethyl)-1H-imidazo[4,5-c]quinolin-1-yl]-2-methylpropan-2-ol, CCOCc1nc2c(N)nc3ccccc3c2n1CC(C)(C)O, R 848;
Retardex, acide benzoique, Ammonium benzoate, Aromatic hydroxy acid;
Riacon, (2-Mercaptoethyl)amine, .beta.-Mercaptoethylamine, 1-Amino-2-mercaptoethylamine;
Riboflavin, Flavin mononucleotide, Pentitol, 1-deoxy-1-(3,4-dihydro-7,8-dimethyl-2,4-dioxobenzo[g]pteridin-10(2H)-yl)-, 5-(dihydrogen phosphate), Riboflavin;
rifamycins, rifamycins;
rimonabant, Acomplia, N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide hydrochloride, rimonabant;
risedronic acid, 2-(3-pyridinyl)-1-hydroxyethylidene-bisphosphonate, 2-(3-pyridinyl)-1-hydroxyethylidenebisphosphonate, Actonel;
risperidone, 3-{2-[4-(6-fluoro-1,2-benzisoxazol-3-yl)piperidin-1-yl]ethyl}-2-methyl-6,7,8,9-tetrahydro-4H-pyrido[1,2-a]pyrimidin-4-one, Risperdal, risperidona;
rituximab, CD20 antibody, rituximab, Genentech brand of rituximab, Hoffmann-La Roche brand of rituximab;
Ro 13-8996, (Z)-(2,4-dichlorobenzyl)oxy-[1-(2,4-dichlorophenyl)-2-imidazol-1-yl-ethylidene]amine, 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-(1-imidazolyl)ethanimine, 1-(2,4-dichlorophenyl)-N-[(2,4-dichlorophenyl)methoxy]-2-imidazol-1-yl-ethanimine;
Ro 23-7553, (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(1R)-5-hydroxy-1,5-dimethyl-hex-3-ynyl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(1R)-5-hydroxy-1,5-dimethylhex-3-ynyl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylenecyclohexane-1,3-diol, (1R,3S,5Z)-5-[(2E)-2-[(3aS,7aS)-1-[(2R)-6-hydroxy-6-methyl-hept-4-yn-2-yl]-7a-methyl-3a,5,6,7-tetrahydro-3H-inden-4-ylidene]ethylidene]-4-methylidene-cyclohexane-1,3-diol;
Ro 24-7429, 7-chloro-N-methyl-5-(1H-pyrrol-2-yl)-3H-1,4-benzodiazepin-2-amine, Ro 24-7429, Ro-24-7429;
Ro 31-6233,1H-Pyrrole-2,5-dione, 3,4-di-1H-indol-3-yl-, 2,3-bis(1H-Indol-3-yl)maleimide, 3,4-bis(1H-indol-3-yl)-3-pyrroline-2,5-quinone;
R04383596, (+/−)-1-(anti-3-hydroxy-cyclopentyl)-3-(4-methoxy-phenyl)-7-phenylamino-3,4-dihydro-1H-pyrimido(4,5-d)pyrimidin-2-one, RO4383596;
Robitet, (2Z)-2-(amino-hydroxy-methylene)-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione, (2Z)-2-(amino-hydroxy-methylidene)-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione, (2Z)-2-(amino-hydroxymethylene)-4-dimethylamino-6,10,11,12a-tetrahydroxy-6-methyl-4,4a,5,5a-tetrahydrotetracene-1,3,12-trione;
rofecoxib, Cahill May Roberts brand of rofecoxib, Merck brand of rofecoxib, Merck Frosst brand of rofecoxib;
roflumilast, 3-cyclopropylmethoxy-4-difluoromethoxy-N-(3,5-di-chloropyrid-4-yl)benzamide, roflumilast;
rokitamycin, 3″-O-propionylleucomycin A5, pro-leucomycin A5, rokitamycin;
romidepsin, FK228, FR 901228, FR-901228;
rooperol, rooperol;
ropivacaine, 1-propyl-2′,6′-pipecoloxylidide, AL 381, AL-381;
roscovitine, 2-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine, CYC 202, CYC-202;
rosiglitazone, 5-((4-(2-methyl-2-(pyridinylamino)ethoxy)phenyl)methyl)-2,4-thiazolidinedione-2-butenedioate, Avandia, BRL 49653;
rosmarinic acid, (2S)-3-(3,4-dihydroxyphenyl)-2-[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyloxy]propanoic acid, Rosmarinate, rosmarinic acid;
rosuvastatin, (3R,5S,6E)-7-(4-(4-fluorophenyl)-6-(1-methylethyl)-2-(ethyl(methylsulfonyl)amino)-5-pyrimidinyl)-3,5-dihydroxy-6-heptenoic acid, (3R,5S,6E)-7-{4-(4-fluorophenyl)-2-[methyl(methylsulfonyl)amino]-6-(propan-2-yl)pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid, (3R,5S,6E)-7-{4-(4-fluorophenyl)-6-isopropyl-2-[methyl(methylsulfonyl)amino]pyrimidin-5-yl}-3,5-dihydroxyhept-6-enoic acid;
Rozevin, (2ALPHA,2′BETA,3BETA,4ALPHA,5BETA)-VINCALEUKOBLASTINE, (3aR-(3aalpha,4beta,5beta,5abeta,9(3R*,5S*,7R*,9S*),10bR*,13aalpha))-methyl 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydro, 1H-Indolizino(8,1-cd)carbazole-5-carboxylic acid, 4-(acetyloxy)-3a-ethyl-9-(5-ethyl-1,4,5,6,7,8,9,10-octahydro-5-hydroxy-9-(methoxycarbonyl)-2H-3,7-methanoazacycloundecino(5,4-b)indol-9-yl)-3a,4,5,5a,6,11,12,13a-octahydro-5-hydroxy-8-methoxy-6-methyl-, me;
RPR 121056, 7-ethyl-10-(4-N-(5-aminopentanoic acid)-1-piperidino)carbonyloxycamptothecin, APC cpd, RPR 121056;
RU 58668, 11beta-(4-(5-(4,4,5,5,5-pentafluoropentyl)sulfonyl)pentyloxy)phenyl)-estra-1,3,5(10)-triene,3,17beta-diol, Estra-1,3,5(10)-triene-3,17-diol, 11-(4-((5-((4,4,5,5,5-pentafluoropentyl)sulfonyl)pentyl)oxy)phenyl)-, (11beta,17beta)-, RU 58 668;
ruboxistaurin, 13-((dimethylamino)methyl)-10,11,14,15-tetrahydro-4,9:16,21-dimetheno-1H,13H-dibenzo(e,k)pyrrolo(3,4-h)(1,4,13)oxadiazacyclohexadecene-1,3(2H)-dione, Arxxant, Lilly brand of ruboxistaurin mesilate hydrate;
rugosin E, rugosin E;
rutecarpine, rutaecarpine, rutecarpine;
Rutin, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-oxan-2-yl]oxymethyl]oxan-2-yl]oxy-chromen-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromen-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chromone;
S-phenyl-N-acetylcysteine, 2-acetamido-3-phenylthiopropanoic acid, phenylmercapturic acid, S-phenyl-N-acetylcysteine;
sabarubicin, 4-demethoxy-7-O-(2,6-dideoxy-4-O-(2,3,6-trideoxy-3-amino-alpha-L-lyxo-hexopyranosyl)-alpha-L-lyxo-hexopyranosyl)-adriamycinone, MEN 10755, MEN-10755;
sabcomeline, (R)-3-quinuclidineglyoxylonitrile-(Z)—(O)-methyloxime, alpha-(methylimino)-1-azabicyclo(2.2.2)octane-3-acetonitrile, sabcomeline;
Safingol, (2S,3R)-2-amino-1,3-octadecanediol, (2S,3R)-2-aminooctadecane-1,3-diol, (R—(R*,S*))-2-aminooctadecane-1,3-diol;
Safrole, 4-Allyl-1,2-methylenedioxybenzene, Safrol, Safrole;
SAGA, (1R,3S)-2,2-dimethyl-3-(1,2,2,2-tetrabromoethyl)-1-cyclopropanecarboxylic acid [(S)-cyano-[3-(phenoxy)phenyl]methyl]ester, (1R,3S)-2,2-dimethyl-3-(1,2,2,2-tetrabromoethyl)cyclopropane-1-carboxylic acid [(S)-cyano[3-(phenoxy)phenyl]methyl]ester, (S)-alpha-Cyano-3-phenoxybenzyl(1R)-cis-2,2-dimethyl-3-((RS)-1,2,2,2-tetrabromoethyl)-cyclopropanecarboxylate;
SAHA, 8-(hydroxyamino)-8-keto-N-phenyl-caprylamide, 8-(hydroxyamino)-8-oxo-N-phenyloctanamide, 8-(hydroxyamino)-8-oxo-N-phenyloctanamide;
saikosaponin, saikosaponin, saikosaponin B, saikosaponin B1;
Salicin, .beta.-D-Glucopyranoside, 2-(hydroxymethyl)phenyl, 2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]oxane-3,4,5-triol, 2-(hydroxymethyl)-6-[2-(hydroxymethyl)phenoxy]tetrahydropyran-3,4,5-triol;
salvin, carnosic acid, salvin;
samarium, 62Sm, samario, samarium;
SAMe, (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-amino-9-purinyl)-3,4-dihydroxy-2-tetrahydrofuranyl]methyl-methylsulfonio]butanoate, (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-oxolan-2-yl]methyl-methyl-sulfonio]butanoate, (2S)-2-amino-4-[[(2S,3S,4R,5R)-5-(6-aminopurin-9-yl)-3,4-dihydroxy-tetrahydrofuran-2-yl]methyl-methyl-sulfonio]butanoate;
sanguinarine, 13-methyl-2H,10H-[1,3]dioxolo[4,54][1,3]dioxolo[4′,5′:4,5]benzo[1,2-c]phenanthridinium, 13-methyl[1,3]benzodioxolo[5,6-c]-1,3-dioxolo[4,5-i]phenanthridinium, sanguinarine;
sapogenins, sapogenin, sapogenins;
Sarasar, ( )4-(2-(4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-1-piperidinecarboxamide, (+)-4[2-[4-(8-Chloro-3,10-dibromo-6,11-dihydro-5H-benzo[5,6]cyclohepta[1,2-b]-pyridin-11(R)-yl-1-piperidinyl]-2-oxo-ethyl]-1-piperidinecarboxamide, 1-Piperidinecarboxamide, 4-(2-(4-((11R)-3,10-dibromo-8-chloro-6,11-dihydro-5H-benzo(5,6)cyclohepta(1,2-b)pyridin-11-yl)-1-piperidinyl)-2-oxoethyl)-;
sauchinone, sauchinone;
saxatilin, saxatilin;
SB 225002, N-(2-hydroxy-4-nitrophenyl)-N′-(2-bromophenyl)urea, SB 225002, SB-225002;
SB 415286, 3-(3-chloro-4-hydroxyphenylamino)-4-(4-nitrophenyl)-1H-pyrrole-2,5-dione, SB 415286, SB-415286;
scandium, 21 Sc, escandio, scandium;
schizandrer A, gomisin C, gomisin-G, PC 315;
scoparone, 6,7-dimethoxycoumarin, 6,7-dimethylesculetin, scoparone;
Scopoletin, .beta.-Methylesculetin, 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy-, 2H-1-Benzopyran-2-one, 7-hydroxy-6-methoxy-(9CI);
Score, 1-((2-(2-Chloro-4-(4-chlorophenoxy)phenyl)-4-methyl-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole, 1-((2-[2-Chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl)methyl)-1H-1,2,4-triazole, 1-({2-[2-chloro-4-(4-chlorophenoxy)phenyl]-4-methyl-1,3-dioxolan-2-yl}methyl)-1H-1,2,4-triazole;
seocalcitol, l(S),3(R)-dihydroxy-20(R)-(5′-ethyl-5′-hydroxyhepta-1′(E),3′(E)-dien-1′-yl)-9,10-secopregna-5(Z),7(E),10(19)-triene, EB 1089, EB-1089;
Serad, (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-naphthylamine hydrochloride, (1S,4S)-4-(3,4-Dichlorophenyl)-1,2,3,4-tetrahydro-N-methyl-1-napthalenamine hydrochloride, (1S,4S)-4-(3,4-dichlorophenyl)-N-methyl-1,2,3,4-tetrahydronaphthalen-1-amine hydrochloride;
sertindole, 1-(2-{4-[5-chloro-1-(4-fluorophenyl)-1H-indol-3-yl]piperidin-1-yl}ethyl)imidazolidin-2-one, 1-[2-[4-[5-chloro-1-(4-fluorophenyl)-indol-3-yl]-1-piperidyl]ethyl]imidazolidin-2-one, Serdolect;
sevoflurane, BAX 3084, fluoromethyl hexafluoroisopropyl ether, fluoromethyl-2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether;
shikonin, shikonin, shikonin, (+)-isomer;
siderophore, ironophore, siderochrome, siderochromes;
Sildenafil, 1-((3-(4,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine, 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one, 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one;
silvestrol, silvestrol;
silybin, 2,3-dehydrosilybin, Alepa-forte, Ardeyhepan;
SK&F 106528, recombinant soluble CD4, SK&F 106528, SK&F-106528;
Sodium pentosan poly sulfate, Sodium pentosan poly sulfate;
sorafenib, 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate, BAY 43-9006, Nexavar;
sorbinil, CP 45634, CP-45634, D-6-fluoro-spiro(chroman-4,4′-imidazolidine)-2′,5′-dione;
Sorbo, 1,2,3,4,5,6-Hexanehexol, 3,3′-Oxydi(1,2-propanediol), alpha,alpha′-Diglycerol;
Sorbose, (2R,3S,4R,5R)-2-(hydroxymethyl)oxane-2,3,4,5-tetrol, (2R,3S,4R,5R)-2-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol, (2R,3S,4R,5R)-2-methyloltetrahydropyran-2,3,4,5-tetrol;
spiroglumide, 4-(3-chlorobenzamido)-5-(8-azaspiro(4.5)decan-8-yl)-5-oxopentanoic acid, CR 2194, CR-2194;
squamocin, squamocin;
SR 144528, N-(1,3,3-trimethylbicyclo(2.2.1)heptan-2-yl)-5-(4-chloro-3-methylphenyl)-1-(4-methylbenzyl)pyrazole-3-carboxamide, SR 144528, SR-144528;
SR 48692, 2-((1-(7-chloro-4-quinolinyl)-5-(2,6-dimethoxyphenyl)pyrazol-3-yl)carbonylamino)tricyclo(3.3.1.1.(3.7))decan-2-carboxylic acid, SR 48692, SR-48692;
ST 638, alpha-cyano-3-ethoxy-4-hydroxy-5-phenylmethylcinnamamide, ST 638, ST-638;
stallimycin, stallimycin;
staurosporine, (5S,6R,7R,9R)-6-methoxy-5-methyl-7-methylamino-6,7,8,9,15,16-hexahydro-5H,14H-5,9-epoxy-4b,9a,15-triazadibenzo[b,h]cyclonona[1,2,3,4-jkl]cyclopenta[e]-as-indacen-14-one, Staurosporin, staurosporine;
Stearin, 1,2,3-Propanetrioltrioctadecanoate, 1,2,3-trioctadecanoyl-sn-glycerol, 1,2,3-Trioctadecanoylglycerol;
Steviol, Kaur-16-en-18-oic acid, 13-hydroxy-, (4.alpha.)-, Steviol;
Stevioside, 1-O-{(5beta,8alpha,9beta,10alpha,13alpha)-13-[(2-O-beta-D-glucopyranosyl-beta-D-glucopyranosyl)oxy]-18-oxokaur-16-en-18-yl}-beta-D-glucopyranose, 13-[(2-O-.beta.-D-Glucopyranosyl-.alpha.-D-glucopyranosyl)oxy]kaur-16-en-18-oic acid.beta.-D-glucopyranosyl ester, Diterpene glycoside;
STIL, (E)-3,4-Bis(4-hydroxyphenyl)-3-hexene, (E)-4,4′-(1,2-Diethyl-1,2-ethenediyl)bisphenol, (E)-4,4′-(hex-3-ene-3,4-diyl)diphenol;
stilbene-disulphonate, stilbene-disulphonate;
Stim, 1,3,7-trimethyl-2,6-dioxo-1,2,3,6-tetrahydropurine, 1,3,7-Trimethyl-2,6-dioxopurine, 1,3,7-trimethyl-3,7-dihydro-1H-purine-2,6-dione;
styrene-methylmethacrylate copolymer, styrene-methylmethacrylate copolymer;
SU 5416, 3-(2,4-dimethylpyrrol-5-yl)methylidene-indolin-2-one, Semaxinib, SU 5416;
SU 6668, (Z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)-propionic acid, (Z)-3-(2,4-dimethyl-5-(2-oxo-1,2-dihydro-indol-3-ylidenemethyl)-1H-pyrrol-3-yl)propionic acid, SU 6668;
SU 9516, 3-(1-(3H-Imidazol-4-yl)-meth-(Z)-ylidene)-5-methoxy-1,3-dihydro-indol-2-one, SU 9516, SU9516;
suberate, octanedioate, suberate;
suberosin, suberosin;
succinic semialdehyde, 3-formylpropanoic acid, 3-formylpropionic acid, 4-oxobutanoic acid;
Sufentanil, Abbot Brand of Sufentanil Citrate, Baxter Brand of Sufentanil Citrate, curasan Brand of Sufentanil Citrate;
Suldox, 4-amino-N-(5,6-dimethoxy-4-pyrimidinyl)benzenesulfonamide; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine, 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; 5-(4-chlorophenyl)-6-ethyl-pyrimidine-2,4-diamine, 4-amino-N-(5,6-dimethoxypyrimidin-4-yl)benzenesulfonamide; 5-(4-chlorophenyl)-6-ethylpyrimidine-2,4-diamine;
sulfadoxine-pyrimethamine, Fansidar, Suldox, sulfadoxine-pyrimethamine;
sulfamethoxazole hydroxylamine, sulfamethoxazole hydroxylamine;
sulfate cellufine, sulfate cellufine;
sulfate-sulfate, sulfate-sulfate;
sulfidonitrogen(.), (NS)(.), mononitrogen monosulfide, nitrogen monosulfide;
sulfo-N-succinimidyl oleate, SSO cpd, sulfo-N-succinimidyl oleate, sulfo-N-succinimidyloleate;
sulfo-succinimidyl-oleate, sulfo-succinimidyl-oleate;
sulfogalactosylglycerolipid, sgg lipid, sulfogalactosylglycerolipid;
sulfones, sulfone, sulfones;
sulfonic acid, acide sulfonique, HSHO3, hydridohydroxidodioxidosulfur;
sulfonyl-phenyl-ethyl, sulfonyl-phenyl-ethyl;
Sulforafan, 1-Isothiocyanato-4-(methylsulfinyl)-butane, 1-isothiocyanato-4-(methylsulflnyl)butane, 1-isothiocyanato-4-methylsulfinyl-butane;
sulindac sulfone, (5-fluoro-2-methyl-1-(3,4,5-trimethoxybenzylidene)-3-(N-benzyl)-indene)-acetamide, 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfonyl)phenyl)methylene)-, (Z)—, Aptosyn;
sultopride, amisulpride, Barnetil, DAN 2163;
sunitinib, 5-(5-fluoro-2-oxo-1,2-dihydroindolylidenemethyl)-2,4-dimethyl-1H-pyrrole-3-carboxylic acid (2-diethylaminoethyl)amide, SU 011248, SU 11248;
Synthos, alpha-TCP, alpha-tri-Calcium phosphate, alpha-Tricalcium phosphate;
T 0901317, N-(4-(1,1,1,3,3,3-hexafluoro-2-hydroxy-propan-2-yl)phenyl)-N-(2,2,2-trifluoroethyl)benzenesulfonamide, T 0901317, T-0901317;
Tacrine, 1,2,3,4-Tetrahydro-9-acridinamine, 1,2,3,4-Tetrahydroaminoacridine, 9-Amino-1,2,3,4-Tetrahydroacridine;
tadalafil, Cialis, IC 351, IC-351;
Tamogel, (Z)-4-(1-[4-(Dimethylaminoethoxy)phenyl]-2-phenyl-1-butenyl)phenol, (Z)-4-Hydroxytamoxifen, 4-((1Z)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-2-phenyl-1-butenyl)phenol;
tandospirone, 3a,4,7,7a-hexahydro-2-(4-(4-(2-pyrimidinyl)-1-piperazinyl)butyl)-4,7-methano-1H-isoindole-1,3(2H)-dione, SM 3997, SM-3997;
Tangeretin, 2-(4-Methoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 4′,5,6,7,8-Pentamethoxyflavone, 4H-1-Benzopyran-4-one, 2-(4-methoxyphenyl)-5,6,7,8-tetramethoxy-;
tanshinone, tanshinone, tanshinone II A, tanshinone II B;
taurocholic acid, 2-[(3alpha,7alpha,12alpha-trihydroxy-24-oxo-5beta-cholan-24-yl)amino]ethanesulfonic acid, 3alpha,7alpha,12alpha-trihydroxy-5beta-cholanic acid 24-taurine, cholic acid taurine conjugate;
tauroursodeoxycholic acid, tauroursodeoxycholic acid, tauroursodeoxycholic acid, (3alpha,5alpha,7alpha)-isomer, tauroursodeoxycholic acid, monosodium salt, (3 alpha,5beta,7alpha)-isomer;
tautomycetin, tautomycetin;
TAXOTERE, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-12b-(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,6,11-trihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl(aR,bS)-b-[[(1,1-dimethylethoxy)carbonyl]am, Docetaxel, Docetaxel anhydrous;
TBDZ, 1H-Benzimidazole, 2-(4-thiazolyl)-, 2-(1,3-thiazol-4-yl)-1H-benzimidazole, 2-(1,3-Thiazol-4-yl)benzimidazole;
TBHQ, 1,4-Benzenediol(1,1-dimethylethyl)-, 1,4-Benzenediol, 2-(1,1-dimethylethyl)-, 2-(1,1-Dimethylethyl)-1,4-benzenediol;
TCAT, 2,3,3-trichloroacryloyl chloride, 2,3,3-trichloroprop-2-enoyl chloride, 2,3,4-Trichloro-2-propenoyl chloride;
technetium, 43Tc, technetium, tecnecio;
Tegafur, 1-(2-Tetrahydrofuryl)-5-fluorouracil, 1-(Tetrahydro-2-furanyl)-5-fluorouracil, 5-Fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione;
Teleocidin, 13-Ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-bis(1-methylethyl)-6H-benzo[g]diazonino[7,6,5-cd]indol-6-one, 6H-Benzo(g)(1,4)diazonino(7,6,5-cd)indol-6-one, 13-ethenyl-1,3,4,5,7,8,10,11,12,13-decahydro-4-(hydroxymethyl)-8,10,13-trimethyl-7,10-bis(1-methylethyl)-, (4S-(4R*,7R*,10S*,13S*))-, Teleocidin;
telithromycin, Aventis brand of telithromycin, HMR 3647, HMR-3647;
temozolomide, 8-carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one, CCRG 81045, CCRG-81045;
temsirolimus, CCI 779, CCI-779, temsirolimus;
terbinafine, (E)-N-(6,6-dimethyl-2-heptenynyl)-N-methyl-1-naphthalenementhamin hydrochloride, Lamisil, SF 86-327;
terephthalic acid, 1,4-Benzenedicarboxylic acid, benzene-1,4-dicarboxylic acid, p-benzenedicarboxylic acid;
Terfenadine, Aliud Brand of Terfenadine, alpha-(4-(1,1-Dimethylethyl)phenyl)-4-(hydroxydiphenylmethyl)-1-piperdinebutanol, Balkis Saft Spezial;
teriflunomide, teriflunomide;
terrein, terrein;
territrem A, territrem A;
territrem B, territrem B;
territrem C, territrem C;
tertiapin, tertiapin;
tetra-mu3-sulfido-tetrairon, 4Fe-4S, IRON/SULFUR CLUSTER, tetra-mu3-sulfido-tetrairon;
tetrachloroethene, 1,1,2,2-tetrachloroethylene, ethylene tetrachloride, PCE;
tetradecanoyl-phorbol-acetate, tetradecanoyl-phorbol-acetate;
Tetrahydrocannabinol, 9 ene Tetrahydrocannabinol, 9-ene-Tetrahydrocannabinol, delta(1)-Tetrahydrocannabinol;
tetramethylrhodamine, tetramethylrhodamine;
tetramethylsilane, silane, tetramethyl-, tetramethylsilane, TMSCH2Li;
tetraphene, 1,2-benzanthracene, 1,2-Benzanthrazen, benz[a]anthracene;
Tetraprenol, (2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-ol, (E,E,E)-Geranylgeraniol, 2,6,10,14-hexadecatetraen-1-ol, 3,7,11,15-tetramethyl-;
tetrasulfanide, HSSSS(−), SSS[S-], tetrasulfanide;
thiamine disulfide, thiamine disulfide;
thiazole, 1,3-thiazole, cicscnl, thiazole;
thioacetamide, Acetothioamide, ethanethioamide, TAA;
thiobenzamide, thiobenzamide;
thiocoraline, thiocoraline;
Thiole, Divinylene sulfide, Furan, thio-, Huile HSO;
thioredoxin dithiol, Reduced thioredoxin, thioredoxin, thioredoxin dithiol;
thioridazine, 10-[2-(1-methyl-2-piperidyl)ethyl]-2-methylsulfanyl-phenothiazine, 10-[2-(1-methylpiperidin-2-yl)ethyl]-2-(methylsulfanyl)-10H-phenothiazine, 2-Methylmercapto-10-(2-(N-methyl-2-piperidyl)ethyl)phenothiazine;
thrombin receptor peptide SFLLRNP, thrombin receptor peptide SFLLRNP;
thrombin Tokushima, thrombin Tokushima;
thromboxane B2, (5Z,13E,15S)-9alpha,11,15-trihydroxythromboxa-5,13-dien-1-oic acid, thromboxane B2, TXB2;
thymol, 1-hydroxy-5-methyl-2-isopropylbenzene, 2-isopropyl-5-methylphenol, 3-p-cymenol;
thymoquinone, 2-isopropyl-5-methylbenzoquinone, 2-methyl-5-isopropyl-p-benzoquinone, di-hydrothymoquinone;
tipranavir, Aptivus, PNU 140690, PNU-140690;
tirilazad, 21-(4-(2,6-di-1-pyrrolidinyl-4-pyrimidinyl)-1-piperazinyl)-16-methylpregna-1,4,9(11)-triene-3,20-dione monomethane sulfonate, Freedox, Pharmacia brand of tirilazad mesylate hydrate;
titanium alloy (TiA16V4), Ti-6A1-V4 alloy, Ti6A14V, titanium 6-aluminum-4-vanadium;
Tmndga, 1,1′-(2,3-Dimethyl-1,4-butanediyl)bis(3,4-dimethoxybenzene), 1,4-Bis(3,4-dimethoxyphentl)-2,3-dimethylbutane, 4,4′-(2,3-Dimethyl-1,4-butanediyl)bis-1,2-dimethoxybenzene;
Tobrex, (1S,2S,3R,4S,6R)-4,6-diamino-3-(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyloxy)-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside, (1S,2S,3R,4S,6R)-4,6-diamino-3-[(2,6-diamino-2,3,6-trideoxy-alpha-D-ribo-hexopyranosyl)oxy]-2-hydroxycyclohexyl 3-amino-3-deoxy-alpha-D-glucopyranoside, (2S,3R,4S,5S,6R)-4-amino-2-[(1S,2S,3R,4S,6R)-4,6-diamino-3-[(2R,3R,5S,6R)-3-amino-6-(aminomethyl)-5-hydroxy-oxan-2-yl]oxy-2-hydroxy-cyclohexyl]oxy-6-(hydroxymethyl)oxane-3,5-diol;
tocotrienols, tocotrienol, tocotrienols;
tofisopam, 1-(3,4-dimethoxyphenyl)-5-ethyl-7,8-dimethoxy-4-methyl-5H-2,3-benzodiazepine, dextofisopam, EGYT-341;
tolrestat, tolrestat;
Tolterodine, 2-[(1R)-3-(di(propan-2-yl)amino)-1-phenyl-propyl]-4-methyl-phenol, 2-[(1R)-3-(di(propan-2-yl)amino)-1-phenylpropyl]-4-methylphenol, 2-[(1R)-3-(diisopropylamino)-1-phenyl-propyl]-4-methyl-phenol;
toluene, Cc1ccccc1, methylbenzene, phenylmethane;
topiramate, 2,3-4,5-bis-O-(1-methylethylidene)-beta-D-fructopyranose sulfamate, Cilag brand of topiramate, Epitomax;
Topotecan, 9 Dimethylaminomethyl 10 hydroxycamptothecin, 9-Dimethylaminomethyl-10-hydroxycamptothecin, Hycamtamine;
Tosylarginine Methyl Ester, Methyl N alpha Tosyl L Arginate, Methyl N-alpha-Tosyl-L-Arginate, TAME;
TPN+, CODEHYDRASE II, coenzyme II, NADP(+);
trans-resveratrol, (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol, (E)-resveratrol, 3,4′,5-stilbenetriol;
trastuzumab, Genentech brand of trastuzumab, Herceptin, Hoffman-La Roche brand of trastuzumab;
Tremode, 1,2-Benzisoxazole-3-methanesulfonamide, 1,2-benzoxazol-3-ylmethanesulfonamide, 3-(Sulfamoylmethyl)-1,2-benzisoxazole;
Tretinoin, all trans Retinoic Acid, all-trans-Retinoic Acid, beta all trans Retinoic Acid;
Triad, Triad, Triad resin, Triad VLC;
triazolam, 8-chloro-6-(2-chlorophenyl)-1-methyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine, Halcion, triazolam;
triazoles, triazole compounds, triazoles;
tributylstannane, SnBu3H, TBT, Tri-n-butyltin;
trichostatins, trichostatin, trichostatins;
Triclosan, 2-Hydroxy-2′,4,4′-trichlorodiphenyl Ether, Aquasept, Clearasil Daily Face Wash;
triethylamine, triethylamine, triethylamine acetate, triethylamine dinitrate;
trimethylaminocarboxyldihydroboran, TCDB, trimethylamin-carboxyl-dihydro-boran, trimethylaminocarboxyldihydroboran;
trioctyl phosphine oxide, trioctyl phosphine oxide;
tripterine, celastrol, tripterine;
triptolide, PG490, triptolide;
triterpenoids, Triterpenoid, triterpenoids;
troglitazone, 5-(4-((6-hydroxy-2,5,7,8-tetramethylchroman-2-yl-methoxy)benzyl)-2,4-thiazolidinedione), CS 045, CS-045;
TTNPB, (E)-4-(2-(5,6,7,8-Tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propen-1-yl)benzoic acid, (e)-4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-naphthalenyl)-1-propenyl)benzoic acid, (e)-4-(2-(5,6,7,8-tetrahydro-5,5,8,8-tetramethyl-2-napthalenyl)-1-propenyl)benzoic acid;
tubocapsanolide A, tubocapsanolide A;
tyrphostin AG 1478, 4-(3-chloroanilino)-6,7-dimethoxyquinazoline, AG 1478, AG-1478;
tyrphostin AG-490, AG 490, AG-490, AG490;
tyrphostin AG17, tyrphostin AG17;
U 0126,1,4-diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene, U 0126, U-0126;
Ubizol, Androsta-1,4-diene-17-carbothioic acid, 6,9-difluoro-11-hydroxy-16-methyl-3-oxo-17-(1-oxopropoxy)-, (6alpha,11beta,16alpha,17alpha)-S-(fluoromethyl) ester, Asmatil, atemur;
Ufur, 1-UFT protocol, 5-fluoro-1-(2-tetrahydrofuranyl)pyrimidine-2,4-dione; 1H-pyrimidine-2,4-dione, 5-fluoro-1-(oxolan-2-yl)pyrimidine-2,4-dione; 1H-pyrimidine-2,4-dione;
Uprima, (−)-10,11-dihydroxyaporphine, 6a-beta-Aporphine-10,11-diol, 6abeta-aporphine-10,11-diol;
uranyl acetate, uranyl acetate;
urethane, carbamic acid ethyl ester, ethyl carbamate, urethane;
Urex, 2-Furfurylamino-4-chloro-5-sulfamoylbenzoic acid, 4-chloro-2-(2-furylmethylamino)-5-sulfamoyl-benzoic acid, 4-chloro-2-(2-furylmethylamino)-5-sulfamoylbenzoic acid;
urinastatin, acid-stable protease inhibitor, Miraclid, MR 20;
Urso, (3alpha,5beta,7beta)-3,7-dihydroxycholan-24-oic acid, (3alpha,5beta,7beta,8xi)-3,7-dihydroxycholan-24-oic acid, (4R)-4-[(3R,5S,7S,8R,9S,10S,13R,14S,17R)-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoic acid;
USAN, (1-p-Chlorobenzoyl-5-methoxy-2-methylindol-3-yl)acetic acid, 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid, 1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indole-3-acetic acid & MAP-30;
valerenic acid, valerenic acid;
valspodar, 3′-keto-Bmt(1)-Val(2)-cyclosporin A, PSC 833, PSC-833;
venlafaxine, 1-[2-(dimethylamino)-1-(4-methoxyphenyl)ethyl]cyclohexanol, COc1ccc(cc1)C(CN(C)C)C2(O)CCCCC2, Elafax;
verlukast, (3-(3-(2-(7-chloro-2-quinolinyl)ethenyl)phenyl)((3-dimethylamino-3-oxopropyl)thio)methyl)thiopropanoic acid, L 660,711, L 660711;
vesnarinone, vesnarinone;
Viagra, 1-((3-(6,7-Dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazolo(4,3-d)pyrimidin-5-yl)-4-ethoxyphenyl)sulfonyl)-4-methylpiperazine citrate (1:1), 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonyl-phenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one; 2-hydroxypropane-1,2,3-tricarboxylic acid, 5-[2-ethoxy-5-(4-methylpiperazin-1-yl)sulfonylphenyl]-1-methyl-3-propyl-4H-pyrazolo[5,4-e]pyrimidin-7-one; 2-hydroxypropane-1,2,3-tricarboxylic acid;
vincristine, 22-oxovincaleukoblastine, leurocristine, vincristine;
vinflunine, vinflunine;
vinorelbine, 5′-nor-anhydrovinblastine, KW 2307, KW-2307;
vinpocetine, Armstrong brand of vinpocetine, Cavinton, Celltech brand of vinpocetine;
violacein, 3-(1,2-dihydro-5-(5-hydroxy-1H-indole-3-yl)-2-oxo-3H-pyrrol-3-ylidene)-1,3-dihydro-2H-indole-2-one, violacein;
Vira-A, (2R,3R,4R,5R)-2-(6-aminopurin-9-yl)-5-(hydroxymethyl)oxolane-3,4-diol, .alpha.-D-Arabinofuranosyladenine, .beta.-Adenosine;
voriconazole, Pfizer brand of voriconazole, UK 109,496, UK 109496;
vorozole, 6-((4-chlorophenyl)-(1H-1,2,4-triazol-1-yl)methyl)-1-methyl-1H-benzotriazole, R 76713, R 83839;
VX680, cyclopropane carboxylic acid(4-(4-(4-methylpiperazin-1-yl)-6-(5-methyl-2H-pyrazol-3-ylamino)pyrimidin-2-ylsulfanyl)phenyl)amide, MK-0457, VE 465;
Warfarin, 4-Hydroxy-3-(3-oxo-1-phenylbutyl)-2H-1-benzopyran-2-one, Aldo Brand of Warfarin Sodium, Aldocumar;
Win 55212-2, (2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl)methanone monomethanesulfonate, 6H-Pyrrolo(3,2,1-ij)quinolin-6-one, 4,5-dihydro-2-methyl-4-(4-morpholinylmethyl)-1-(1-naphthalenylcarbonyl)-, (R)—, WIN 55,212;
withaferin A, 5,6-epoxy-4,22,27-trihydroxy-1-oxoergosta-2,24-dienoic acid delta-lactone, withaferin A;
WLN: QR BG, 2-Chloro-1-hydroxybenzene, 2-Chlorophenol, 2-Hydroxychlorobenzene;
WLN: RVR, .alpha.-Oxodiphenylmethane, .alpha.-Oxoditane, alpha-oxodiphenylmethane;
xanthohumol, 1-(2,4-dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one, desmethylxanthohumol, xanthohumol;
Xaxa, 2-(ACETYLOXY)BENZOIC ACID, 2-Acetoxybenzenecarboxylic acid, 2-acetoxybenzoic acid;
Xylit, (2S,4R)-pentane-1,2,3,4,5-pentol, 1,2,3,4,5-Pentanepentol, Adonit;
Y 27632, N-(4-pyridyl)-4-(1-aminoethyl)cyclohexanecarboxamide, Y 27632, Y 27632, (4(R)-trans)-isomer;
yristate, (1aR,1bS,4aR,7aS,7bS,8R,9R,9aS)-9a-acetoxy-4a,7b-dihydroxy-3-(hydroxymethyl)-1,1,6,8-tetramethyl-5-oxo-1a,1b,4,4a,5,7a,7b,8,9,9a-decahydro-1H-cyclopropa[3,4]benzo[1,2-e]azulen-9-yl tetradecanoate, -one 9a-acetate, (+)-(8CI), Err:508;
Z 338, N—(N′,N′-diisopropylaminoethyl)-(2-(2-hydroxy-4,5-dimethoxybenzoylamino)-1,3-thiazole-4-yl)carboxyamide, YM 443, YM-443;
zafirlukast, 4-(5-cyclopentyloxycarbonylamino-2-methylindol-3-yl-methyl)-3-methoxy-N—O-tolylsulfonylbenzamide, Accolate, Aeronix;
zardaverine, 6-(4-difluoromethoxy-3-methoxyphenyl)-3(2H)pyridazinone, zardaverine;
Zeldox, 2H-Indol-2-one, 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-, 5-[2-[4-(1,2-benzothiazol-3-yl)-1-piperazinyl]ethyl]-6-chloro-2-indolinone, 5-[2-[4-(1,2-benzothiazol-3-yl)piperazin-1-yl]ethyl]-6-chloro-1,3-dihydroindol-2-one;
zerumbone, zerumbone;
Zidovudine, 3′ Azido 3′ deoxythymidine, 3′-Azido-2′,3′-Dideoxythymidine, 3′-Azido-3′-deoxythymidine;
zileuton, A 64077, A-64077, Abbot 64077;
Zocor, (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate, 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester, 2,2-dimethylbutanoic acid [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-2-tetrahydropyranyl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl]ester;
zopiclone, 6-(5-chloro-2-pyridyl)-6,7-dihydro-7-oxo-5H-pyrrolo(3,4-b)pyrazin-5-yl 4-methyl-1-piperazinecarboxylate, AbZ brand of zopiclone, Aliud brand of zopiclone;
Trospium chloride, 2-hydroxy-2,2-diphenyl-acetic acid [(1R,5S)-spiro[8-azoniabicyclo[3.2.1]octane-8,1′-azolidin-1-ium]-3-yl]ester chloride, 2-hydroxy-2,2-diphenylacetic acid [(1R,5S)-3-spiro[8-azoniabicyclo[3.2.1]octane-8,1′-azolidin-1-ium]yl]ester chloride, 3-((hydroxydiphenylacetyl)oxy)-spiro(8-azoniabicyclo(3.2.1)octane-8,1′-pyrrolidinium chloride;
In preferred embodiments the present invention is defined as follows:
1. The method of treating or preventing pain in a subject comprising the administration of a therapeutic compound selected from the compounds of table 1.
2. The method of reducing pain in a subject or to treat train comprising the administration of an antagonist of one or more of the genes or gene products thereof, selected from genes CACNA2D3 (alpha-2-delta-3), PIK3CG or any gene selected from one or more of the genes listed in table 1, in particular selected from CG10033, CG10095, CG10142, CG10153, CG10158, CG10186, CG10186, CG10228, CG10265, CG1031, CG10332, CG10332, CG10481, CG10537, CG10550, CG1058, CG10583, CG10603, CG10603, CG10612, CG10641, CG10667, CG10686, CG10689, CG10689, CG10691, CG10706, CG10711, CG10728, CG10746, CG10800, CG10823, CG1086, CG10882, CG10932, CG10936, CG10954, CG10988, CG1100, CG1100, CG1101, CG11033, CG11081, CG11183, CG1119, CG11280, CG1130, CG11352, CG11456, CG11508, CG1152, CG11555, CG11577, CG11586, CG11590, CG11592, CG11594, CG11637, CG11637, CG11638, CG11642, CG11715, CG1180, CG1180, CG11820, CG11857, CG11865, CG11878, CG11893, CG11895, CG1193, CG11930, CG11942, CG11967, CG11992, CG12004, CG12030, CG12035, CG12052, CG12079, CG12082, CG12093, CG12131, CG12135, CG12199, CG12209, CG12235, CG12269, CG12290, CG12334, CG12373, CG12559, CG12637, CG1264, CG12641, CG12641, CG12645, CG12663, CG12749, CG12796, CG12797, CG12831, CG12878, CG12932, CG12938, CG12954, CG12975, CG13035, CG13047, CG13061, CG13069, CG13074, CG13096, CG13110, CG13130, CG13130, CG13162, CG13194, CG13196, CG13196, CG13243, CG13308, CG13319, CG13403, CG13559, CG13575, CG13623, CG1371, CG1387, CG13998, CG14028, CG1406, CG14065, CG14086, CG14214, CG14217, CG14240, CG14252, CG14274, CG14351, CG14362, CG14374, CG14374, CG14376, CG14506, CG14514, CG14590, CG14659, CG14710, CG14750, CG14755, CG14804, CG14818, CG14940, CG14952, CG14980, CG15059, CG15120, CG15153, CG15167, CG15254, CG15307, CG15321, CG15324, CG15427, CG15570, CG15604, CG15604, CG15884, CG16778, CG1683, CG16840, CG16852, CG16854, CG16873, CG16899, CG16932, CG16975, CG17003, CG17027, CG1709, CG17137, CG17146, CG17150, CG17189, CG17234, CG1725, CG17255, CG17266, CG17293, CG17295, CG17521, CG1759, CG17612, CG17673, CG17697, CG17943, CG1800, CG1804, CG18069, CG18088, CG18130, CG18249, CG18332, CG18332, CG18350, CG18350, CG18350, CG18350, CG18372, CG1845, CG18480, CG18624, CG18624, CG18666, CG1915, CG1921, CG1921, CG1966, CG1968, CG1982, CG2038, CG2060, CG2079, CG2100, CG2109, CG2128, CG2158, CG2161, CG2257, CG2257, CG2286, CG2346, CG2371, CG2371, CG2503, CG2522, CG2747, CG2848, CG2848, CG2872, CG2872, CG2901, CG3000, CG30004, CG30004, CG30005, CG30039, CG30050, CG30073, CG30291, CG30342, CG30383, CG30384, CG30404, CG3083, CG3105, CG31065, CG31068, CG31110, CG31267, CG31299, CG31300, CG31623, CG31713, CG31716, CG31718, CG3181, CG3184, CG31841, CG31842, CG31876, CG31886, CG31908, CG31936, CG31955, CG31962, CG32016, CG32025, CG32045, CG32057, CG32121, CG3213, CG32148, CG32150, CG32176, CG32193, CG32219, CG32227, CG3224, CG32278, CG32296, CG32296, CG32313, CG32333, CG32346, CG3241, CG32531, CG32533, CG32540, CG32604, CG32614, CG32678, CG32678, CG32678, CG32678, CG3269, CG32698, CG3270, CG32703, CG32736, CG32779, CG32779, CG32779, CG32792, CG3291, CG3295, CG3298, CG33002, CG33106, CG33106, CG33106, CG33106, CG33106, CG33106, CG33128, CG33135, CG33147, CG33149, CG33166, CG33202, CG33261, CG33275, CG33275, CG3330, CG33346, CG33350, CG3344, CG33484, CG33500, CG33500, CG3351, CG33512, CG33512, CG33530, CG33547, CG33547, CG33653, CG33980, CG34059, CG34140, CG34140, CG34159, CG3421, CG34339, CG34341, CG34364, CG34383, CG34400, CG34401, CG34401, CG34416, CG3474, CG3520, CG3569, CG3581, CG3604, CG3613, CG3619, CG3619, CG3619, CG3707, CG3711, CG3717, CG3735, CG3905, CG3943, CG3949, CG3955, CG3981, CG4013, CG4040, CG4083, CG4094, CG4109, CG4217, CG42250, CG4247, CG4247, CG4260, CG4279, CG4279, CG4351, CG4365, CG4396, CG4459, CG4477, CG4502, CG4550, CG4560, CG4584, CG4587, CG4612, CG4633, CG4633, CG4648, CG4655, CG4673, CG4692, CG4698, CG4742, CG4775, CG4795, CG4798, CG4799, CG4806, CG4807, CG4830, CG4875, CG4875, CG4887, CG4946, CG4975, CG4977, CG5003, CG5012, CG5012, CG5013, CG5014, CG5014, CG5121, CG5134, CG5160, CG5179, CG5183, CG5198, CG5201, CG5219, CG5219, CG5261, CG5287, CG5330, CG5405, CG5411, CG5473, CG5499, CG5516, CG5519, CG5565, CG5580, CG5611, CG5643, CG5644, CG5703, CG5723, CG5725, CG5725, CG5727, CG5757, CG5788, CG5800, CG5818, CG5819, CG5821, CG5842, CG5884, CG5889, CG5890, CG5902, CG5934, CG5940, CG5949, CG5969, CG5977, CG5986, CG6006, CG6098, CG6136, CG6143, CG6177, CG6210, CG6249, CG6340, CG6395, CG6457, CG6496, CG6536, CG6549, CG6553, CG6571, CG6575, CG6582, CG6583, CG6605, CG6620, CG6637, CG6673, CG6703, CG6721, CG6724, CG6822, CG6824, CG6930, CG6930, CG6946, CG6948, CG6963, CG6971, CG6971, CG6972, CG6987, CG6998, CG7006, CG7007, CG7007, CG7010, CG7015, CG7025, CG7059, CG7081, CG7099, CG7100, CG7109, CG7129, CG7145, CG7160, CG7175, CG7175, CG7187, CG7194, CG7211, CG7223, CG7225, CG7292, CG7311, CG7342, CG7358, CG7371, CG7376, CG7422, CG7430, CG7443, CG7467, CG7494, CG7494, CG7497, CG7507, CG7556, CG7583, CG7636, CG7664, CG7708, CG7708, CG7712, CG7728, CG7730, CG7800, CG7800, CG7811, CG7816, CG7856, CG7873, CG7946, CG7957, CG8005, CG8008, CG8009, CG8014, CG8014, CG8029, CG8039, CG8048, CG8107, CG8110, CG8114, CG8203, CG8233, CG8288, CG8325, CG8326, CG8394, CG8432, CG8436, CG8440, CG8487, CG8520, CG8625, CG8631, CG8651, CG8732, CG8764, CG8849, CG8912, CG8914, CG8985, CG8985, CG9022, CG9022, CG9032, CG9067, CG9102, CG9160, CG9172, CG9231, CG9280, CG9311, CG9323, CG9350, CG9388, CG9447, CG9453, CG9460, CG9519, CG9537, CG9548, CG9603, CG9636, CG9636, CG9650, CG9696, CG9739, CG9742, CG9753, CG9753, CG9825, CG9825, CG9901, CG9901, CG9948, or an ortholog thereof, preferably wherein the antagonist is selected from an antibody or an inhibitory RNA, particularly a siRNA.
3. The method according to definition 1 or 2, characterized in that a the compound or antagonist is administered in a effective therapeutic dose.
4. The method of any one of definitions 1 to 3, characterized in that the compound is administered topical, enteral or parenteral, in particular preferred oral or rectal, intravenous, intraarterial, intramuscular, subcutaneous, intradermal or intraperitoneal, transdermal, transmucosal or inhalational.
5. The method of any one of definitions 1 to 4, characterized in that the subject is mammal, preferably a human.
6. The method of any one of definitions 1 to 5, characterized in that the compound or antagonist is provided in a medicament.
7. The method of any one of definitions 1 to 6, characterized in that the compound or antagonist is provided together with a pharmaceutically acceptable carrier or buffer.
8. The method of any one of definitions 1 to 6, characterized in that the compound or antagonist is administered in a dosage of between 0.01 mg/kg and 1 g/kg.9. Use of a compound as defined in definition 1 or an antagonist as defined in definition 2, preferably further defined as in any one of definitions 3 to 8, for the manufacture of an analgesic or for the treatment of pain.
10. Compound as defined in definition 1 or an antagonist as defined in definition 2 for use in a therapeutic method for the treatment of pain, preferably as further defined in any one of definitions 3 to 8.
11. Method according to any one of definitions 1 to 8, use of definition 9 or compound of definition 10, wherein pain is selected from or associated with chronic or acute pain or hyperalgesiaain, somatogenic pain, neuropathic pain, psychogenic pain, heat induced pain, physical pain, nociception, hyperalgesia, rheumatic pain, headache, low back pain, pelvic pain, myofascial pain, vascular pain, migraine, wound associated pain, inflammatory pain, arthritic pain, diabetic pain, pain from cancer, somatic visceral pain, phantom pain, or any combination thereof.
12. The method of modulating the gene expression or gene function in a cell, wherein the gene is selected from one or more of the genes listed in table 1, in particular selected from CACNA2D3, PIK3CG, CG10033, CG10095, CG10142, CG10153, CG10158, CG10186, CG10186, CG10228, CG10265, CG1031, CG10332, CG10332, CG10481, CG10537, CG10550, CG1058, CG10583, CG10603, CG10603, CG10612, CG10641, CG10667, CG10686, CG10689, CG10689, CG10691, CG10706, CG10711, CG10728, CG10746, CG10800, CG10823, CG1086, CG10882, CG10932, CG10936, CG10954, CG10988, CG1100, CG1100, CG1101, CG11033, CG11081, CG11183, CG1119, CG11280, CG1130, CG11352, CG11456, CG11508, CG1152, CG11555, CG11577, CG11586, CG11590, CG11592, CG11594, CG11637, CG11637, CG11638, CG11642, CG11715, CG1180, CG1180, CG11820, CG11857, CG11865, CG11878, CG11893, CG11895, CG1193, CG11930, CG11942, CG11967, CG11992, CG12004, CG12030, CG12035, CG12052, CG12079, CG12082, CG12093, CG12131, CG12135, CG12199, CG12209, CG12235, CG12269, CG12290, CG12334, CG12373, CG12559, CG12637, CG1264, CG12641, CG12641, CG12645, CG12663, CG12749, CG12796, CG12797, CG12831, CG12878, CG12932, CG12938, CG12954, CG12975, CG13035, CG13047, CG13061, CG13069, CG13074, CG13096, CG13110, CG13130, CG13130, CG13162, CG13194, CG13196, CG13196, CG13243, CG13308, CG13319, CG13403, CG13559, CG13575, CG13623, CG1371, CG1387, CG13998, CG14028, CG1406, CG14065, CG14086, CG14214, CG14217, CG14240, CG14252, CG14274, CG14351, CG14362, CG14374, CG14374, CG14376, CG14506, CG14514, CG14590, CG14659, CG14710, CG14750, CG14755, CG14804, CG14818, CG14940, CG14952, CG14980, CG15059, CG15120, CG15153, CG15167, CG15254, CG15307, CG15321, CG15324, CG15427, CG15570, CG15604, CG15604, CG15884, CG16778, CG1683, CG16840, CG16852, CG16854, CG16873, CG16899, CG16932, CG16975, CG17003, CG17027, CG1709, CG17137, CG17146, CG17150, CG17189, CG17234, CG1725, CG17255, CG17266, CG17293, CG17295, CG17521, CG1759, CG17612, CG17673, CG17697, CG17943, CG1800, CG1804, CG18069, CG18088, CG18130, CG18249, CG18332, CG18332, CG18350, CG18350, CG18350, CG18350, CG18372, CG1845, CG18480, CG18624, CG18624, CG18666, CG1915, CG1921, CG1921, CG1966, CG1968, CG1982, CG2038, CG2060, CG2079, CG2100, CG2109, CG2128, CG2158, CG2161, CG2257, CG2257, CG2286, CG2346, CG2371, CG2371, CG2503, CG2522, CG2747, CG2848, CG2848, CG2872, CG2872, CG2901, CG3000, CG30004, CG30004, CG30005, CG30039, CG30050, CG30073, CG30291, CG30342, CG30383, CG30384, CG30404, CG3083, CG3105, CG31065, CG31068, CG31110, CG31267, CG31299, CG31300, CG31623, CG31713, CG31716, CG31718, CG3181, CG3184, CG31841, CG31842, CG31876, CG31886, CG31908, CG31936, CG31955, CG31962, CG32016, CG32025, CG32045, CG32057, CG32121, CG3213, CG32148, CG32150, CG32176, CG32193, CG32219, CG32227, CG3224, CG32278, CG32296, CG32296, CG32313, CG32333, CG32346, CG3241, CG32531, CG32533, CG32540, CG32604, CG32614, CG32678, CG32678, CG32678, CG32678, CG3269, CG32698, CG3270, CG32703, CG32736, CG32779, CG32779, CG32779, CG32792, CG3291, CG3295, CG3298, CG33002, CG33106, CG33106, CG33106, CG33106, CG33106, CG33106, CG33128, CG33135, CG33147, CG33149, CG33166, CG33202, CG33261, CG33275, CG33275, CG3330, CG33346, CG33350, CG3344, CG33484, CG33500, CG33500, CG3351, CG33512, CG33512, CG33530, CG33547, CG33547, CG33653, CG33980, CG34059, CG34140, CG34140, CG34159, CG3421, CG34339, CG34341, CG34364, CG34383, CG34400, CG34401, CG34401, CG34416, CG3474, CG3520, CG3569, CG3581, CG3604, CG3613, CG3619, CG3619, CG3619, CG3707, CG3711, CG3717, CG3735, CG3905, CG3943, CG3949, CG3955, CG3981, CG4013, CG4040, CG4083, CG4094, CG4109, CG4217, CG42250, CG4247, CG4247, CG4260, CG4279, CG4279, CG4351, CG4365, CG4396, CG4459, CG4477, CG4502, CG4550, CG4560, CG4584, CG4587, CG4612, CG4633, CG4633, CG4648, CG4655, CG4673, CG4692, CG4698, CG4742, CG4775, CG4795, CG4798, CG4799, CG4806, CG4807, CG4830, CG4875, CG4875, CG4887, CG4946, CG4975, CG4977, CG5003, CG5012, CG5012, CG5013, CG5014, CG5014, CG5121, CG5134, CG5160, CG5179, CG5183, CG5198, CG5201, CG5219, CG5219, CG5261, CG5287, CG5330, CG5405, CG5411, CG5473, CG5499, CG5516, CG5519, CG5565, CG5580, CG5611, CG5643, CG5644, CG5703, CG5723, CG5725, CG5725, CG5727, CG5757, CG5788, CG5800, CG5818, CG5819, CG5821, CG5842, CG5884, CG5889, CG5890, CG5902, CG5934, CG5940, CG5949, CG5969, CG5977, CG5986, CG6006, CG6098, CG6136, CG6143, CG6177, CG6210, CG6249, CG6340, CG6395, CG6457, CG6496, CG6536, CG6549, CG6553, CG6571, CG6575, CG6582, CG6583, CG6605, CG6620, CG6637, CG6673, CG6703, CG6721, CG6724, CG6822, CG6824, CG6930, CG6930, CG6946, CG6948, CG6963, CG6971, CG6971, CG6972, CG6987, CG6998, CG7006, CG7007, CG7007, CG7010, CG7015, CG7025, CG7059, CG7081, CG7099, CG7100, CG7109, CG7129, CG7145, CG7160, CG7175, CG7175, CG7187, CG7194, CG7211, CG7223, CG7225, CG7292, CG7311, CG7342, CG7358, CG7371, CG7376, CG7422, CG7430, CG7443, CG7467, CG7494, CG7494, CG7497, CG7507, CG7556, CG7583, CG7636, CG7664, CG7708, CG7708, CG7712, CG7728, CG7730, CG7800, CG7800, CG7811, CG7816, CG7856, CG7873, CG7946, CG7957, CG8005, CG8008, CG8009, CG8014, CG8014, CG8029, CG8039, CG8048, CG8107, CG8110, CG8114, CG8203, CG8233, CG8288, CG8325, CG8326, CG8394, CG8432, CG8436, CG8440, CG8487, CG8520, CG8625, CG8631, CG8651, CG8732, CG8764, CG8849, CG8912, CG8914, CG8985, CG8985, CG9022, CG9022, CG9032, CG9067, CG9102, CG9160, CG9172, CG9231, CG9280, CG9311, CG9323, CG9350, CG9388, CG9447, CG9453, CG9460, CG9519, CG9537, CG9548, CG9603, CG9636, CG9636, CG9650, CG9696, CG9739, CG9742, CG9753, CG9753, CG9825, CG9825, CG9901, CG9901, CG9948, or an ortholog counterpart thereof, comprising administering a compound of table 1 to said cell.
13. The method of definition 12, wherein the cell is a nerve cell.
14. The method of definition 12 or 13, wherein administration treats, alleviates or prevents pain or hyperalgesia in a subject.
The present invention is further illustrated by the following figures and examples.
A: Compounds testing performed on pregabalin, cilomilast, zardaverine and roflumilast as described in Example 4.1.3.2. Data are presented as mean values±SEM, n=8-10. Significantly different by Mann-Whitney U test compared to T=0 paw withdrawal thresholds (* p<0.05, ** p<0.01, *** p<0.001).
B: Compounds testing performed on pregabalin, bosutinib and adefovir as described in Example 4.1.3.3. Data are presented as mean values±SEM, n=8-10. Significantly different by Mann-Whitney U test compared to T=0 paw withdrawal thresholds (* p<0.05, ** p<0.01, *** p<0.001).
C: Compounds testing performed on pregabalin, dasatinib and tenofovir as described in Example 4.1.3.1. Data are presented as mean values±SEM, n=8-10. Significantly different by Mann-Whitney U test compared to T=0 paw withdrawal thresholds (* p<0.05, ** p<0.01, *** p<0.001).
B: Von Frey's hairs assay for Indomethiacin, Cimilast, Zardaverine, Roflumilast. Data are presented as mean values±SEM, n=8-10. Significantly different by Mann-Whitney U test. * p<0.05, ** p<0.01, *** p<0.001 significantly different from post surgery withdrawal thresholds.
C: Von Frey's hairs assay for Indomethiacin, Bosutinib, Adefovir. Data are presented as mean values±SEM, n=8-10. Significantly different by Mann-Whitney U test. * p<0.05, ** p<0.01, *** p<0.001 significantly different from post surgery withdrawal thresholds.
All UAS-IR transgenic fly lines were obtained from the VDRC RNAi library (Dietzl et al., 2007) with the exception of α2δ second hairpins, which were obtained from the Harvard trip stocks. elav with UAS-Dicer 2 was a gift from B. Dickson (Dietzl et al., 2007). Painless(EP(2)2451) was a gift from D. Tracey. Df(2R)Exel712 was obtained from the Exelexis stock collection (Thibault et al., 2004). NP1574-Gal4 was obtained from the Kyoto Institute of Technology Drosophila Genetic Resource Center (Hayashi et al., 2002). The point mutant stj lines stj1 and stj2, the stj deficiency Df(2R)Exel7128, and the stj P[acman] rescue (stj+; 1259) flies have been previously described (Ly et al., 2008). These flies were generated by introducing a BAC containing the wild type stj locus into predetermined attP sites in the genome using ΦC31 integrase (Venken et al., 2009). UAS-Lamin: GFP was a gift from N. Stuurman. UAS-shibirets1 and UAS-CD8: GFP were obtained from Bloomington.
For adult thermal preference and avoidance of noxious heat ˜20 four day old flies were placed in an experimental chamber (Nunclon dish 35 mm×10 mm) sealed with scotch tape. All tests were performed in the dark. The bottom of the chamber was heated to 46° C. over 15 seconds by floating on a water bath while the subnoxious zone was measured to be 31° C. at the end of the 4 minute experiment. % Avoidance was calculated by counting the number of flies that failed to avoid the noxious temperature compared to the total number of flies in the chamber. For experiments involving UAS-shibirets1, flies were transferred to the experimental chambers followed by a temperature shift to 30° C. for 60 minutes. Larval pain assays were performed as described (Tracey et al., 2003). Since 3rd instar stj2 mutant larvae exhibit motor defects, we only used 1st and 2nd instar stj2 larvae and stage-matched control larvae for our experiments. Mechanosensation (Kernan score) was performed as described (Kernan et al., 1994). To set up the experimental assay and to determine a cut-off, where we would always hit painless, multiple control (F1 from w1118 ♂×virgin elav-Gal4; UAS-DCR2♀) and painless mutant flies were tested for thermal avoidance and an avoidance histogram generated. For assessing noxious temperature-induced paralysis, wild type flies were placed in 5 ml polystyrene round bottom tubes (BD Falcon) and exposed to different temperatures (37-46° C. with 1° increments) until 100% of flies were paralyzed. Basic coordination was assessed by tapping the test chamber on the bench and observing general coordination as flies move away from the site of impact as described previously (Dietzl et al., 2007).
For screening, transgenic males harboring a UAS-IR transgene were crossed with elav-Gal-4; DCR2-Gal4 females and F1 progeny were tested for avoidance of noxious heat (46° C.) in our experimental chambers. In our pilot studies, a noxious temperature of 46° C. was found to give the most robust differences between control and painless mutant flies. Of note, 46° C. is the same temperature used to identify painless in larvae (Tracey et al., 2003). For the screening we chose a 4 minute cut-off, based on the difference between control and pain mutant flies. For each fly line, ˜20 adult flies were transferred to the experimental chambers. During retesting flies were also scored for basic coordination before testing by tapping the flies to the bottom of the test chamber after loading and assessing whether flies were slow or uncoordinated when climbing back up the wall of the chamber. For noxious heat avoidance, flies were given a choice between the noxious and non-noxious temperature and after 4 minutes, the number of flies successfully avoiding the noxious heat and the number in the noxious heat zone (which were incapacitated by assay end) were recorded to calculate percent avoidance ((total-failed)/total)×100) for each test. The Z-score was generated as compared to wild type responses (w1118×elav; DCR2). A Z-score was generated as follows: ((mean control avoidance−mean test avoidance)/standard deviation control). Flies failing to avoid the noxious temperature in the first round were confirmed with multiple retests. All elav-Gal4>UAS-IR lines with a Z-score>1.65 in the primary screen were tested an average of 6.78 independent times using second UAS-IR transformants. Based on previous use of this RNAi library (Dietzl et al., 2007; Mummery-Widmer et al., 2009) the false positive rate is estimated at 2-7%. To decrease the number of false positives we excluded 55 hairpins with potential off-target effects (more than 6 Can repeats and/or S19 score<0.8 was considered unspecific), leaving 622 transgenic lines corresponding to 580 candidate nociception genes (
During hit confirmation for our screen, flies were also assessed for general coordination defects (Dietzl et al., 2007) that could potentially impede noxious thermal avoidance. In addition, to further test whether our hits had a defect that is specific to noxious thermal avoidance and/or exhibited additional alterations in innate behavioral programs (Benzer, 1967), we evaluated fly lines for general coordination by geotactic repulsion and phototactic attraction. To determine if our candidate thermal nociception hits were unable to avoid noxious heat due to increased temperature-sensitivity we assayed temperature-induced paralysis at 38° C., a system that was originally used to identity classic temperature-sensitive paralytic mutants such as shibire and para (Grigliatti et al., 1973; Siddiqi and Benzer, 1976). No significant correlations were observed between thermal nociception genes and phototactic attraction (r2=0.0026), geotactic avoidance (r2=0.00165), or temperature sensitivity (r2=0,005742). Finally, to determine if our candidate pain genes are simply the result of increased temperature-induced paralysis at 46° C., we exposed pain hits to a chamber set to 46° C. and recorded the kinetics of temperature-induced paralysis.
Of the 580 genes corresponding to the RNAi hits with thermal nociception phenotypes, 391 genes were annotated by GOstat. To find additional information about gene-function of the remaining 189 genes, we searched three other databases for functional information associated with the Drosophila genes and an additional 80 genes were functionally annotated using the following tools:
1. Panther db (http://www.pantherdb.org/).
2. Overlap with neuronal precursor genes published by Brody T., et al. (Brody et al., 2002).
3. NCBI Gene (Gene Ontology) (http://www.ncbi.nlm.nih.gov/gene).
To identify orthologs between Drosophila and mouse or Drosophila and human, we used pre-computed orthology predictions obtained from Compara r49, Homologene (03/08), Inparanoid v6.1, Orthomcl v2 (Kuzniar, et al., Trends Genet 24, 539 (November, 2008). Since each database query outputs results using a different gene identifier, we transformed all the different identifiers to a single unique Entrez ID, for each gene. Both one-to-one, and many-to-many mappings were observed between the Drosophila and the mammalian genes. In cases where on Drosophila gene mapped to multiple mammalian orthologs, all the predicted orthologs of a given gene, were considered for further downstream analysis. In cases where a mammalian gene of interest had multiple Drosophila orthologs, the fly gene with highest Z-score for the corresponding RNAi hit was mapped.
Gene Ontology (GO) analysis was performed using GOstat (http://gostat.wehi.edu.au/). GO analysis was run with Drosophila genes whose RNAi hits have a Z-score>1.65. Over- or under-represented (p<0.1) GO terms with corrections for multiple testing (Benjamin-Yekutieli correction) were identified and compared to all Drosophila genes reported in the flybase (fb). Since terms that occur at a deeper level in the GO tree hierarchy, therefore containing lesser numbers of genes, are considered more biologically informative, we discarded terms containing more than 500 genes from further analysis. Significant GO terms were manually pooled and organized into “functional groups” based on their shared roles in a biological function.
Pathway analysis was performed using the Drosophila Pathway database in GeneSpring GX. Briefly, the Pathway database in GeneSpring GX contains binding partners from two sources: 1. those reported in open-source public databases like BIND and IntAct (IMEX consortium) and 2. extracted from Pubmed abstracts using a proprietary natural language processing technique. The tool UI allows a query of the database to build networks of molecular relations (edges) amongst molecules (nodes) of interest. Data from the IMEX consortium only represent protein binding and promoter binding molecular interactions. Using filters in GeneSpring GX, we selected only binding molecular relations reported by the IMEX consortium to create this network, thereby including only experimentally proved physical interactions between the corresponding protein molecules.
A hypergeometric test, similar to the test used for GO enrichment analysis, was used to identify over-represented gene lists (C2 from Msigdb, BROAD Institute) and pathways (KEGG) amongst the pain hits. The hypergeometric test considers only the percentage representation of genes corresponding to a biological pathway in the pre-computed pain gene list. This analysis was performed on the gene list identified as mouse or human orthologs corresponding to adult pain hits (Z-score>1.65) in Drosophila.
For the combined systems map, significant KEGG pathways, C2 gene sets and selected GO functional categories were manually grouped into uniform functional categories. Functional categories chosen for depiction were selected relevant to the biology of pain function. The complete list of functional categories is available in tables S4 and S5. Of these, 37 functional categories were chosen for construction of the systems map. For each functional category, the corresponding genes that mapped to the KEGG pathways, C2 gene sets and GO term, included in the category were extracted. Drosophila orthologs for these genes were found and assigned to the category and visually represented into a systems map. For the construction of Drosophila KEGG pathway systems map, pathways rendered over 90% enriched by GSA analysis, were manually annotated into functional categories. Pain hit genes and their binding partners that belong to any pathway were extracted and assigned to the appropriate higher level functional category. Data was represented as a systems map connecting these functional categories.
GSA uses lists of genes from biological pathways or processes, to find if the pathway or the process as a whole has been significantly altered by the experimental treatment. A null hypothesis is that “genes of a functionally irrelevant pathway are not clustered at the top of a rank ordered (based on Z-score) list of all genes in the experiment”. The rank order list of 11293 unique genes with Z-scores was obtained from our screen assaying a total of 16051 UAS-IR transformants. Individual gene lists were constructed corresponding to 146 Drosophila KEGG pathways and 45 significant GO terms (corrected p<0.1). Binding partners were identified in yeast-2-hybrid screens reported in the biomolecular interaction network database BIND, i.e. binding partners experimentally confirmed to interact with the candidate thermal nociception genes. An enrichment score (Es) for a gene list (s) was calculated based upon the pain Z-score using the formula: Es=sum of average Z-scores of all genes in s
(Number of Genes in s)
For every s, 100 bootstrap permutations were carried out to generate random functionally unrelated gene lists of the same size and their enrichment scores calculated as Er. A gene set s is considered significant (p<0.1) if Es>Er (90th quantile). This GSA approach removes any bias artificially created by the ad-hoc Z-score cut-off >1.65.
Brains and ventral nerve cords from stj-Gal4>UAS-Lamin:GFP and stj-Gal4>UAS-CD8:GFP fly lines were dissected in PBS, fixed in 4% paraformaldehyde in PBS for 30 min at room temperature (RT), washed three times for 10 min in PBS containing 0.3% Triton X-100, blocked for 1 hr at RT in PBT containing 5% normal goat serum, and incubated with primary anti-GFP (Invitrogen) and NC82 (Iowa hybridoma bank) counterstaining antibodies in blocking solution overnight at 4 C. Samples were washed three times for 10 min in PBT at RT, and secondary antibodies were applied in blocking solution for 2 hrs at RT. After washing three times for 10 min in PBS, samples were mounted in Vectashield (Vector Labs). Alternatively, to stain for STJ, adult brains were dissected in Grace's Insect Medium, fixed in 4% formaldehyde in PBS with 1% Triton X-100 (PBS/Tx), rinsed 2 times in 0.3% PBS/Tx and washed 2 times in 0.5% PBS/Tx for 15 min. Samples were blocked overnight at 4 C in 5% NGS with 0.1% PBS/Tx and the primary antibodies were incubated 3 days at 4 C in block solution. Samples were washed as was done after fixation and incubated with the secondary antibodies at 4 C for 2 days. Then samples were washed as before with the final wash step in PBS before being transferred to 50% PBS/glycerol and then mounted. Antibodies against STJ were raised in either rabbit (HH129) or guinea pig (125 or 127). Confocal images were captured on a Zeiss LSM510 Meta, Axiovert 200 M, and processed with LSM510 Image Examiner. For larval imaging, stj-GAL4 was crossed to UAS-mCD8:GFP. Larvae raised at 22° C. were dissected in modified HL3 solution (110 mM NaCl, 5 mM KCl, 10 mM NaHCO3, 5 mM HEPES, 30 mM sucrose, 5 mM Trehalose, and 10 mM MgCl2) (pH, 7.2) and fixed in 3.7% formaldehyde. Stainings were performed using standard protocols described (Verstreken et al., 2003). Images were captured using a Zeiss 510 confocal microscope (Carl Zeiss, Inc.) using a Plan Neofluar 40×, 1.3 N.A. objective and processed with LSM Image Browser 4.2 (Carl Zeiss, Inc.). Primary antibodies to GFP (rabbit, chicken, Abcam used 1:500) and FUTSCH were diluted 1:200. STJ antibodies were all diluted to 1:100. Secondary antibodies tagged with Alexa 405, Alexa 488, Alexa 568 (Invitrogen) or Cy3 were used at 1:200. In situ hybridizations on adult flies were performed as previously described (Couto et al., 2005).
For gene targeting of α2δ3 in mice, a targeting vector was inserted into exon 15 of the murine α2δ3 gene. The linearized construct was electroporated into embryonic stem (ES) cells derived from the 129/OlaHsd mouse sub-strain. Correctly targeted ES cell clones were confirmed by Southern blotting and used to generate chimeric mice. Germline transmitted F1 mice were backcrossed to C57BL/6 females. All behavioral and fMRI studies were conducted in accordance with guidelines of the European Union Council (86/609/EU) and following Austrian regulations for the use of laboratory animals.
A physical examination of α2δ3 mutant and control mice to assess general characteristics such as activity, behavior towards siblings, posture, grooming, breathing patterns and movement, abnormal discharge, malformations was performed. A step-wise necropsy exam was then performed to identify potential lesions and abnormalities in all organs. Harvested organs were fixed, paraffin-embedded, sectioned, stained using hematoxylin and eosin, and then assessed for possible histopathologies.
Blood samples were collected by terminal cardiac puncture and serum was assessed for electrolytes, inorganic ions, lipid profile, glucose and creatine kinase, and basic markers of renal and kidney functions. Serum data were assayed in a Hitachi 912 automatic analyzer. Whole blood smears were stained with Wright's Stain in order to perform a differential leukocyte count.
For the hot plate assay, age and sex-matched wild type and α2δ3 mutant mice were acclimated to the hot plate apparatus (Ugo Basile, Comerio, Italy) and then tested for hot plate latency at 50-56° C. Jumping, biting, licking, and clutching of hind paws was considered a nociceptive response as described previously (Jourdan et al., 2001). For the tail-flick test, a light beam was focused onto the tip of the tail, and the latency to tail withdrawal was taken as a measure of the nociceptive threshold to radiant heat. The mechanical pain test was performed by applying an ascending series of noxious von Frey hairs to the dorsal surface of each hindpaw until a hindlimb withdrawal response was observed (Whishaw et al., 1999). Inflammatory thermal hyperalgesia was produced in the mouse right hind paw by intraplantar injection of Complete Freund's Adjuvant (CFA) (20 μl of a solution containing 5 mg of CFA in 10 ml of a 1:1 emulsion of saline and mineral oil). Before and after CFA injection, nociceptive responses to heat were measured using the hot-plate test (54° C.). To evaluate the inflammatory response elicited by CFA, paw swelling was measured using a spring loaded caliper (Mitutoyo, Japan). The rotarod test was used to evaluate basic coordination and balance. Mice were placed on a smooth rod that acts as a rotating treadmill (AccuScan Instruments, Columbus, Ohio). The rotarod rotates slowly at first and then progressively increases in speed. Mice were tested three times and the fall speed was recorded. Moreover, mice were evaluated for their response to a novel environment using an open field test (MED Associates, St. Albans, Vt.). Briefly, each animal was placed in the center of its assigned chamber. Activity of individual mice was monitored by photo-beam breaks and recorded for the ten minute test session. Mice were assessed for a “depression” phenotype using the tail suspension assay (MED Associates, St. Albans, Vt.). Each mouse was suspended from a metal hanger such that the end of the hanger is ⅛th of an inch or less from the base of the tail. Total times of immobility were recorded during a 6 minute period.
PI3Kγ knock out (T. Sasaki et al., Science 287, 1040 (Feb. 11, 2000) and kinase dead knock in (E. Patrucco et al., Cell 118, 375 (Aug. 6, 2004)) mice are described.
Baseline thermal and mechanical sensitivities were assessed using the Hargreaves and von Frey test (Ugo Basile Biological Research Apparatus Co., Comerio, Varese—Italy) following acclimation with the test apparatus. For paw withdrawal latencies, responses were determined by testing left and right paws. The hot plate test was done using a microprocessor-controlled unit (Ugo Basile). For initial phenotyping, WT and PI3Kγ KO littermates were used. For subsequent tests, PI3Kγ KO mice were backcrossed >8 times to C57B6 mice and compared to sex and age matched wild type C57B6 controls. Inflammatory pain was induced by intraplantar injection of Complete Freund's Adjuvant (CFA) (20 μl of a solution containing 5 mg of CFA in 10 ml of a 1:1 emulsion of saline and mineral oil) and behavior was tested on a hot plate as above. Paw swelling indicative of inflammation was evaluated by use of a spring loaded caliper (Mitutoyo). Capsaicin behavior was assessed by time spent licking over 5 minutes following intraplantar injection of capsaicin (3 μg in 10 μl; dissolved in 5% ethanol, 5% Tween-80 and 90% saline; Sigma). For acetone-induced cold pain, a drop (50 μL) of acetone was placed against the centre of the plantar surface of the hindpaw and responses were recorded (I. Racz et al., J Neurosci 28, 12125 (Nov. 12, 2008). Other behavioral test were as described previously. Briefly, for skilled reaching task, each mouse was placed on a restricted diet and conditioned in the reaching box for 5 days. On the 6th day mice were placed in the reaching box and reaching was scored for 5 minutes beginning with the first attempt. For circadian activity, mice were individually housed in cages with photosensors. The mice were monitored for 24 hours with a 12/12 light dark cycle and the number of cage crosses was recorded. For open field activity, mice were individually housed in clear plastic cages with infrared sensors and left for 10 minutes in conditions of low noise and dim light. Total horizontal activity was tracked and fecal pellets were counted at the end of the test. For rotorod, mice were trained for 3 days at very low speed and then tested while gradually increasing rotation speed. Mean latency on rod was recorded. For water maze, a 1.2 diameter milk pool was used with a 14×14 cm stationary platform hidden 7 mm beneath the liquid surface. Mice were placed in the pool in randomized quadrants and given 60 seconds to locate the safe platform. At the end of each trial mice that failed to locate the platform were placed on it for 10 seconds. After 14 trials over 7 days, the platform was moved to a new quadrant. Mean latency to find the platform is presented. For T-maze, mice were placed in a T shaped maze with one arm of the maze blocked off. On the second day the blocked arm was opened, and time spent in the new area was recorded. For passive avoidance, mice were placed in a clear plastic box with metal bars wired to distribute 0.12 milliamps built into the base. A black plastic platform was fixed in the center of the box. Mice were placed in the black “safe” platform, and when they step from the platform they were given a 1 second shock, and then removed from the apparatus. This process was repeated until mice no longer step from the safe platform.
Six to eight week-old recipient mice underwent a lethal total-body irradiation (1000 Rad). Freshly isolated donor bone marrow cells were then injected into syngenic recipient mice (5×106 cells per mouse) 24 hours after irradiation. PCR analyses of blood cells and tail DNA indicated that ˜95% of blood circulating leukocytes were of donor origin.
Electrophoresis and Western blotting were performed using the Invitrogen Novex Mini-cell system as per the manufacture's instruction. Membranes were blocked with 5% milk powder in PBS. Primary antibodies were diluted in PBS/Tween/BSA. The following primary antibodies were used: mouse anti-Actin, dilution 1/1000 (Sigma); goat anti-α2δ1, dilution 1/500, (Everest Biotech Oxfordshire, UK), and rabbit anti-α2δ3, dilution 1/500. To generate the anti-α2δ3 antibody, rabbits were immunized with the peptide VSERTIKETTGNIAC conjugated to KLH. Serum was affinity purified against the immobilized peptide. Secondary antibodies were used at a dilution of 1 in 5000 (Promega, Madison, Wis.).
Since our α2δ3 knock-out mice carry a LacZ reporter, we used β-Gal staining as a marker to assess α2δ3 expression. Tissues from 7-12 week old heterozygote mice were analysed for LacZ expression. Organs from these mice were frozen, sectioned (10 μm) and analysed for LacZ expression using X-Gal staining followed by Nuclear Fast Red counterstaining. For whole mount brain staining, the brain was cut longitudinally, fixed, and stained using X-gal. The reaction was stopped with a PBS wash and then fixed with buffered formaldehyde. In addition to staining in the brain (
Lumbar dorsal root ganglia (DRG) with the cell bodies of primary afferents that project into the hind paw were harvested from adult C57BL/6J mice, treated enzymatically with Liberase Blendzymel (Roche) and trypsin (Invitrogen), and dissociated mechanically with a fire-polished Pasteur pipette as previously published (Obreja et al., 2002; Obreja et al., 2005). The resulting cell suspension was washed, plated on glass coverslips coated with poly-L-lysine/laminin (Sigma) and cultivated in synthetic serum-free medium (supplemented TNB™, Biochrom, Vienna) at 37° C. in 5% CO2.
Using the whole-cell voltage-clamp configuration of the patch-clamp technique, ionic currents and membrane potentials were recorded from isolated neurons after 16-24 hours at room temperature as previously published (Obreja et al., 2005; Obreja et al., 2002). Currents and the membrane potential recorded using an EPC10 (HEKA, Germany) and the Pulse v8.74 software (HEKA). Borosilicate glass micropipettes (Science Products, Hofheim, Germany) pulled with a horizontal puller (Sutter Instruments Company, Novato, Calif., USA). For calcium current recordings the extracellular solution was composed of (mM); 130 NMDG, 20 TEACl, 5 CsCl, 2 CaCl2, 1 MgCl2 (Sigma), 10 HEPES and 20 Glucose (Merck) and adjusted to pH 7.3 with HCl (Merck). The intracellular solution contained 120 CsCl, 20 TEACl, 10 EGTA, 2 MgATP (Sigma), 10 HEPES and 20 Sucrose (Merck) adjusted to pH 7.3 with CsOH (Merck). Calcium currents were evoked by test potentials from −80 to 60 mV in 10 mV steps from a holding potential of −80 mV and digitized at 50 kHz. All recorded traces were corrected for leakage and capacitive currents using a P/5 protocol.
The individual recorded Calcium IV-plots were fitted with a modified Boltzmann equation with a high-voltage block.
The conductance (G) is dependent on the amount and subtypes of Ca2+ channels that are present in the cell. The activation is determined by the half-maximal activation of the Ca2+ current (Vh) and the e-fold change around Vh (S) in the IV. Voltage-dependent block of the Ca2+ current at high voltages is described by the maximal speed of the blockage (Bs) at the half-maximal voltage of the block (Bh). The reversal of the current is determined by the recersal potential (Vr). All data were analyzed in Origin 7.0 (OriginLab).
Alternatively, for PIK3CG, the following protocol was used:
Using the whole-cell voltage-clamp configuration of the patch-clamp technique, ionic currents were recorded from isolated DRG neurons at −80 mV holding potential as previously published (Obreja et al., 2005; Obreja et al., 2002). The external solution (ECS) contained (in mM) 145 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2 (all Sigma), 10 glucose and 10 HEPES (Merck), at pH 7.3 adjusted with NaOH. Borosilicate glass micropipettes (Science Products, Germany) were filled with internal solution (ICS) containing (in mM) 138 Caesium methanesulfonate, 2 MgCl2, 2 Na2-ATP, 0.2 Na-GTP, 0.5 CaCl2, 5 EGTA (all Sigma) and 10 HEPES (Merck), at pH 7.3 adjusted with CsOH (Merck). After filling, electrode resistance was 3-5 MW. Currents were filtered at 2.9 kHz, sampled at 3 kHz and recorded using an EPC 9 and the Pulse v8.74 software (HEKA). Experiments were performed at room temperature and only one neuron was tested per Petri dish. An automated seven-barrel system with common outlet next to the cell under investigation (<100 μM) was used for fast drug administration and heat stimulation (Dittert et al., J Neurosci Methods 82, 195 (Aug. 1, 1998). Capsaicin was applied at different concentrations (0.001, 0.01, 0.1, 0.5, 1.0, 5.0 and 10 μM; Sigma; 1 mM stock solution solved in ethanol) for 10 seconds each. Heat-activated inward currents (Iheat) were elicited by applying ramp-shaped heat stimuli at 120 s intervals with linear temperature increases from 25 to 50-55° C. within 5 seconds. Current values were sampled at the rising phase of the temperature ramp, normalized to 24° C. (bath temperature) and data represented as an Arrhenius plot (Vyklicky et al., J Physiol 517 (Pt 1), 181 (May 15, 1999). The temperature co-efficient Q10 was used to characterize temperature dependence of the membrane. In the linear range, the activation energy Ea was determined from the slope of the regression line (r>0.99) using the formula:
−Ea=2.303R log10(I2/I1)/((1/T2)−(1/T1))
R gas constant (8.314 JK−1mol−1)
I1 current at lower absolute temperature T1
I2 current at higher absolute temperature T2
The Tthreshold was determined from the point of intersection of the two regression lines.
Q10 was calculated using the equation: Q10=exp(10Ea/(RT1T2)).
Male mice were anesthetized with isoflurane and placed on a cradle inside the MR machine (Bruker BioSpec 47/40 (200 mT/m) with a free bore of 40 cm, equipped with an actively RF-decoupled coil system and a quadratur head coil) under extensive physiological monitoring (respiration, temperature, heat function). The contact heat stimuli (40° C., 45° C., 50° C., and 55° C., plateau for 5 sec after 15 sec of heat increase) were applied at the right hind paw (presented at 3 min 25 s intervals, 3 time each temperature) using a custom made computer controlled Peltier heating device with no influence from and to the MR scanner. For tactile stimulation, the C1 vibrissa of the mice was moved with an air driven device integrated into cradle shifting the vibrissa by an inverted comb with an amplitude of 5 mm at 7 Hz. For the resting state measurement a series of 300 sets of functional images (matrix 64×64, field of view 15×15 mm, slice thickness 0.5 mm, axial, 22 slices) were collected using the Echo Planar Technique (EPI, single shot: TR=2000 ms, TEef=24,38 ms) within a 10 min recording period. Next a set of 750 functional EPI images where acquired with two times k-space averaging resulting in a TR of 4000 ms and a total measuring time of 50 min. Finally, 22 corresponding anatomical T2 reference images (field of view 15×15 mm, matrix 256×128, TR=2000 ms, slice thickness 0.5 mm, TEef=56 ms, RARE) were assembled. Functional analysis was performed using Brain Voyager QX and our own software MagNan (Knabl et al., 2008). In brief, the following preprocessing was performed: Motion correction algorithm as implemented in BrainVoyager was applied (trilinear interpolation, motion detected always below 1 pixel). Slice time correction was performed with a Cubic Spline, followed by a high pass temporal filtering (9 cycles) and a 2D Gaussian smoothing of the data (FWHM kernel: 2 pixel, in-plane direction). Next a GLM analysis with separate predictors for each stimulation temperature was calculated. To detect significantly activated voxels statistical parametric maps (SPM) of these contrasts were generated for individual animals and FDR thresholded (q=0.05, two sided). Different groups of significant activated voxels (n>4) were labeled belonging to certain brain structures based on the mouse atlas from Paxinos (second edition). The corresponding peak activity was determined for each stimulation temperature based on the stimulus specific GLM predictors. The mean activity of each activated brain structure was averaged across all significant activated voxels and subjected to a statistical t-test comparing α2δ3 mutant and control mice. A second level random effect analysis variance (ANOVA) was performed for Z-score maps between the different mice genotypes. Areas of significant group activation differences (corrected P<0.05) were used as masks to only show the calculated peak activation maps in these regions (
To find brain areas which exhibit the most robust response differences between α2δ3 mutant and control mice, we performed a correlation based principal component analysis (PCA) of BOLD responses with temperature specific input vectors (activation probability, volume and peak height, time, symmetry, and width) per identified brain structure. We then calculated within the coordinate space of the first 3 principal components (88.85% of total variance) the Euclidian distance for all predefined defined pain regions between α2δ3 mutant and control mice. Because the PCA vectors span a coordinate space optimized to cover the variance of the input vectors, large Euclidian distances indicate large differences in response properties between control and α2δ3 mutant mice for a given brain structure. Largest Euclidian distances were observed for the caudate putamen (left) and the primary somato-sensory cortex (left). Enlarged distances were also found for the ventral tegmental area (VAT, left), the primary (right) and secondary (left) somatosensory cortex, the insula (right), entorhinal cortex (left), hippocampus (right) and motor cortex (left). The lowest Euclidian distances were found for the “sensory input” and thalamus, indicating highest similarity between control mice and α2δ3 mutants in heat-induced activation of these brain structures. Minimally 1 day after recovery from the functional experiments the mice obtained a single manganese injection (isotonic and neutral MnC12 solutions: 0.4 mmol/kg, ip). 24 h after the MnC12 injection the DTI and MEMRI measurements were performed using the same scanner and coil system as mentioned previously. First we measured the DTI using an EPI SpinEcho approach (TEeff: 31.6, TR 5000 ms, Bandwith: 150 kHz, segments: 1, NEX: 2, 126 diffusion directions and maximal B-value of 600.00 s/m2 and total measuring time of 21 min 50 s). Geometrical scan properties were matrix: 128×128, slices: 15 with 1.0 mm thickness, field of view: 18×18 mm. Fractional anisotropy maps were calculated using the Bruker PV 5.0LP3 software version and after segmentation and affine registration of the individual brains they were subjected to a voxelwise Student's t-test. For imaging of the Ti contrast of manganese uptake we used a modified driven equilibrium Fourier transform sequence (MDEFT, scan parameters: TR=15.00 ms, TE=5.1 ms, Bandwidth: 25 kHz; FA=15°, inversion delay (ID)=1000 ms and four segments. The ID of the MDEFT preparation (responsible for the Ti contrast) was optimized for the contrast to noise ratio 24 h after MnC12 administration. The geometric parameters of the 3D scans were: matrix: 256×256×64, field of view=22×22×19.84 mm. 10 averages resulted in a total measuring time of 5 h 41 min 20 s. Again the after segmentation and registration, voxel based Student's t-test were performed to assesed potential differences in basal neuronal activity. The functional connectivity was assessed by thresholding the correlation-matrix at such a value that every node (brain structure) has at least one edge (connection). Now the total amount of connections were calculated over all structures of the somato-sensory pain matrix.
We genotyped 5 single nucleotide polymorphisms (SNPs) spaced evenly through a2d3 using the 5′ exonuclease method (Tegeder et al., 2006). a2d3 haplotypes were identified using the SAS/genetics software package (SAS Institute, Inc.), which implements a modified expectation-maximization algorithm to reconstruct haplotypes from population genotype data. Linkage disequilibrium between SNPs was used to describe the non-independence of alleles. The PCR reaction mixture consisted of 2.5 ml Master Mixture (Applied Biosystems), 100 nM detection probe for each allele, 900 nM forward and 900 nM reverse amplification primers, and 20 ng genomic DNA in a total reaction ‘volume of 25 μl. Amplification and detection were performed with an ABI Prism 7700 Sequence Detection System. Allele-specific signals were distinguished by measuring endpoint 6-FAM or VIC fluorescence intensities at 508 nm and 560 nm, respectively, and genotypes were generated using Sequence Detection System Software Version 1.7 (Applied Biosystems, CA). Genotyping error rate was directly determined by re-genotyping 25% of the samples, randomly chosen, for each locus. The overall error rate was <0.005.
We genotyped 5 single nucleotide polymorphisms (SNPs) spaced through the PIK3CG locus using the 5′ exonuclease method. PIK3CG haplotypes were identified using the SAS/genetics software package (SAS Institute, Inc.), which implements a modified expectation-maximization algorithm to reconstruct haplotypes from population genotype data. Linkage disequilibrium between SNPs was used to describe the non-independence of alleles. The PCR reaction mixture consisted of 2.5 ml Master Mixture (Applied Biosystems), 100 nM detection probe for each altele, 900 nM forward. and 900 TIM reverse amplification primers, and, 20 ng genomic DNA in a total reaction volume of 25 ml, Amplification and detection were performed with an ABI Prism 7700 Sequence Detection System. Allele-specific signals were distinguished by measuring endpoint 6-FAM or VIC fluorescence intensities at 508 nm and 560 nm, respectively, and genotypes were generated using Sequence Detection System Software Version 1.7 (Applied Biosystems, CA). Genotyping error rate was directly determined by re-genotyping 25% of the samples, randomly chosen, for each locus. The overall error rate was <0.005.
We genotyped 189 (for a2d3) and 192 (for PIK3CG) normal volunteers who had previously been phenotyped for ratings of experimental pain (Diatchenko et al., 2005). Included subjects were all pain-free Caucasian females 18-34 years of age taken from a larger prospective cohort study designed to examine putative risk factors for the development of temporomandibular joint disorder (TMJD). All subjects gave informed consent following protocols approved by the UNC Committee on Investigations Using Human Subjects. Volunteers were phenotyped with respect to their sensitivity to 16 experimental pain procedures corresponding to multiple pain modalities, including pressure pain, ischemic pain, and temporal summation of heat pain (i.e., windup). Heat sensitivity measures were obtained with a 10 mm diameter computer-controlled contact thermal stimulator placed on the skin of the forearm. We used principal components analysis (PCA), as performed by the SAS statistical package (version 9.1, SAS Institute, Cary N.C.), as a data reduction exercise. From our raw pain scores, we derived a thermal windup score (Factor 3).
We collected DNA from 169 (for a2d3) and 160 (for PIK3CG) Caucasian adults who participated in a prospective observational study of surgical diskectomy for persistent lumbar root pain (Atlas et al., 2001). The primary endpoint was persistent leg pain over the first postoperative year, using four ‘leg pain’ variables normalized to Z-scores with mean 0 and standard deviation 1. The primary pain outcome variable for each individual was the mean of these four Z-scores. Genotype-phenotype associations for each SNP were sought by regression analysis. The covariates were a number of demographic, psychological and environmental factors, including sex, age, worker's compensation status, delay in surgery after enrollment and Short-Form 36 general health scale. Stepwise regression (Zaykin et al., 2002) was applied to assess the association between pain scores and haplotypes with frequencies >1%, obtained from the Ensemble database v.38. These haplotypes accounted for 94% of chromosomes studied. If a haplotype was identified to be significantly (P<0.05) associated with pain scores, phenotype-diplotype association analysis was performed by regression analysis. The collection of DNA and genetic analyses were carried out with the approval of the National Institute of Dental and Craniofacial Research institutional review board and informed consent was obtained from all subjects.
For analysis of adult heat-dose avoidance responses between control and painless flies (
To identify genes required for nociception, we developed a high throughput behavioral assay to determine the response of adult Drosophila to noxious heat as a stimulus. When exposed to a surface at a constant temperature of 25° C., flies distribute evenly in the experimental chamber, but when given a choice between a noxious (46° C.) and non-noxious (31° C.) surface, flies rapidly avoid the harmful temperature (FIG. 1A,B). painless mutant flies respond normally to sub-noxious temperatures (≦39° C.), but fail to avoid noxious heat (46° C.) (
Using this assay, we performed a genome-wide behavioral screen using the Vienna global Drosophila RNAi library (Dietzl et al., 2007). The pan-neuronal specific elav-Gal4 driver line was crossed to flies containing UAS-IR (IR, inverted repeat) transgenes covering the expressed genome (
To identify novel genes regulating pain, we tested 16051 elav-Gal4>UAS-IR combinations targeting 11664 different Drosophila genes (82% of the Drosophila genome version 5.7) for effects on noxious temperature avoidance (
One of the genes that we picked up in this screen was straightjacket (CG12295, stj), a member of the α2δ family of genes that function as subunits of voltage-gated Ca2+ channels (
We confirmed that stj is required for noxious heat avoidance in adult Drosophila using a second independent hairpin (
We next assessed whether stj also controls thermal nociception in the larval heat pain paradigm (Tracey et al., 2003). In larvae, we found expression of stj-Gal4>UAS-CD8:GFP in multidendritic sensory neurons (
We next tested whether the fly stj data is predictive of altered nociceptive behavior in mammals. The closest stj ortholog in mammals is α2δ3 (mouse α2δ3 is 33% identical and 60% similar to the STJ protein and the domain structures are conserved throughout evolution (Ly et al., 2008). To examine the role of α2δ3 in vivo we studied α2δ3 mutant mice generated by homologous recombination. Correct recombination and loss of protein expression were confirmed by Southern (
Importantly, similar to Drosophila stj mutants, α2δ3 mutant mice showed a defect in acute thermal nociception in the hot plate assay, with diminished responsiveness at 50, 52, 54 and 56° C. (
Since knock-down of straightjacket in Drosophila and knock-out of α2δ3 in mice results in impaired sensitivity to thermal pain, we expected that polymorphisms at the α2δ3 (CACNA2D3) locus might be associated with heat pain variance in humans. To assay for potential association of α2δ3 haplotypes relative to pain sensitivity we screened 4 single nucleotide polymorphisms (SNPs) within or close to the human CACNA2D3 gene (
Thermosensitive neurons have been also implicated in chronic pain in humans. To explore this we compared pain levels in 169 Caucasian adults who participated in a prospective observational study of surgical discectomy for persistent lumbar root pain, caused by an intervertebral disc herniation (Atlas et al., 2001) for an association with CACNA2D3 SNPs. The minor alleles of two CACNA2D3 SNPs (rs1851048 and rs6777055) were associated with less pain within the first year following surgery (
Nociceptive processing involves the relay of sensory information from primary nociceptor neurons to second order neurons in the dorsal horn of the spinal cord which then transfer nociceptive information to the brain stem, thalamus, and higher order brain centres. Since our α2δ3 knock-out mice carry a LacZ reporter, we used β-Gal staining as a marker to assess α2δ3 expression. In the brain, β-Gal labeled the thalamus, pyramidal cells of the ventro-posterior paraflocculus of the cerebellum, caudate, putamen, the dentate gyms of the hippocampus, the olfactory bulb and olfactory tubercle, as well as diffusely throughout the cortex (
To address this, we employed non-invasive functional magnetic resonance imaging (fMRI) using the blood oxygenation level dependent (BOLD) signal to generate a activation maps of brain regions affected by noxious topical heat stimuli. In wild type mice (n=20), noxious thermal stimuli activate brain structures known as the “pain matrix” such as the thalamus (
To additionally assess temporal information flow of the pain signal within different cerebral structures, we calculated a cross-correlation matrix of the response time profiles for each predefined region of the somato-sensory pain matrix (
Although we found a marked impairment in the activation of known higher order pain centers, one puzzling finding from our fMRI data was that we did not find statistically significant differences between control and α2δ3 mutant mice in total activation volume and peak height when neuronal activity was surveyed in the entire brain (
To image basal neuronal activity integrated over a 24 hour time period, we employed manganese labeling (MEMRI) (Silva et al., 2004). We observed similar activity in all imaged brain regions among a group comparison of control and α2δ3 mutant mice indicating that the observed stimulus induced sensory cross-activations are not due to altered basal neuronal activity. Moreover, diffusion tensor imaging (DTI) showed no overt structural changes with respect to fractional anisotropy between the thalamus and higher order pain centers or the thalamus and the visual, auditory, and olfactory centers. Further, cross-correlation analysis of the time profiles of the structures of the the pain matrix from resting-state BOLD imaging showed no defects in spontaneous spreading from the thalamus to higher order pain centers in α2δ3 mutant mice. Finally, network analysis of this resting state brain activity showed no overt changes in total functional connectivity within the pain matrix (1087 connections in wild type versus 1040 connections in α2δ3 mutant mice) and also apparently normal multisensory-thalamo-cortical network connectivity (1922 connections in wild type versus 2099 connections in α2δ3 mutant mice). Although we cannot exclude subtle developmental changes in defined neuronal populations of α2δ3 mutant mice, these data suggest that the observed heat induced sensory cross-activations (and defective transmission of the thermal pain signal from the thalamus to higher order pain centers) are not due to altered basal neuronal connectivities.
To assess whether loss of a2d3 also results in sensory cross-activation in other sensory modalities, we performed BOLD imaging in response to tactile vibrissal stimulation (Hess et al., 2000). Among control and a2d3 mutant mice, we observed apparently normal activation of the brain region that encompasses the barrel field; the barrel field is the primary cortical somato-sensory brain centre for processing of vibrissal stimulation. Remarkably, although we observed apparently normal activation of the barrel field, tactile stimulation again resulted in sensory cross-activation of visual, auditory, and olfactory brain centers in a2d3 knock-out mice (FIG. 7A,C). Thus, in α2δ3 mutant mice, noxious heat stimulation as well as tactile stimulation trigger sensory cross-activation of brain regions involved in vision, hearing, and olfaction.
Using a genome-wide neuronal-specific RNAi knock-down strategy in adult Drosophila, we performed the first global screen for an innate behavior, and identified several novel genes required for thermal nociception (see example 2). We report the construction from this data of an evolutionary-conserved, global network map, identifying molecular components and key pathways involved in thermal pain perception. This systems map predicts multiple novel candidate genes and pathways that are conserved across phyla, providing a starting point for finding novel mammalian pain genes. One prominent pathway identified was phospholipid signaling and SNP mapping showed that a polymorphism in the phospholipid kinase PI3Kgamma locus is significantly associated with altered pain sensitivity in humans. Importantly, the role of PI3Kgamma in pain perception was confirmed in mutant mice that exhibit pronounced hypersensitivity to noxious heat and capsaicin. Using knock-in mice, pain hypersensitivity was mapped to the PI3Kgamma lipid kinase activity. Mechanistically, PI3Kgamma acts as a negative regulator of TRPV1 ion channel activity in DRG neurons. Our data provide the first systems map for a complex innate behavior in any species that allowed us to identify a previously unknown pain gene, PI3Kg, in mice and humans.
Using a genome-wide strategy of neuron specific RNAi knock-down in adult Drosophila, we report the first global screen for an innate behavior, avoidance of noxious heat, and identification of hundreds of novel genes required for its manifestation (see example 2). To interrogate this unprecedented resource beyond direct fly mammalian gene homologue comparisons we examined the Drosophila nociception genes using data-mining and bioinformatics to define a conserved global systems network of pain. Potential mouse and human orthologs of our candidate pain genes were first identified using compara49, inparanoid, inparanoid6.1, inparanoid6.1 to ensembl, homologen08, and orthomclv2 databases (
Gene ontology (GO) analyses of human and mouse orthologs of the thermal nociception hits showed a marked enrichment of genes involved in neurotransmission and secretion, housekeeping systems such as mitochondrial structure, ATP synthesis, metabolism, or calcium signaling (FIG. 15A,B). We next generated an interaction map based on first degree binding partners for these mammalian orthologs, because we assume that our candidate thermal nociception genes perform many of their functions in protein complexes. All binding partners were identified in yeast-2-hybrid screens reported in the biomolecular interaction network database BIND, i.e. binding partners experimentally confirmed to interact with the candidate genes. Importantly, among the first degree binding partners in this interaction network, we found fly allatostatin C receptor 1, which has some homology with mammalian opioid receptors, Lmx1b which regulates central serotonergic responses to opioids, the nuclear factor-erythroid 2-related factor 2, which has anti-nociceptive effects by inducing upregulation of heme oxygenase-1, and tyrosine hydroxylase, the enzyme required for dopamine and catecholamines production. Thus, we present strong evidence that our screen identifies many known regulators of thermal pain and multiple uncharacterized genes and pathway previously never associated with pain perception.
To construct a systems map of thermal nociception we performed an enrichment analysis of KEGG pathways and Broad Institute C2 pathway gene sets, on the mouse and human “pain” orthologs and their first degree binding partners (in part shown in
Importantly, the connectivity of the entire systems map remains intact even after omitting all binding partners (
In example 2 we demonstrated a role in mammalian heat pain perception of a direct Drosophila thermal nociception hit, a2d3. Importantly, our bioinformatic analyses allowed us to expand our systems map to also include mammalian gene sets and genes that have no direct fly orthologs. We therefore wanted to validate whether this in silico approach has indeed also the power to identify novel mammalian pain genes. We first investigated whether polymorphisms in the gene sets predicted by our conserved network are associated with significant differences in pain sensitivity in humans. One of the genes identified by this approach was the catalytic p110 subunit of the phosphatidylinositol-3-OH kinase (PI3Kγ, PIK3CG). Class I phosphatidylinositol-3-OH kinases (PI3K) are lipid kinases that convert phosphatidylinositol 4,5-bisphosphate (PIP2) into phosphatidylinositol (3,4,5)-trisphosphate (PIP3). Mammals have four class I PI3K, three of which (α, β, and δ) are primarily activated by tyrosine kinase signaling pathways, while PI3Kγ is the principal PI3K that relays signals via GPCRs. Of note, PI3Kα, β, and d all showed no significant association with pain sensitivities in humans. PI3K and GPCR signaling were prominent nodes in our conserved systems map (
To validate whether the PI3Kgamma nucleotide polymorphism found in our GWAS is indeed associated with pain in humans, we screened 5 SNPs within or close to the human PIK3CG gene (
To confirm this PIK3CG association in an independent cohort, we compared pain levels in 160 Caucasian adults who participated in a prospective observational study of surgical discectomy for persistent lumbar root pain, caused by an intervertebral disc herniation. Again, a polymorphism in the SNP rs757902 was associated with significantly increased pain during the first year following surgery (
To confirm that PI3Kγ indeed controls mammalian pain sensitivity, we analysed PI3Kγ−/− mice. These mutant mice exhibited normal posture and appearance and no significant differences were observed in hearing, sight, and vocalization. PI3Kγ−/− mice also behaved similar to littermate controls in a skilled reaching task (
When we tested for pain responses, PI3Kγ−/− mice exhibited an exaggerated behavioral response to radiant heat plantar stimulation, using the Hargreaves test (
PI3Kγ is a key mediator of inflammatory cell migration to the site of injury. We therefore tested PI3Kγ mutant mice for potential defects in inflammation-induced pain sensitization, i.e. thermal hyperalgesia. PI3Kγ−/− mice developed comparable levels of thermal hyperalgesia (
To test if the enhanced basal thermal sensitivity observed in PI3Kγ−/− mice is intrinsic to noxious heat TRPV1 expressing nociceptors, we employed electrophysiology on isolated wild type and PI3Kγ−/− dorsal root ganglia (DRG) neurons in vitro. Both control and PI3Kγ−/− DRG neurons responded to a thermal ramp (
Our data provide the first systems map for a complex innate behavior in any species. This network map revealed many genes and gene sets previously reported to be involved in mammalian nociception. Importantly, the network also allowed us to predict a novel regulator of pain perception, PI3Kgamma. Although multiple GPCRs operate in the nervous system and PI3Kgamma is the main lipid kinase coupled to GPCRs, no behavioral defects had been reported before in PI3Kgamma mutant mice. Most importantly, these results directly translate to humans, since we found a PI3Kgamma polymorphism that significantly associates with altered pain sensitivity in healthy volunteers and pain levels in chronic back pain patients. Of note, humans carrying a minor allele variant at the PI3K3CG locus, as well as our PI3Kgamma mutant mice exhibit increased pain indicating that our systems approach using whole genome fly screening and construction of a conserved network map can identify positive as well negative regulators of pain perception. These data reinforce the extraordinary conservation of the neurobiological mechanisms of nociception, from its manifestation as avoidance of damage in flies to the complex sensation of pain in humans, a conservation that provides an opportunity from a fly screen to find novel human pain genes.
Our whole-genome, neuron-specific RNAi screen provides a global functional analysis of a complex, innate behavior. We have uncovered hundreds of novel target genes for nociception, a large proportion of which had completely unknown functions until now.
One of the screen hits was the calcium channel subunit straightjacket/α2δ3 and phospholipid kinase PI3Kgamma. In both larva and adult Drosophila, we show that straightjacket or PI3Kgamma are indeed involved in nociception, validating the screening results that yielded more than 100 genetic targets. Importantly, similar to the fly, genetic deletion of α2δ3 in mice also results in impaired acute heat pain responses. These results translate to humans, since we found α2δ3 polymorphisms that significantly associate with reduced pain sensitivity in healthy volunteers and lower levels of chronic pain in lumbar back pain patients. These data reinforce the extraordinary conservation of the neurobiological mechanisms of nociception, from its manifestation as avoidance of damage in primitive creatures like flies, to the complex sensation of pain in humans. Ligands and antagonists of the novel genetic targets were identified, that can be used in novel therapeutic approaches for the treatment and amelioration of pain and its symptoms.
The basic principle of animal models of human pain involve the induction of a pain-like state in the organism resulting in characteristic behavioural and physical responses, such as hypersensitivity to touch (mechanical allodynia) and temperature (cold allodynia). The assessment of the efficacy of potential analgesics is determined based on said compound's ability to attenuate/ameliorate these symptoms.
The Bennett and Xie chronic constriction injury (CCI) model is a model of mononeuropathic pain (Bennett and Xie, 1988). Rodents are subjected to a surgical procedure where gut ligatures are tied loosely around the sciatic nerve at the mid-thigh level. Symptoms of neuropathy develop in the operated paw over the following days including tactile allodynia and cold allodynia which are measured using Von Frey's hairs and paw withdrawal from a cold plate, respectively. Operated animals also exhibit other symptoms of spontaneous pain including thermal hyperalgesia, ectopic and spontaneous firing of sensory afferents, autotomy, licking and guarding of paw and sleep architecture abnormalities (Blackburn-Munro and Erichsen, 2005). Furthermore, electrophysiological studies have demonstrated the presence of both sensory nerve hyperexcitability and central sensitisation (wind up) in the dorsal horn and elsewhere (Blackburn-Munro and Erichsen, 2005). The Bennett and Xie model is thought to have predictive validity as an 88% concordance has been observed between activity in the model (any endpoint) and clinical efficacy in neuropathic pain (Kontinen and Meert 2003). Multiple drug classes including NSAIDs are ineffective in the clinical treatment of neuropathic pain and fail to ameliorate symptoms in the Bennett model despite the presence of an inflammation in the initial phase after surgery (eg Schafers et al., 2004; Takahashi et al., 2004, LaBuda and Little, 2005). Pregabalin, a drug approved for the treatment of various types of (chronic) pain, including neurophathic pain associated with diabetic peripheral neuropahty in humans, is effective at ameliorating symptoms of pain in the CCI model.
Mechanical allodynia was assessed by Von Frey's hairs. These consist of a series of wires of progressive thickness each of which bend when a critical pressure (1.4, 2, 4, 6, 8, 10, 15 g) is applied. Animals were placed in floorless Perspex testing boxes resting on a wire mesh tray. Von Frey's hairs were then applied through the mesh floor to the sole of the left and right hind paws until either the animal sensed discomfort and moved the paw or the pressure applied to the Von Frey's hair exceeded the critical level and it was observed to bend. Von Frey's hairs were applied in ascending order until either a pain response (the paw was moved) was registered or the cut-off of 15 g was reached, using the Von Frey hair with the highest rating. Hairs were applied to each heel 8-10 times at a frequency of approximately 1 Hz. If a limb was moved in response to a probe, further testing was halted and the sensitivity to a mechanical stimulus was deemed to have been reached.
Sensitivity to cold (cold allodynia) was assessed by placing animal subjects on a cold plate held at 10° C. The latency (time) to lift the respective hind paw clear off the cold plate was measured. A cut-off of 180 s was applied.
This example demonstrates the effectiveness of compound(s) according to the invention in ameliorating mechanical and cold allodynia in rats with peripheral mononeuropathy induced by loose ligation of the sciatic nerve as described in Bennett and Xie, 1988.
The test apparatus according to Example 4.1.1 was used for assessing mechanical and thermal sensitivities.
Male Sprague-Dawley rats were habituated to the mechanical test apparatus (Von Frey's hairs, described in Example 4.1.1) during 5-10 min periods spread over two days and once to the cold plate set at 10° C. for 3 minutes. Following habituation animals underwent a surgical procedure requiring anaesthetization under isoflurane, shaving of the left (ipsilateral) hind limb and swabbing with antiseptic followed by administration of sodium pentobarbitone. An incision was made to reveal the left sciatic nerve which was tied off with four loose ligatures of chromic cat gut. The exposed muscle was sutured with non-absorbable silk and the wound closed with surgical clips.
The animals were monitored in the hours post surgery and on a daily basis thereafter. Animals showing signs of ill health or autotomy were removed from the study. Approximately 12 and 18 days after surgery the animals were reassessed for sensitivity to Von Frey's hairs and to the cold plate.
Animal subjects meeting pre-defined criteria for hypersensitivity to mechanical (ipsilateral hind-paw moved at a pressure of ≦4 g) and thermal stimuli (≦78 s withdrawal latency) in the operated (ipsilateral) hind-paw were allocated according to baseline mechanical and cold sensitivity scores to produce balanced treatment groups of 8 to 10 animals in each group.
Each group of animals according to Example 4.1.2 was administered a single dose of either a positive control drug (pregabalin formulated in a vehicle of 0.5% methyl cellulose to a concentration of 12 mg/mL and administered po in a 5 mL/kg dosing volume to give a dose of 60 mg/kg) or a compound according to the invention. Animal subjects were reassessed for mechanical and cold allodynia 30 min, 90 min, 180 min and 24 hours after administration of the respective compound, using Von Frey's hairs and a cold plate set at 10° C. The cold plate assessment was performed 5 mins after each Von Frey test.
The procedure as described in Example 4.1.2.1. was performed with the compounds according to the invention being dasatinib and tenofovir. In total, five groups of animals were included: one group of 10 animals received the positive control drug, pregabalin, at 60 mg/kg and four groups of 8 animals each received either 10 mg/kg dasatinib, 30 mg/kg dasatinib, 50 mg/kg tenofovir or 500 mg/kg tenofovir, respectively (
The procedure as described in Example 4.1.2.1. was performed with the compounds according to the invention being cilomilast, zardaverine and roflumilast. In total, five groups of animals were included: one group of 10 animals received the positive control drug, pregabalin, at 60 mg/kg and four groups of 8 animals each received either 3 mg/kg cilomilast, 30 mg/kg cilomilast, 20 mg/kg zardaverine or 1.8 mg/kg roflumilast, respectively (
The procedure as described in Example 4.1.2.1. was performed with the compounds according to the invention being bosutinib and adefovir. In total, five groups of animals were included: one group of 10 animals received the positive control drug, pregabalin, at 60 mg/kg and four groups of 8 animals each received either 60 mg/kg bosutinib, 200 mg/kg bosutinib, 2 mg/kg adefovir or 20 mg/kg adefovir, respectively (
Each group of animals according to Example 4.1.2 was administered either a positive control drug (pregabalin formulated in a vehicle of 0.5% methyl cellulose to a concentration of 12 mg/mL and administered po in a 5 mL/kg dosing volume to give an effective dose (e.g. 60 mg/kg)) or a compound according to the invention. Dosing was carried out one or several times daily for two days to eight weeks. Animal subjects were reassessed for mechanical and cold allodynia either daily, weekly, biweekly, monthly or at the end of the study at one or several time points: 30 min, 90 min, 180 min, 12 hours, 24 hours, 48 hours, 72 hours and 1 week after administration of the respective compound, using Von Frey's hairs and a cold plate set at 10° C.
Complete Freunds Adjuvant (CFA) consists of heat-killed mycobacterium suspended in mineral oil. When injected systemically into rodents, an immune response is triggered resulting in chronic inflammation of many organs such as skin, liver, spleen, eyes, bone marrow and particularly peripheral joints. The inflammatory response results in bone resorption and periosteal bone proliferation. Importantly this inflammatory state results in spontaneous pain and ectopic nerve cell firing. Thus, the resultant adjuvant disease exhibits polyarthritic symptoms. When CFA is injected unilaterally into the limbs it elicits a monoarthritic-like condition and is thus used to model chronic inflammatory conditions. Unilateral injection allows the analysis of ipsilateral and contralateral effects of localised joint pain (Millan et al., 1988). Injection of CFA results in oedema of the affected joint, mechanical allodynia and mechanical and thermal hyperalgesia (Butler et al., 1992; Hsieh et al., 2010; Meotti et al., 2006; Staton et al., 2007). As these features resemble the clinical pathology of rheumatoid arthritis, CFA-induced chronic inflammation has been widely used as a model of this condition.
A wide variety of treatments acting via different mechanisms that have generated positive data in rat adjuvant-induced arthritic models have proven effective in subsequent clinical trials for rheumatoid arthritis (Hegen et al., 2008). Indeed, an analysis by Whiteside (Whiteside et al., 2008), concluded that activity in the rat CFA test could be used to predict the exposure needed for clinical efficacy. Both morphine-like opioids, steroids and NSAID analgesics can attenuate inflammation-associated allodynia/hyperalgesia and normalise nociceptive sensitivity (Jett et al., 1999, da Silva Filho et al., 2004).
This example demonstrates the effectiveness of a compound according to the invention in ameliorating mechanical and cold allodynia in rats with inflammatory pain induced by injection of an adjuvant (CFA) into the limbs.
The test apparatus according to Example 4.1.1 was used for assessing mechanical and thermal sensitivities.
53 male Sprague-Dawley rats were habituated to the test apparatus and tested for basal sensitivity to mechanical and thermal stimuli in both the right (ipsilateral) and left (contralateral) paws using Von Freys hair and a radiant heat source, respectively, on the day prior to Complete Freunds Adjuvant (CFA) administration (Day 0). The following morning (Day 1), animals were subjected to a subplantar injection of 50% complete CFA in a 100 uL injection volume into the ipsilateral hind-paw. Two days later (Day 3), baseline mechanical and thermal sensitivities were reassessed in the CFA-injected (ipsilateral) and non-injected (contralateral) hind-paws. 42 rats meeting pre-defined criteria for hypersensitivity to mechanical (ipsilateral hind-paw moved at a pressure of <4 g) and thermal stimuli (>30% difference in latency time between ipsi- and contra-lateral hind-paws) were assigned to treatment groups of 8 to 10 animals in each group. One hour later, at T=0, drug administration commenced.
One group of animals according to Example 4.2.1 was administered a single dose of the drug indomethacin (positive control), an NSAID with demonstrated efficacy in the CFA model and in human inflammatory/arthritic diseases. Indomethacin was formulated in 50% 0.1 M Na2CO3; 47.5% phosphate buffered saline (PBS): taken to pH 7 with 2.5% 1M HCl at a concentration of 2 mg/mL to give a dose of 10 mg/kg when administered intraperitoneally in a 5 mL/kg injection volume. The remaining groups of animals were administered a single dose of compound(s) according to the invention. 30, 90, 180 min and 24 h post-dose, all groups of rats were reassessed for mechanical allodynia and thermal hyperalgesia in both the treated and untreated hind-paws, using Von Frey's hairs and a cold plate set at 10° C. in accordance with Example 0. All readings were compared to the basal sensitivity reading (T=0) of the (ipsilateral) paw in each animal.
The procedure as described in Example 2A was performed with the compounds according to the invention being dasatinib and tenofovir. In total, five groups of animals were included: one group of 10 animals received the positive control drug, indomethacin, intraperitonally at a dose of 10 mg/kg Four groups of 8 animals each received either 10 mg/kg dasatinib, 30 mg/kg dasatinib, 50 mg/kg tenofovir or 500 mg/kg tenofovir, respectively (
The procedure as described in Example 2A was performed with the compounds according to the invention being cilomilast, zardaverine and roflumilast. In total, five groups of animals were included: one group of 10 animals received the positive control drug, indomethacin, at 10 mg/kg and four groups of 8 animals each received either 3 mg/kg cilomilast, 30 mg/kg cilomilast, 20 mg/kg zardaverine or 1.8 mg/kg roflumilast, respectively (
The procedure as described in Example 1 was performed with the compounds according to the invention being bosutinib and adefovir. In total, five groups of animals were included: one group of 10 animals received the positive control drug, indomethacin, at 10 mg/kg and four groups of 8 animals each received either 60 mg/kg bosutinib, 200 mg/kg bosutinib, 2 mg/kg adefovir or 20 mg/kg adefovir, respectively (
Each group of animals according to Example 2 was administered either a positive control drug (indomethacin, which was formulated in 50% 0.1 M Na2CO3; 47.5% phosphate buffered saline (PBS): taken to pH 7 with 2.5% 1M HCl at a concentration of 2 mg/mL to give an effective dose (e.g. 10 mg/kg when administered intraperitoneally in a 5 mL/kg injection volume)), or a compound according to the invention. Dosing was carried out one or several times daily for two days to eight weeks. Animal subjects were reassessed for mechanical and cold allodynia either daily, weekly, biweekly, monthly or at the end of the study at one or several time points: 30 min, 90 min, 180 min, 12 hours, 24 hours, 48 hours, 72 hours and 1 week after administration of the respective compound, using Von Frey's hairs and a cold plate set at 10° C. according to Example 0.
The half maximal inhibitory concentration (IC50) is a measure of the effectiveness of a compound in inhibiting biological or biochemical function. Concentration-response plots are used to determine the effects of an inhibitor on an enzymatic reaction.
The cloning of catalytic domains of human PDE4D as well as the expression and purification of the PDE catalytic domains were based on the protocols described in Card et al., 2004. Measurement of phosphodiesterase activity takes advantage of the selective binding of 5-AMP or 5-GMP (and not cAMP or cGMP) to yttrium silicate beads with embedded scintillant. 0.1-1 nM PDE was incubated with 50 nM 3H-cAMP or 70 nM 3H-cGMP (Amersham, 5-60 Ci/mmol) in 50 mM Tris (pH 7.5), 8.3 mM MgCl2, 1.7 mM EGTA, and 0.01% BSA at 30C for 30 min in 384-well assay plates. The assay was terminated by adding one-third volume of 5 mg/ml yttrium silicate beads in 18 mM ZnAcetate/ZnSO4 solution (3:1). A minimum of 30 min after mixing and centrifuging the reaction, hydrolysis was quantified by reading in a scintillation counter (Trilux, Conclusions Wallac). The cAMP and cGMP concentrations used, where possible, were far below the Km of the enzyme to ensure that the IC50 values obtained are good approximations of Ki (Mehats et al., 2002).
Patients with a long term or chronic pain condition are eligible for the study.
After initial screening, a total of 20 to 200 patients are randomized to one of two treatment groups. Patients in one treatment group receive a compound according to the invention at a pharmaceutically active dose and patients in the other (control) treatment group receive either placebo or an active control drug at a pharmaceutically active dose. A preferred active control drug is pregabalin. Preferably, the study is carried out in a double-blinded fashion.
Treatment duration is between 1 and 15 weeks, and efficacy evaluation is carried out as the average of the pain scores recorded for the past 1 to 7 days (preferably 7 days) relative to the day chosen for efficacy evaluation, comparing the group receiving the compound according to the invention with the control group.
The pain scores are preferably assessed based on patients' daily pain diaries, in which they record their daily pain score on an 11-point (0=“no pain” to 10=“worst possible pain”) numeric rating scale (NRS) [Arezzo et al., 2008].
The primary endpoint of the study is preferably a comparison of the average pain score for the last 7 available pain diary entries at the end of the treatment phase.
A clinical study according to Example 6 is carried out with the following key inclusion criteria: patients are men or women ≧18 years of age with type 1 or type 2 diabetes with HbA1C≦11% and painful diabetic peripheral neuropathy of at least 3 months' duration. Patients score at least 40 mm on the Short-Form McGill Pain Questionnaire (SF-MPQ) Visual Analog Scale (VAS) [Arezzo et al., 2008], or any other standard VAS. At randomization, patients have completed at least four daily pain diary entries (using an 11-point NRS) and should have an average daily pain score ≧4 over the past 7 days.
A clinical study according to Example 6 is carried out with the following key inclusion criteria: patients are men or women ≧18 years of age with persistent pain for at least 6 months after the onset of herpes zoster rash. Patients score at least 40 mm on the Short-Form McGill Pain Questionnaire (SF-MPQ) Visual Analog Scale (VAS) [Arezzo et al., 2008], or any other VAS.
A clinical study according to Example 6 is carried out with patients selected according to inclusion criteria in Example 7 as well as Example 8.
The binding and selectivity of a compound for a receptor can be assayed, for instance, by carrying out biochemical binding assays such as KinomeScan kinase binding assays as described in Karaman et al., 2008. For an assay to determine the binding of a compound to the target FRK, the kinase construct NP 002022.1 may be used. The assay can be performed with either the full length protein or with a kinase construct that spans the catalytic domain.
The present invention relates to new therapies to treat pain and related diseases, as well as pharmaceutical compounds for use in said therapies.
| Number | Date | Country | Kind |
|---|---|---|---|
| 10190922.4 | Nov 2010 | EP | regional |
| Number | Date | Country | |
|---|---|---|---|
| Parent | 13884920 | May 2013 | US |
| Child | 14273081 | US |
